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Addiction is considered a chronic relapsing disorder with biological, psychological 
and social causes and consequences (McLellan, 2002). The DSM (American 
Psychiatric Association, 1995, p. 9-10) and the ICD (World Health Organization, 
1992) define substance use disorders as a substance dependence syndrome 
and/or substance abuse (DSM) or harmful use (ICD). Substance use disorders 
are characterized by a cluster of physiological, behavioral, and cognitive 
phenomena in which the use of a substance takes on a much higher priority for a 
given individual than other behaviors that once had greater value. A central 
descriptive characteristic is the desire (often strong, sometimes overpowering) to 
take the substance (which may, or may not, have been medically prescribed). 
Treatment goals range from cure through care to palliation (Van den Brink & 
Van Ree, 2003). Even though addiction is considered to be a chronic relapsing 
disease, the ambition of many patients, therapists and policy makers is still the 
cure of this disease, i.e. stable abstinence. This dissertation focuses on this goal. 
In order to obtain this goal, it is believed that pharmacological interventions 
should be integrated with psychosocial treatments to obtain optimal results 
(Kleber et al., 2003). For instance, it is said that naltrexone-assisted detoxification 
followed by naltrexone maintenance treatment should be integrated with 
psychosocial support measures, such as CRA (De Jong et al, 2004; Roozen et 
al., 2000). Obviously, such an integrated treatment approach should be 
systematically evaluated before it can be implemented in general practice. The 
introduction ends with the research questions for this evaluation and a brief 
outline of the content of this thesis. 
 
1.1. Substance use disorder: a chronic relapsing disorder 
General introduction 
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1.1.1. Prevalence of substance use 
Recent data from the United Nations suggests that worldwide about 180 
million people - 4.2 per cent of people aged 15 years and above - were 
consuming illicit drugs in the late 1990s (United Nations Office for Drug Control 
and Crime Prevention, 2001). This estimated number includes 9 million heroin 
users, 29 million people consuming amphetamine-type stimulants, and 14 million 
people using cocaine. In addition, there are worldwide about 1.2 billion smokers 
of tobacco products (World Health Organisation, 2004). 
Twelve percent of the US population reported using cocaine one or more times 
in their lifetime (American Psychiatric Association, 1995). It is estimated that there 
are currently one million cocaine dependent persons in the US (Substance Abuse 
and Mental Health Services Administration, 1999). In Western Europe there are 
some 1.2 million-heroin dependent persons and the US estimates that there are 
approximately 1 million heroin dependent persons (United Nations Office for Drug 
Control and Crime Prevention, 2001, p.4; Substance Abuse and Mental Health 
Services Administration, 1999). In the US there are about 3.1 million people using 
marijuana on a daily or almost daily basis over a 12-month period (National 
Survey on Drug Use and Health, 2002; National Institute on Drug Abuse, 2004). 
An estimated 15 million Americans are dependent on alcohol (National Institute 
on Alcohol Abuse and Alcoholism, 2004), which indicates that about 14% of 
American adults had either alcohol dependence or abuse sometime in their lives 
(Helzer, Burnam, & McEvoy, 1991). Although there are no exact data available, 
Europe is the region of the world with the highest production and consumption of 
alcohol and 5% of European adults are currently dependent on alcohol (Eurocare, 
2004). 
In the Netherlands, with a population of about 16 million inhabitants, there are 
approximately 26,000-30,000 heroin dependent persons and 820,000 alcohol-
abusing people (Netherlands National Drug Monitor, 2003). About 366,000 of 
these problematic alcohol users are dependent (Bijl, Van Zessen, & Ravelli, 
1997). Furthermore, in the Netherlands it is estimated that there are 
approximately four million smokers (Netherlands National Drug Monitor, 2003) 
CRA and NTX in the treatment of addiction 
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and an estimated 2.4 million are dependent on nicotine (Netherlands National 
Drug Monitor, 2001; Health Counsel of the Netherlands, 2002a, p. 63). Recently, 
the percentage of heavily smoking people has fallen (Netherlands National Drug 
Monitor, 2003; Koolhaas, 2004). The percentage of cannabis users is currently 
about 3% (408,000; Netherlands National Drug Monitor, 2003). Cannabis is the 
most popular of all illicit drugs (Netherlands National Drug Monitor, 2003). In the 
general population, the percentage of present cocaine users is 0.4% and 0.5% for 
amphetamine users (Netherlands National Drug Monitor, 2003). Unfortunately, no 
exact numbers of cocaine and amphetamine dependent persons are available for 
the Netherlands (Health Counsel of the Netherlands, 2002a).  
 
1.1.2. Consequences of substance use disorders 
Substance use disorders are associated with medical, economic, psychiatric, 
family, and legal problems (McLellan et al., 1994). It affects health by 
accompanying coexisting medical illness of drug users (Kresina et al., 2004; 
Stein, 1990), which is often related to the route of drug administration. Many 
substance users seem to have severe problems with infectious diseases (De la 
Fuente et al., 1996; Kresina et al., 2004) such as bacterial endocarditis, 
osteomyelitis, septic arthritis, and most commonly, skin infections such as 
abscesses and cellulitis (Stein, 1990; Leri, Bruneau, & Stewart, 2003). Above all, 
injection drug use is a profound risk factor for the transmission of HIV infection 
(US Centres for Disease Control and Prevention, 1993; Jurgens, 2003), Hepatitis 
A, B, C and D, and other retroviral infections (O’Connor & Selwyn, 1997; Macalino 
et al., 2004; Vlahov et al., 2004). Due to environmental and social factors related 
to substance dependence, diseases such as pneumonia, tuberculosis and 
sexually transmitted diseases can impair the health status of drug users. 
Along with the medical complications listed above, the use of substances can 
also have profound direct implications on health. For instance, heroin and other 
opiates can cause arrhythmias and noncardiac pulmonary edema, and may 
reduce cardiac output (Frishman et al., 2003). Alcohol can cause a variety of 
problems such as central nervous system complications (e.g. Korsakov 
General introduction 
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syndrome), cardiovascular problems (e.g. chronic cardiomyopathy, hypertension, 
and arrhythmia) (Frishman et al., 2003), and gastrointestinal diseases (e.g. liver 
cirrhosis, pancreatitis) (O’Connor, 1994). Problematic cocaine use on the other 
hand is mainly associated with cerebral- or cardio vascular diseases such as 
cerebral vasculitis, intracranial hemorrhage, cerebral infarction, and stroke 
(O’Connor et al., 1992; Su et al., 2003). Heavy use of 3,4 methylenedioxy-
methamphetamine (MDMA/XTC) is associated with neurotoxic effects on 
serotonin neurons (Reneman et al., 2001). Smoking is associated with Chronic 
Obstructive Pulmonary Diseases (COPD) and lung cancer (Health Counsel of the 
Netherlands, 2002a). 
The often co-occurring social impairments and the presence of comorbid 
psychiatric disorders such as depression, anxiety, and personality disorders are 
associated with negative treatment outcomes (De Jong et al., 1993; Moos, Finney 
& Cronkite, 1990). These problems precipitate often in disrupted interpersonal 
relationships, absenteeism, job loss, criminal behavior, and poor academic or 
work performance (American Psychiatric Association, 1995, p. 12). Maladaptive 
coping strategies and limitation of activities, mainly focused on obtaining and 
using substances are, in general, linked with elevated levels of life threatening 
behavior. These include criminal behavior, violence, property crimes and other 
types of crimes, and often lead to imprisonment. It is estimated that about 40% 
(range 19%-56%) of all prisoners have a substance related disorder (Blaauw, 
Roesch & Kerkhof, 2000; Koeter & Luhrman, 1998; Health Council of The 
Netherlands, 2002b). Other life threatening types of behavior may lead to 
accidents, suicide, violence, AIDS, and cause death among drug users (Hulse et 
al., 1999; Rossow & Lauritzen, 1999). Consequently, the mortality of substance 
dependence is high (Hulse et al., 1999). "Economic reliance on the drug trade, 
and drug addiction, leaves many individuals open to exploitation by criminals and 
criminal organizations; threatening the health of men, women and children, the 
rule of law, and ultimately, the vitality and strength of all our communities" (United 
Nations Office for Drug Control and Crime Prevention, 2001, p. 173). 
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1.1.3. Substance use disorders have a chronic intermittent course 
More than thirty years ago, Hunt, Barnett and Branch  (1971) demonstrated 
the high relapse rates of addiction treatment outcome and found that treatment is 
associated with high rates of recidivism across a wide range of addictive 
behaviors. In addition, the data showed that about two-thirds of all participants 
relapsed within the first 90 days (Marlatt & Gordon, 1985, p. 35). The temporal 
patterning of relapse in a spectrum of different addictions exhibits a remarkable 
consistent curve (Marlatt & Gordon, 1985, p. 34). The curve characterizes a 
cumulative one (percentage of abstainers remaining at interval over a given 
period) and has a downward slope. 
A predominant factor that often results in relapse is treatment dropout or 
treatment non-compliance (McCusker et al., 1996). In general, dropout in 
substance abuse treatment is very high (see De Weert-Van Oene, 2000). Dropout 
in outpatient alcohol and drug programs generally varied, between 44-80%. 
Dropout in alcohol and drug inpatient programs typically varied, between 18-96% 
(Stark, 1992). 
The recurrences of relapse and dropout have influenced our view of addiction. 
For many people substance use has become a chronic relapsing disorder, and 
repeated treatment episodes are required before the individual achieves long-term 
abstinence (O'Brien & McLellan, 1996; McLellan et al., 2000; McLellan, 2002). 
The chronic nature of addiction is suggested to be the result of the prolonged 
effects of drugs on the brain (Leshner, 1997). This chronicity is illustrated in a 
twenty year follow-up study of heroin dependent patients, published more than 
thirty years ago, ascertaining that 23% died (mostly of unnatural causes), 
outcome was uncertain in 10%, about 25% were still known to be using drugs and 
35-42% had reached stable abstinence (Vaillant, 1973). More recent, the same 
author conducted a study to determine the course of male alcohol abusing 
patients from the age of 40 years to 60 or 70 years. It was found that, by 60 years 
of age, 18-28% of the patients had died, 11-30% were abstinent, 11% were 
controlled drinkers, and 28-59% were known to be still abusing alcohol (Vaillant, 
1996). In addition, the author stated that a return to controlled drinking without 
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eventual relapse was unlikely. Alcohol abuse could continue for decades without 
remission or progression of symptoms (Vaillant, 1996).  
More evidence for the chronic nature of opioid dependence is provided by the 
study of Hser. This study showed that, while the number of deaths increased 
steadily over time, heroin use patterns were remarkably stable for the group as a 
whole. Furthermore, the authors stated that for some, heroin addiction has been a 
lifelong condition associated with severe health and social consequences (Hser et 
al., 2001). Accordingly, Hser stated: “Abstinence for 5 years significantly reduced 
the likelihood of relapse, but even among those who achieved 15 years of 
abstinence, a quarter still relapsed” (cited from Zickler, 2001). 
In summary, addiction appears to be a chronic relapsing disorder with a strong 
biopsychological underpinning and with serious medical, psychological and social 
consequences. Treatment should take all these aspects into account in order to 
promote positive outcomes. To address the chronicity, abstinence oriented 
treatments are viable, as it was shown that cocaine abstinence achieved during 
treatment was the single best predictor of cocaine abstinence during follow-up 
(Carroll et al., 1994; Higgins et al., 2000a,b; Kosten et al., 1992). Similar 
outcomes have been found in studies of individuals attempting to discontinue use 
of cigarettes, and individuals attempting to lose weight and maintain weight loss, 
suggesting a common mechanism for treatment success (Higgins et al., 2000b). It 
may be concluded that recovery oriented treatment approaches, which facilitate 
short-term abstinence, predict long term-treatment success (Weisner et al., 2003). 
Additionally, these findings highlight the beneficial impact of readmission and the 
principles of recycling.  
 
1.2. Treatment goals 
 
In the western world, the disease model (Jellinek, 1960) is prevalent. For most 
patients with alcohol dependence, abstinence is still the primary and optimal goal 
(American Psychiatric Association, 1995; Rosenberg & Davis, 1994). However, 
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there is a wealth of complementary treatment options that emphasize alternative 
goals, such as controlled drinking or the prevention of medical complications. In 
the field of opiate management, these treatments are labeled ‘harm reduction’ 
and ‘risk minimization’, and are embodied in programs such as buprenorphine or 
methadone maintenance treatment. Presently, methadone maintenance is 
regarded as a cornerstone in the treatment of heroin dependence (Fiellin & 
O’Connor, 2002). Harm reduction addresses substance dependence from a 
health perspective and considers any reduction of concomitant negative effects 
as valuable (Gunn, White & Srinivasan, 1998). “Harm reduction encompasses 
abstinence as a desirable goal, but recognizes that when abstinence is not 
possible, it is not ethical to ignore the other available means of reducing human 
suffering” (Gunn, White & Srinivasan, 1998, p. 1191).  
The clients’ motivation -especially readiness for treatment- is an important 
predictor of retention and therapeutic engagement (Joe, Simpson & Broome, 
1998). In general, motivational enhancement is considered as an important part of 
a broader treatment package. Motivational enhancement depicts a set of 
techniques based on Motivational Interviewing, which can be used to increase 
patients’ motivation to initiate a commitment toward the preferred treatment goal. 
Motivational Interviewing principles are based on motivational psychology and are 
designed to produce rapid, internally motivated change (Miller & Rollnick, 1992). 
"This treatment strategy does not attempt to guide and train the subject, through 
recovery, but instead employs motivational strategies to mobilize the client's own 
change resources" (Miller et al., 1992, p. 1). 
In Motivational Interviewing, the responsibility for the change in behavior is left to 
the patient; it is assumed that patients can use available resources to change 
behavior and that training is not required. By using Motivational Interviewing 
techniques, the subject moves from the pre-contemplation stage through the 
contemplation stage to the preparation stage, where plans can be made for 
behavior change, in accordance with the treatment goal. Accordingly, the Health 
Counsel of the Netherlands (2002a, p. 73), distinguished three hierarchically 
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1. ‘Cure’ by the achievement of stable abstinence. In general, ‘curing’ addiction 
is considered to be possible only when substance-using behavior is fully 
discontinued. Cure is focused on stable abstinence. This goal can only be 
reached by the combination of: 
• detoxification. The main objective is to relieve withdrawal symptoms, 
evoked by discontinuation of substance use. Each substance has a 
specific intrinsic pharmacological profile, which has implications for the 
severity and duration of withdrawal symptoms and the detoxification 
process. Withdrawal symptoms can be controlled by means of either 
inpatient- or outpatient treatment. For instance, alcohol dependent patients 
may require inpatient detoxification with additional pharmacological 
attenuation therapy with tranquilizers, in patients with a history of severe 
or abnormal withdrawal reactions. Related to the chosen detoxification 
technique, it is important to manage and monitor withdrawal symptoms 
and detect complications such as delirium tremens, dehydration, and other 
somatic or psychiatric deterioration. This is especially important for the use 
of accelerated invasive procedures in which antagonists precipitate acute 
severe withdrawal symptoms, such as rapid opioid detoxification (Roozen 
et al., 2002). In general, the detoxification process does not address 
underlying mechanisms related to initiation and maintenance of addiction, 
and thus is not an adequate treatment in itself (Mattick & Hall, 1996). It 
can only be considered as an initial start towards the goal of long-term 
recovery. Detoxification should be followed by: 
• relapse prevention, which implies a focus on the prevention of relapse 
after abstinence is initiated. Relapse prevention constitutes a collection of 
interdependent pharmacological and psychosocial techniques designed to 
foster abstinence. The methods and techniques involved in the current 
study will be explained in the next paragraphs: psychosocial treatment 
methods (1.4.1) and pharmacological treatment (1.4.2).  
 
2. When cure (stable abstinence) is not obtainable, care, stabilization or risk 
minimization, i.e. reduction in frequency and intensity of substance use and 
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associated sequels, and reduction in the use and effects of substances 
(American Psychiatric Association, 1995, p. 16) becomes the objective. The 
subject will be referred to a maintenance program, which is designated to 
stabilize or regulate the use of illegal substances. Currently, pharmacological 
maintenance strategies are only available for smoking (nicotine replacement 
therapy) and opiate dependence (methadone and buprenorphine 
maintenance). Patients may also benefit from additional psychosocial 
treatments. These interventions will be outlined in paragraph 1.4.1. 
• The aim of Nicotine Replacement Therapy by the available forms 
(nicotine gum, transdermal patch, the nicotine nasal spray, nicotine 
inhaler and nicotine sublingual tablets/lozenges) is to replace nicotine 
from cigarettes to reduce smoking. The commonly used transdermal 
patches are available in different sizes, and deliver between 7 mg and 22 
mg of nicotine over a 24-hour period, resulting in plasma levels similar to 
the trough levels seen in heavily smoking persons (Fiore, 1994). NRTs 
are effective as part of a strategy to promote smoking cessation (Silagy et 
al., 2002, 2004). 
• In the case of opiate dependence, methadone and buprenorphine are the 
most frequently applied substitution compounds. In the treatment of 
opiate use disorder, the use of methadone, a long acting opioid agonist, is 
considered as an effective pharmacological maintenance treatment for 
heroin dependence. It acts by reducing acute subjective effects of heroin 
and other illicit opiates through the mechanism of cross-tolerance (Litten 
& Allen, 1999). A meta-analysis demonstrated that methadone is 
statistically significantly more effective than non-pharmacological 
approaches in retaining patients in treatment and in the suppression of 
heroin use, but methadone was not statistically superior in the reduction 
of criminal activities (Mattick et al., 2002a). Another pharmacological 
agent is buprenorphine, which differs from methadone in exhibiting 
reduced (partial) agonist activity with increasing doses (Lewis, 1985). 
Buprenorphine has a higher affinity for µ-opioid receptor sites than 
methadone and heroin, and it has been reported to be an alternative to 
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methadone for maintenance treatment of opioid dependent patients. 
Buprenorphine reduces heroin use, blocks subjective and physiological 
effects of other opiates, and augments treatment retention (Litten & Allen, 
1999). A recent review has shown that buprenorphine suppressed heroin 
use significantly better than placebo, but it is not more effective than 
methadone at adequate dosages (Mattick et al., 2002b). An advantage of 
buprenorphine over methadone is its low liability of physical dependence 
and, therefore, it can be withdrawn or tapered with relative ease (Litten et 
al., 1997). However, there is a worrying increase in the number of reports 
of illegal intravenous injection of crushed buprenorphine tablets to which 
deaths were attributed (Kintz, 2002).  
 
3. Palliation is considered as the third goal, aimed to treat symptoms and to 
reduce suffering associated with chronic addiction in patients with short 
lifetime expectancy. Palliation focuses on the individual experience of the 
advanced disease process, not on the disease process itself. The goals of 
palliation are aimed at reducing suffering, increasing comfort, and quality of 
life. When cure or risk minimization is no longer obtainable, palliation can be 
considered as an option for patients who are facing a terminal illness.  
 
1.3. Detoxification strategies 
 
Detoxification can be conducted in both an outpatient or inpatient setting. 
Inpatient detoxification allows the patient to be closely monitored; a controlled 
setting may minimize the exposure to the substance of use, and can accelerate 
the process of detoxification. Outpatient detoxification has the advantage of being 
less disruptive to the patient's life. The choice of setting depends on factors such 
as the type of substance, multiple substance use, amount and length of history of 
dependence (there is a potential for developing dangerous abstinence symptoms 
including seizure or delirium), psychosocial issues (lack of social support at 
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home), the patient's age, and co-existing medical and/or psychiatric conditions 
(psychopathology, suicidal ideations, comorbid medical conditions) and 
insufficient response to earlier outpatient detoxification. 
In general, there are two strategies for the management of withdrawal 
symptoms: (1) suppression of withdrawal by a cross-tolerant medication (e.g. 
benzodiazepines, or an opioid agonist such as methadone), and (2) decreasing 
signs and symptoms of withdrawal by alteration of another neuropharmacological 
process (e.g. alfa adrenergic agonists such as clonidine or lofexidine). Either one 
or both strategies together may be used to manage withdrawal syndromes 
effectively. In order to suppress withdrawal with cross-tolerant medication, a 
longer-acting medication typically is used to provide a milder, controlled 
withdrawal and involves dose tapering. 
Through the use of opioid antagonists, i.e. naltrexone, with or without general 
anesthesia, opiate detoxification can be accelerated and completed within 24-72 
hours, respectively. A recent review found that it was impossible to draw any 
conclusions about the long-term effectiveness, or the cost-effectiveness, of 
withdrawal induced by opioid antagonists under heavy sedation or anesthesia 
(Gowing et al., 2002a). Although rapid detoxification with the use of opioid-
antagonists combined with α-2 (adrenergic) agonists is considered as feasible 
(Gowing et al., 2002b), the anesthesia-managed approach remains experimental 
(Gowing et al., 2002a).  
 
1.4. Relapse prevention strategies 
 
In general, treatments aimed at changing addictive behaviors involve both 
“knowing how”, which is related to self-control and adopting skills, and “wanting 
to”, which is related to motivation. Changing addictive behaviors is the main 
treatment goal in both cure and care. To facilitate change, a broad spectrum of 
psychosocial and pharmacological treatments has been developed. Several 
psychosocial treatments have been associated with positive treatment outcomes. 
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In addition, there are also evidence based pharmacological agents available. 
Because addiction is a condition with a biopsychosocial etiology, pharmaco-
therapy should be part of an integrated treatment approach, which also addresses 
psychosocial elements (Health Counsel of the Netherlands, 2002a, p. 27). 
Several psychosocial and pharmacological treatments are considered to be 
effective in the treatment of substance use disorders (e.g. American Psychiatric 
Association, 1995, p. 2; Carroll, 1998; Miller & Wilbourne, 2002; National Institute 
on Drug Abuse, 1999; Van den Brink & Van Ree, 2003).  
A number of reviews have demonstrated the positive effect of the Community 
Reinforcement Approach (CRA; Finney & Monahan, 1996; Holder et al., 1991; 
Miller et al., 1995, 1998 and 2003; Miller & Wilbourne, 2002). CRA and CRA 
components have been placed high on the list of strongly supported treatment 
methods for alcohol problems. These outcomes provide consistent empirical 
evidence for the value of CRA. 
A short overview based on Carroll (1998, p. 8-12) is provided in the next 
section to illustrate several psychosocial interventions used in the management of 
addiction.  
 
1.4.1. Psychosocial relapse prevention strategies 
Psychosocial relapse prevention treatments are conducted in inpatient or 
residential programs, such as therapeutic communities, and in outpatient 
programs, such as intensive or minimal interventions. The contents of these 
programs are often based on interventions such as Twelve-Step Facilitation, 
Interpersonal Psychotherapy, Motivational Interviewing and Cognitive Behavioral 
Therapy (Project MATCH Research Group, 1997). These general programs are 
used to treat a variety of substance use disorders. 
 
Twelve-Step Facilitation 
Twelve-Step Facilitation (Nowinski et al., 1992, 1994) views problematic 
alcohol use as a behavioral, cognitive, spiritual and medical disease. In general, 
Twelve-Step Facilitation consists of a brief, structured, and manual-driven 
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approach provided on an individual basis in 12 to 15 sessions, to facilitate 
recovery from substance use disorders. Next to abstinence, a principal objective 
of Twelve-Step Facilitation is to mobilize the participant's commitment to and 
participation in Alcoholics Anonymous or related fellowships for other substances 
than alcohol. Participants are stimulated to attend self-help meetings and to 
document their Alcoholics Anonymous attendance and participation (Project 
MATCH Research Group, 1993). 
The disease-model approaches consider substance use disorders as a 
disease that can be controlled but never cured. The emphasis in these disease 
model approaches is on patients' loss of control over substance use and other 
aspects of their lives. Similarly, the major change agent in disease-model 
approaches is involvement with Alcoholics Anonymous and learning to cope with 
nearly all drug-related problems by going to meetings or deepening involvement 
with fellowship activities. 
Twelve-Step Facilitation may also be clinically useful (Project MATCH 
Research Group, 1997) in combination with additional pharmacotherapy such as 
disulfiram aimed at total abstinence (Carroll et al., 2000). 
 
Interpersonal Psychotherapy 
Interpersonal Psychotherapy (Rounsaville & Carroll, 1993), also known as 
Supportive-Expressive Therapy (Luborsky, 1984), “is based on the concept that 
psychiatric disorders and substance dependence are related to disorders in 
interpersonal functioning, which may be associated with problems such as 
substance use disorders. Interpersonal Psychotherapy has four distinct 
characteristics: (1) adherence to a medical model of psychiatric disorders, (2) 
focus on patients' difficulties in current interpersonal functioning, (3) brevity and 
consistency of focus, and (4) use of an exploratory stance by the therapist that is 
similar to that of supportive and expressive therapies” (cited from Carroll, 1998, p 
11). In the more exploratory short-term dynamic Interpersonal Psychotherapy 
approaches, substance use is viewed as a symptom of other difficulties and 
conflicts. Interpersonal Psychotherapy focuses less directly on the use of 
substances than suggested in concurrent psychosocial therapies. Interpersonal 
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Therapy can be combined with pharmacotherapy (c.f. Weissman, Klerman, 
Prusoff, Sholomskas, & Padian, 1981) and may be both viable and effective in the 
treatment of substance use disorders (Carroll, Rounsaville & Gawin, 1991).  
 
Cognitive Behavioral Therapy   
Cognitive Behavioral Therapy encompasses a wide range of cognitive and 
behavioral treatments, all of which perceive substance dependence to be 
understandable in terms of its antecedents and consequences (Carroll, 1998, p. 
8). Cognitive Behavioral Therapy includes the Community Reinforcement 
Approach (CRA; Meyers & Smith 1995), Beck's Cognitive Therapy (Beck et al., 
1991) and Marlatt’s Relapse Prevention (Marlatt & Gordon, 1985). 
Cognitive therapy "is a system of psychotherapy that attempts to reduce 
excessive emotional reactions and self-defeating behavior by modifying the faulty 
or erroneous thinking and maladaptive beliefs that underlie these reactions" (Beck 
et al., 1991, p. 10, cited from Carroll, 1998, p. 9). In cognitive therapy, the 
therapist's approach to focus on cognitions is Socratic and based on leading the 
patient through a series of questions. The treatment is believed to reduce 
substance use by helping the patient change the way he or she thinks. 
Cognitive Behavioral Therapy “differs from cognitive therapy primarily in terms 
of the emphasis on identifying, rather than understanding and changing, 
underlying beliefs about the self and the self in relationship to substance 
dependence as a primary focus of treatment. In Cognitive Behavioral Therapy, 
initial strategies stress behavioral aspects of coping (e.g., avoiding or leaving the 
situation, distraction, etc.) rather than "thinking" one's way out of a situation” 
(Carroll, 1998, p. 9). The accent is on self-control strategies, to recognize the 
processes and habits that underlie and maintain substance use and determine 
what can be done to change them. 
Cognitive Behavioral Therapy can be combined with pharmacotherapy (Carroll 
et al., 2004; Mattick et al., 2003). When used in combination with medication, the 
scope of Cognitive Behavioral Therapy interventions expands to include a focus 
on enhancing medication compliance, such as medication response and 
monitoring compliance during sessions. There is evidence that Cognitive 
CRA and NTX in the treatment of addiction 
 
 28 
Behavioral Therapy is an effective treatment to modify substance-using behavior 
(Baker et al., 2001; Carroll, 2000, Covi et al., 2002, Mattick, Ward & Hall, 1998; 
Maude-Griffin et al., 1998; Monti, et al., 1997; Rigter et al., 2004). 
 
Motivational Interviewing 
As outlined, Motivational Interviewing is a crucial intervention to use at the 
beginning of treatment and can subsequently be employed through the whole 
treatment. In the course of Motivational Interviewing, the subject may start 
pharmacotherapy to increase the probability that abstinence can be maintained 
(De Wildt et al., 2002). By using Motivational Interviewing techniques, the patient 
shifts through distinct stages (pre-contemplation, contemplation, preparation and 
action), where, in the preparation stage, plans can be made for additional 
pharmacotherapy when necessary or indicated. Motivational Interviewing can also 
lead to the application of coping skills training based on Cognitive Behavioral 
Therapy (Marlatt & Gordon, 1985), which maintains that learning and practice of 
specific substance-related coping skills fosters abstinence. There is cumulating 
evidence that Motivational Interviewing is an effective treatment strategy and is 
also cost-effective (Burke, Arkowitz & Menchola, 2003; Dunn, Deroo & Rivara, 
2001; Holder et al. 2000; Rigter et al., 2004). 
 
1.4.2. Pharmacological relapse prevention strategies 
Pharmacological strategies to prevent relapse are not available for every 
substance use disorder. Adequate evidence based pharmacological intervention 
are currently not available for the treatment of cocaine dependence (de Lima et 
al., 2002) or amphetamine addiction (Srisurapanont et al., 2001). However, 
effective interventions are available for alcohol and opioid dependence. The 
pharmacological treatments can be divided into three main strategies (Health 
Counsel of the Netherlands, 2002a): 
1 To diminish the positive reinforcing effects of the substance. This can be 
achieved by the administration of (high doses) of an agonist (e.g. 
methadone), partial agonist (e.g. buprenorphine) or antagonist (e.g. 
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naltrexone) in the treatment of opiate dependence. These agents occupy or 
block the receptor site, thereby discouraging substance use. With cure as the 
treatment goal and relapse prevention of all opioid use as an intermediate 
goal, only opioid antagonists are relevant, i.e. naltrexone. 
2 To reduce craving. Some pharmacological agents have been associated with 
the reduction of craving, such as acamprosate and naltrexone in the reduction 
of alcohol craving; 
3 To initiate an aversive reaction in case substance use is resumed, e.g. 
disulfiram in the treatment of alcohol dependence. 
 
Naltrexone 
For both the treatment of opioid and alcohol dependence, naltrexone appears 
to be an effective treatment. Naltrexone, an opioid antagonist, blocks the intrinsic 
properties of psychoactive substances, which act on the opioid receptor sites by 
competitively occupying these, and thereby promotes abstinence. However, 
despite the demonstrated pharmacological properties, there is limited legitimacy 
for the use of naltrexone in maintenance treatment of detoxified patients with 
opioid use disorders since treatment compliance is generally low resulting in high 
relapse rates (Kirchmayer et al., 2002; Roozen et al., 2002). The induction of 
naltrexone through a rapid detoxification procedure might increase the efficacy of 
naltrexone in a maintenance program (O’ Connor & Fiellin, 2000). 
In the treatment of alcohol disorders it has repeatedly been found that 
naltrexone is more favorable in terms of relapse rates and percentage of drinking 
days than placebo (Roozen et al., 2002). Therefore, naltrexone is regarded as an 
effective adjuvant therapy for alcohol dependence in adults (Bouza et al., 2004). 
 
Acamprosate 
Another treatment option for patients with alcohol problems is acamprosate 
(see also Bouza et al., 2004). Acamprosate is thought to reduce craving that is 
often experienced by patients with alcohol use disorders. The specific mechanism 
of action is not fully understood, because it is a small flexible molecule with 
similarities to several neuro-active amino acids and is used in high doses 
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(Littleton & Zieglgansberger, 2003). All these factors suggest that it may have 
multiple actions. The effects of acamprosate seem to be that it inhibits the 
glutamatergic transmitter system involved in both the negative reinforcing effects 
of alcohol and the conditioned "pseudo-withdrawal" associated with cue-induced 
relapse (Littleton & Zieglgansberger, 2003). 
Reviews have yielded strong evidence that acamprosate is more effective than 
placebo (Garbutt et al., 1999; Miller & Wilbourne, 2002). This finding was also 
replicated in a recent trial (Kiefer et al., 2003) investigating the single and 
combined effects of acamprosate and naltrexone in alcohol dependence. It has 
been shown that the addition of naltrexone to acamprosate is more effective than 
placebo or acamprosate alone. 
 
Disulfiram 
Controlled clinical trials have shown inconsistent results regarding the 
effectiveness of disulfiram. Disulfiram inhibits aldehyde dehydrogenase, leading 
to elevations in acetaldehyde levels after ethanol consumption. This increase in 
acetaldehyde levels produces adverse experiences as a result of a variety of 
physiological effects, such as nausea, hypotension and flushing.  
A recent review yielded limited evidence for the use of disulfiram for the 
decrease of drinking frequency (Garbutt et al., 1999). There is also little evidence 
for improved continuous abstinence rates (Garbutt et al., 1999). However, 
supervised disulfiram administration might be an effective method to enhance 
compliance, which is often poor (see Brewer, 1993; Fuller & Gordis, 2004). There 
is also some evidence for the effectiveness of the combination of acamprosate 
and disulfiram in the treatment of alcohol dependence (Besson et al., 1998; Fuller 
& Gordis, 2004; Wilde & Wagstaff, 1997). 
 
Bupropion 
In the treatment of smoking cessation, antidepressant medications (bupropion, 
nortriptyline) have proven to be effective, but the effect size is modest at best - 
just as with the anti-heroin and anti-alcohol medications- (Hughes, Stead & 
Lancaster, 2003). Another possible treatment option for the treatment of nicotine 
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addiction is the use of opioid antagonists such as naltrexone, which may 
attenuate the reinforcing effects of nicotine (David, Lancaster & Stead, 2003). 
 
1.5. Integration of pharmacological and psychosocial treatments 
 
The effect size of most studies of pharmacological interventions is rather modest, 
partly because of limited treatment compliance. In the early history of medicine, 
Hippocrates (c.460-377BC) admonished physicians to be alert to patients’ 
compliance with medical regimens (Hippocrates, On Decorum, translation, 1923). 
Unfortunately, current pharmacological interventions still generally suffer from 
poor compliance (McLellan & O’Brien, 1996). 
To increase the effect sizes of pharmacological agents, efforts to improve 
compliance are pivotal in substance abuse treatment (McLellan & O'Brien, 1996). 
Consequently, research should pursue improvement of sustained release 
formulation or longer-acting forms of these agents, such as implants or injection 
depots. In the search for new strategies, a new viable treatment option may be 
the use of vaccines, by inducing drug-specific antibodies in the bloodstream that 
bind to the drug of abuse and prevent its entry into the brain (Kantak, 2003). But 
even this innovative approach is only likely to work with individuals who are highly 
motivated to stop using drugs altogether and as part of a comprehensive 
treatment program (Kantak, 2003). Integrated treatments have, therefore, become 
an important focus for clinical research and will probably include biological, 
behavioral, and social-context components (Leshner, 1997).  
In this respect, several new and evidence-based psychosocial interventions 
have been mentioned in the contemporary literature (Miller et al., 2002) in which 
pharmacological components can be integrated to create a multi-modal treatment 
package (Carroll, 1998; Carroll et al., 2004; O’Malley 1996). For example, nicotine 
replacement therapy combined with additional support has been promulgated in 
the contemporary literature (Hughes et al., 1996; Law & Tang, 1995; Mooney & 
Hatsukami, 2001).  
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Despite the use of combined and integrated forms of pharmacotherapy and 
psychotherapy in general addiction treatment services, the added value of these 
combinations is not well studied (Kranzler, 2000). Combination therapy in the 
treatment of alcohol dependence has been less successful with no obvious 
advantages or added value of psychosocial interventions when combined with 
acamprosate (De Wildt et al., 2002). In addition, the evidence is scant with regard 
to the type and intensity of psychosocial treatment that should be combined with 
the medication to optimize its efficacy (Pelc et al., 2002; Soyka et al., 2002). 
 
1.6. The Community Reinforcement Approach as an integrative 
treatment 
 
A form of treatment that creatively combines psychosocial and pharmacological 
approaches is the Community Reinforcement Approach (CRA). In search of an 
innovative approach to reduce an individual’s alcohol problem and departing from 
Skinner’s operant learning paradigm, Nathan Azrin and George Hunt composed 
this treatment form in the early seventies. CRA is propagated as an integrated 
therapy that focuses on the reinforcement of an alternative lifestyle that is more 
rewarding than substance use  (Meyers & Smith, 1995). The treatment stratifies 
environmental contingents to pursue non-substance-using behavior, by 
enhancing and supporting the subject’s ability to cope with several major life-
areas. Primarily, CRA does not address directly internal psychological changes, 
but focuses on environmental contingencies. The first trials were conducted to 
assess the efficacy of their intervention (e.g. Hunt & Azrin, 1973).  In the second 
CRA trial (Azrin, 1976), disulfiram was added to the CRA treatment. In addition, a 
concerned significant other was utilized to monitor compliance with the 
medication regimen. The involvement of a concerned other was also utilized to 
influence the subject to increase both the quality of life of the subject and the 
concerned significant other. The form that is best known now is the one described 
by Meyers and Smith (1995). They introduced aspects from Motivational 
Interviewing (Miller & Rollnick, 1992) and coping skills (e.g. Marlatt & Gordon, 
General introduction 
 
 33   
1985). CRA pays attention to coping skills (e.g. substance refusal skills), social 
skills (e.g. communication skills), vocational skills (e.g. job-club), reciprocal marital 
counseling (e.g. the concerned significant other reinforces non-substance use 
with concomitant behavior which the subject appreciates (and withholds rewards 
when substance abuse occurs), and recreational elements (e.g. leisure time)).  
Stephen Higgins (Higgins et al. 2004) has extended CRA with a formal, 
laboratory controlled contingency management component: tangible or contrived 
reinforcers (vouchers) are provided to initiate and maintain abstinence for cocaine 
dependent individuals. These vouchers are redeemable for items consistent with 
a drug-free lifestyle and are contingent upon the patient’s provision of drug-free 
urine toxicology specimens. 
CRA is regarded to be an effective approach (Miller et al., 1995, 1998 and 
2003; Miller & Wilbourne, 2002). Nevertheless, the use of CRA has been limited 
in general practice. 
 
1.7. Limited dissemination of CRA 
 
As outlined above, CRA is regarded as a multi-modal biopsychosocial treatment, 
which consists of of multiform evidence-based components. Despite the 
description by Meyers and Smith (1995), CRA leads to misconceptions. Many 
researchers consider CRA as an expanding concept consisting of a variety of 
approaches, which causes doubts about the content and method of CRA. For 
example, one of the promoters of CRA often encounters misconceptions, in which 
it is assumed that Higgins’ vouchers are being considered as CRA in and of 
themselves. Other people assume that CRA is similar to Motivational Interviewing 
simply because they hear about getting behavior change without confrontation 
(Smith, 2003). It seems that the variations in the description of the method and 
content of CRA have created confusion about, and a disinterest in, the method 
among many clinicians.  
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Despite the success of CRA, for many years the CRA methodology was only 
accessible to a few researchers (Miller & Meyers, 2002, p. 165). Until a couple of 
years ago there was no CRA manual available with adequate descriptions of the 
approach, and video’s or trained clinicians who organized workshops to promote 
CRA were non-existent (Miller & Meyers, 2002, p. 166). In addition, research 
outside the USA has been virtually absent, which has compromised the 
availability of CRA promoters in Europe. 
Another reason why CRA is hardly applied might be the inclusion of 
interventions such as home visits to search for natural rewarding resources 
contingent on positive environmental reinforcement, to foster abstinence. To 
implement this method in routine practice might be regarded as too time 
consuming and labor intense. Most treatment modalities do not attend to social 
reinforcement of environmental contingencies. 
CRA’s historical development, the inclusion of several therapeutic 
interventions, the intensity and duration, it's reported effectiveness, the 
compatibility with the pharmacological approach and possible misconceptions, all 
speak to the need for scientific evaluation of the concept and its effectiveness for 
the treatment of alcohol, opioid, tobacco and cocaine dependent patients. 
 
1.8. Research Questions  
 
The available evidence and, in contrast, the limited dissemination and 
implementation of CRA in clinical routine practice warrants investigation of CRA. 
Although several reviews have outlined its benefit in terms of the cost-
effectiveness of CRA in the treatment of problematic alcohol using patients (Wolfe 
& Meyers, 1999), studies of the treatment effectiveness of CRA, without a 
contingency management approach (vouchers), for patients with substance 
dependence is rather scant. Another limitation concerns the methodology of the 
seminal conducted studies. Poor methodology with an overestimation of the effect 
might be partially responsible for the initial impressive effects. To our knowledge, 
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most of the reviews regarding the effectiveness of CRA have not appraised the 
effectiveness of CRA when compared to treatments such as usual care, in a 
broad variety of addiction types.  
In addition, current reviews do not address CRA integrated with 
pharmacological agents other than disulfiram or methadone. In the treatment of 
opioid and alcohol use disorders, naltrexone constitutes a viable option, 
compared to other available agents aimed to prevent relapse. In addition, data 
about the effects of CRA combined with naltrexone are absent. Therefore the 
following questions were formulated: 
 
1. Is CRA, with and without pharmacotherapy, effective in the treatment of 
alcohol, opioid, tobacco and cocaine dependence? (Chapters three, five, six, 
and seven); 
2. What is the (incremental) effectiveness of naltrexone in the treatment of 
alcohol and opioid use disorders? (Chapter four); 
3. What is the conceptual and empirical content of CRA? (Chapter two). 
 
1.9. Dissertation outline 
 
In Chapter two, a conceptual and empirical analysis of CRA is given. In 
contemporary literature, the term Community Reinforcement Approach is used for 
an array of interventions. Pertaining to the promise of the many reports and the 
high rankings of CRA in several meta-analyses (Miller et al., 1995, 1998 and 
2003; Miller & Wilbourne, 2002), it seems worthwhile to identify which elements of 
the CRA approach are currently being used. Therefore, the array of interventions 
used within the CRA framework in the contemporary literature is examined and 
outlined. 
In Chapter three a systematic review of the effectiveness of CRA in the 
treatment of alcohol, cocaine and opioid dependence is conducted. The rationale 
is based on the fact that the cost-effectiveness of CRA has placed it high on the 
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list of strongly supported treatment methods for alcohol problems (Wolfe & 
Meyers, 1999). Furthermore, CRA has been applied in the treatment of a broad 
variety of substance use disorders other than alcohol dependence, e.g. cocaine 
and opioid dependence. Nevertheless, systematic reviews or meta-analyses, in 
which the effectiveness of CRA is compared with usual care, are scant. This 
review is conducted within the Cochrane Collaboration Review Group framework, 
with the objective to determine whether CRA therapy is more effective than usual 
care for alcohol, cocaine and opiate addiction.  
In Chapter four another systematic review is conducted to summarize and 
update the evidence on the effectiveness of naltrexone (Gonzalez & Brogden, 
1988) in the maintenance treatment of opioid and alcohol use disorders. 
Systematic reviews and meta-analyses have been published on the effectiveness 
of naltrexone in the treatment of alcohol dependence (Srisurapanont & 
Jarusuraisin, 2005) and naltrexone maintenance in opioid dependent patients 
(Kirchmayer et al., 2003). The review aims to study the effects of naltrexone 
compared to placebo in the maintenance treatment of opioid and alcohol 
dependence and to study the added value of naltrexone when combined with 
psychosocial treatment. 
In Chapter five empirical data are provided concerning CRA combined with 
naltrexone in the treatment of opioid-dependence. In this study, the effects of 
naltrexone maintenance treatment on addictive behaviors and the predictive value 
of psychiatric comorbidity are described, and contrasted with a randomly drawn 
reference group, consisting of patients participating in a standard methadone 
program. 
In Chapter six, the relatively new development of antagonists-accelerated 
opioid detoxification, with or without general anesthesia, is investigated. Following 
naltrexone-assisted detoxification, naltrexone maintenance treatment in 
combination with CRA was tested in the so-called EDOCRA1 study. By means of 
a naturalistic design employing a follow up of 16 months after detoxification, 
addictive behaviors, craving, health, and quality of life are evaluated. 
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In Chapter seven the effects of naltrexone with Transdermal Nicotine Patches 
combined with or without CRA in a smoking population of recovered spontaneous 
pneumothorax patients is explored. Smoking is associated with many serious 
health problems such as cancer and coronary and cerebrovascular heart 
diseases. Another smoking-related condition is spontaneous pneumothorax. 
Preliminary evidence suggests that long-term exposure to cigarette smoke is 
associated with alterations in the responsivity of the endogenous opioid system 
and the hypothalamic-pituitary-adrenal axis that may contribute to the 
development of nicotine dependence (Krishnan-Sarin, Rosen & O'Malley, 1999). 
Several studies have suggested involvement of the opioid system and that 
naltrexone might have an effect on nicotine craving (Brauer et al., 1999, 
Hutchison et al., 1999, Wewers et al., 1998).  
Transdermal Nicotine Patches are used concomitantly to attenuate nicotine 
withdrawal by tapering the nicotine level. These biological interventions are 
integrated in CRA, which focuses on improving the psychosocial conditions of 
patients with substance use disorders by increasing motivation, enhancing 
therapy attendance and skills training. In addition, social support and increasing 
self-efficacy are important contributions for long-term cessation (Breteler, 
Schotborg & Schippers, 1996). The aim of this chapter is to investigate the effects 
and feasibility of this new combination therapy in terms of craving and abstinence. 
Chapter eight provides a concise summary, discusses the results and provides 
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Community Reinforcement Approach in treating 
addiction: a conceptual and historical analysis 





The Community Reinforcement Approach (CRA) ranks high as an effective 
treatment in the management of addictive disorders. CRA treats substance abuse 
behavior by modifying positive reinforcements in the individual’s community context, 
and through behavioral skills training. Which components exactly produce CRAs' 
effectiveness is not fully clear, since the label has been used to cover a variety of 
procedures. This study examines the content of CRA and its development. We 
describe and tabulate components used within the CRA framework as they appear 
in treatment studies. A computerized literature search identified 15 protocols. These 
were unbundled resulting in a broad spectrum of CRA components. Recent studies 
varied in the number of components. The complexity of CRA has obscured the 
mechanism of treatment actions. Dismantling studies to assess the auxiliary value 
of each component, within the CRA framework, are recommended. 
 CRA: a conceptual and historical analysis  
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2.1. Introduction 
 
Since 1973 when Hunt and Azrin (Hunt & Azrin, 1973) introduced the Community 
Reinforcement Approach (CRA), the intervention has been shown to be effective 
according to reviews of the treatment-outcome literature (Finney & Monahan, 1996; 
Holder et al., 1991; Miller et al., 1995, 1998 and 2003; Miller & Wilbourne, 2002). 
CRA considers substance use disorders as behaviors that can be modified by 
positive reinforcement in the individual’s natural environment. According to this 
model, sampling and practicing alternative rewarding activities in the community are 
essential to initiate and maintain abstinence (Schottenfeld et al., 2000). 
Hunt and Azrin based the CRA on the operant learning theory postulated by 
B.F. Skinner (Skinner, 1938). Knowledge of how the environment interacts on the 
organism is essential to manipulate the environmental context of behavioral 
events, as the events themselves cannot be influenced (Hayes, Barnes-Holmes & 
Roche, 2001).  
The reinforcing effect of substance use can interfere with concurrent normal 
reinforcers producing a postponement or omission in the distribution of these 
positive reinforcers. As Hunt and Azrin, state, "pleasant social interactions and 
individual recreational activities cannot be performed satisfactorily, if at all, when 
one is an alcoholic" (Hunt & Azrin, 1973, p. 92). The following consequences of 
substance use have been identified: (1) the negative interference of substance 
use leading to a loss of engaging rewarding activities as a result of a time-out. 
This is caused by the delay in engaging in rewarding activities resulting in a 
decrease of power of these normal reinforcers; (2) The intrinsic reinforcing effects 
of substance use, which have the potential to corrupt, and eventually, to supplant 
the sampling and the performance of rewarding activities. 
Therefore, CRA attempts to modify substance abuse by increasing normal 
positive reinforcement from areas such as vocational, familial and social, to 
compete with the reinforcing effects of substance use (c.f. Azrin, 1976).  
Recent research has confirmed an inverse relationship between substance 
use and substance–free activities (Correia, Benson & Carey, 2005). Reinstalling 
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the reinforcing power of personal activities and manipulating the delay and time-
out of positive reinforcements (Holz & Azrin, 1963) is fundamental in the unifying 
CRA concept. "Consequently, for maximum effectiveness of this time-out 
dimension, the normal reinforcers should be grouped closely together in time, as 
well being of qualitatively great value" (Hunt & Azrin, 1973, p. 92). 
CRA stems from the community mental health approach, which suggests that 
mental disorders are influenced by forces induced in and maintained by the 
community (Hunt & Azrin, 1973). By focusing on environment-organism 
interactions, Hunt and Azrin designated an adaptation of this approach to treat 
alcohol abuse, called "community-reinforcement approach to alcoholism" (Hunt & 
Azrin, 1973, p. 92.). 
Recent CRA versions include social skills training, stress management training, 
cognitive modifications, relapse prevention (Meyers & Smith, 1995), and 
motivational interviewing (Miller et al., 1999a). Moreover, the role of medication in 
CRA has evolved over the years. In the beginning, no medication was involved. 
Later, disulfiram was introduced, and still later, methadone, naltrexone, and 
buprenorphine became part of the treatment. 
CRA has been applied to a variety of substance use disorders other than alcohol 
abuse and dependence, such as cocaine dependence (e.g. Higgins et al., 2003), 
opioid addiction (e.g. Abbott et al., 1998a), and nicotine dependence (Roozen et al., 
accepted). Although almost all studies have aimed at abstinence as the treatment 
goal, other options, like stabilizing and controlling use, i.e. harm prevention, are also 
targeted as a treatment goal. 
Since the original presentation, a variety of protocols on CRA have been 
developed and different manuals have been published. This study aims to identify 
the core components of CRA and investigates whether there is an evolution in the 
content of CRA. This could help in clarifying the active components and their 
mechanisms of change, which is the key to the continued refinement of 
psychosocial treatments (McCaul & Monti, 2003). The objective is to examine and 
outline the array of interventions that have been applied in studies evaluating the 
effects of CRA, and to analyze the components of CRA conceptually and 
historically. 
 CRA: a conceptual and historical analysis  
 
 51   
2.2. Methods 
2.2.1. Search strategy 
A computer search was done on the following databases: Biological Abstracts, 
ERIC, LISA, MEDLINE, OSH, Periodical Abstracts, PsycINFO, SERFILE, 
Sociological Abstracts, EMBASE and CINAHL. All databases were searched from 
the date of commencement of the beginning of each database. The search was 
conducted in March 2002, using the search strategy of the UK Cochrane Center 
(October 1996), based on the first two stages of the Medline search strategy 
recommended in the Cochrane Handbook (Appendix V of Section V) published by 
Dickersin et al. (1994). This was run in conjunction with a specific search that 
included combinations of the following keywords: alcohol abuse, substance 
abuse, drug abuse, alcohol(-) related disorder(s), opioid(-)related disorder(s), 
opiate(-)related disorder(s), cocaine(-)related disorder(s), community 
reinforcement approach, community reinforcement, CRA, disulfiram, 
acamprosate, methadone, heroin, naltrexone and buprenorphine. The selection 
involved a screening of the Cochrane Library, 2002, issue 1, and a relevant 
reference search in all identified articles, manuscripts and chapters about CRA. 
 
2.2.2. Criteria for considering studies 
Types of studies. Randomized controlled trials (RCTs), clinical controlled trials 
(CCTs), matched controlled trails, naturalistic design studies, single-group studies 
and pilot studies were included. To avoid clinical heterogeneity and to prevent 
intervention descriptions that might cause bias, case reports or studies with a very 
small sample size (n < 5) were excluded. We focused on the content of CRA, 
regardless of the effects of the protocols. 
Types of participants. Studies with subjects with alcohol, cocaine and opiate 
abuse or dependence (DSM-IV) between 18 and 65 years of age were included.  
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Types of interventions. Studies that labeled their intervention as CRA were 
included whether or not combined with pharmacological agents (e.g. disulfiram) or 
other operant approaches, such as voucher-based contingency management. 
Treatment-packages based on CRA behavioral components (Azrin et al., 1994), 
which encompass multiple components such as a social-club with 
social/recreational activities (Mallams et al., 1982), reciprocity counseling/behavioral 
marital therapy (Azrin, Naster & Jones, 1973; Azrin, Nunn & Frantz, 1980; Azrin et 
al., 1981), Job Club (Azrin & Besalel, 1980, 1983; Azrin, Flores & Kaplan, 1975; 
Azrin & Philips, 1979; Azrin et al., 1981), family-member involvement (Sisson & 
Azrin, 1986) and vouchers (Higgins et al., 2003) were included. Studies were 
included in which a description and/or reference was given regarding the 
intervention components. 
 
2.2.3. Data extraction 
From the method section of the included studies, data was extracted on CRA 
treatment components. These components were stratified according to type of 
substance, setting, goal of treatment, and pharmacological support (Table 2.1). 
 
2.3. Results 
2.3.1. Studies identified 
The search identified 66 references via PsycINFO, 90 references via 
MEDLINE, 24 via EMBASE and 2 via CINAHL. Consulting the additional 
databases, Biological Abstracts, ERIC, LISA, OSH, Periodical Abstracts, 
SERFILE, Sociological Abstracts and the Cochrane database, yielded 97 different 
references. After deleting duplicates from all the databases consulted, 167 unique 
references remained. 
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The first selection was based on titles, keywords and abstracts, and resulted in 
selecting 26 empirical studies in which CRA was (one of) the treatment(s) and 
rejecting 141 studies. 
Five of the rejected empirical studies reported on Community Reinforcement 
and Family Training (CRAFT). CRAFT, focusing on family members, was 
developed on the assumption that concerned others can help to persuade 
resistant substance abusers to seek treatment (Meyers, Miller & Smith, 2001). 
Because of this different focus, CRAFT studies were not considered to be within 
the scope of this conceptual analysis and were thus discarded. 
Of the selected 26 studies, three studies were considered as case reports or 
case studies and were excluded (Budney et al., 1991; Fix, 2001; Vick & Houden, 
1991). 
Three additional studies were identified through reference checking (Azrin et al., 
1994, 1996; Mallams et al., 1982). Thus 26 empirical CRA studies remained. These 
26 studies were pared down further as follows. 
Three studies (Higgins et al, 1995; 1997; 2000(b)) were follow-up studies of 
earlier publications and reported on the same treatment protocol (Higgins et al., 
1993; 1994; 2000(a)). Two studies reported on the same trial in substance 
abusers (Azrin et al., 1994, 1996) and another four studies reported on the same 
two alcohol trials (Miller et al., 1992; Miller et al., 2001a,b) and homeless people 
(Smith et al., 1998; Smith & Delaney, 2001). The study of Abbott et al. (1999) was 
based on the same data-set as Abbott et al. (1998a), comparing subjects who 
had entered a program with or without methadone as transfers from other 
community methadone programs without the use of CRA and was therefore 
excluded. The study on AIDS risk behavior (Abbott et al., 1998b) was based on 
Abbott et al. (1998a). Both were counted as one study. Miller et al. (2001a,b) 
consisted of 2 complementary chapters (2 search hits) and were therefore 
considered as one trial in this conceptual analysis. The study of Mallams et al. 
(1982) evaluated only one CRA aspect (social club) and was discarded. 
Additionally, the alcohol study from Miller et al., (1999b) conducted on Native 
Americans, at the Na'nazhoozhi Center in Gallup, New Mexico, blended CRA with 
motivational interviewing, and traditional native spirituality (Miller, 2003) and was 
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therefore left out in this analysis. At the end of this process, 15 studies containing 
distinctive CRA treatment protocols were included. 
 
2.3.2. Study characteristics 
Alcohol. Six studies dealt with CRA in alcohol patients (Azrin, 1976; Azrin et 
al., 1982; Hunt & Azrin, 1973; Kalman et al., 2000; Miller et al., 2001a,b; Smith et 
al., 1998). The first two studies, which were the seminal studies for CRA as a 
treatment modality, were inpatient studies (Azrin, 1976; Hunt & Azrin, 1973). 
These were followed by an outpatient study (Azrin et al., 1982). The alcohol study 
carried out by Miller et al. (2001a,b) included two sub-groups: (1) disulfiram-
eligible and (2) disulfiram-ineligible subjects. One alcohol study dealt with 
homeless alcohol-dependent subjects (Smith et al., 1998). Finally, one study 
reported on sociopathic alcoholics (Kalman et al., 2000). 
Cocaine. Four studies (Higgins et al., 1991, 1993, 1994, 2000a) compared the 
effects of CRA with contingent and non-contingent ‘incentives’ on abstinence in 
the treatment of cocaine. The study of Higgins et al. (1994) investigated CRA 
without ‘incentives’.  
Opioids.  Three studies dealt with the management of opioid addiction. One 
study (Bickel et al., 1997) evaluated the effect of a buprenorphine dose-taper 
combined with CRA and ‘incentives’. Furthermore, one study investigated the 
effects of CRA in a rapid detoxification procedure and the effects of CRA 
combined with naltrexone maintenance aimed at abstinence (Roozen et al., 1997; 
see also Roozen et al., 2003). Another study (Abbott et al., 1998a) investigated 
the effects of CRA in a methadone maintenance program. 
Multiple substances. Two studies focused on multiple substance use 
disorders. One study investigated CRA in a population with an opiate as well as a 
cocaine addiction (Schottenfeld et al., 2000). The study carried out by Azrin et al. 
(1994, 1996) included subjects with different substance use disorders. 
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2.3.3. Treatment protocols and manuals 
The treatment methods in the early studies (Azrin, 1976; Azrin et al., 1982; Hunt 
& Azrin, 1973) constitute the initiation of CRA and can be considered as unique 
protocols. Because of overlap, we considered the treatment method described in 
Azrin, 1976 and Hunt & Azrin, 1973 as complementary to Azrin et al. 1982 (Azrin et 
al., 1982, Miller, 2001, p. 11). We considered Azrin et al. (1994) as a unique 
protocol. Many of the other studies described their treatment protocols rather briefly 
and referred basically to published manuals. The manuals that we found are those 
of Meyers and Smith (1995) and Budney and Higgins (1998). 
Four studies referred to Meyers and Smith (1995) and were therefore 
considered as one group (Abbott et al., 1998b; Smith et al., 1998; Kalman et al., 
2000; Roozen et al., 1997). The interventions conducted by Higgins et al. (1991, 
1993, 1994, 2000a) were based on the manual by Budney and Higgins (1998). 
The CRA protocol of the study on opioids (Bickel et al., 1997) was based on 
Higgins et al., (1993), which is in turn connected to the cocaine manual (Budney 
& Higgins, 1998). The CRA description of Schottenfeld et al., 2000) refers 
explicitly to this cocaine manual and was also combined into one group. 
Eventually, 6 unique treatment protocols, presented as CRA, were included in this 
analysis (Table 2.1). 
 
2.3.4. Treatment components 
Studies differed in the number and the kind of interventions that they included as 
part of CRA. Some components were described as part of a more encompassing 
technique that is compartmentalized in our analysis. Relapse prevention, being a 
core element in the Meyers and Smith (1995) approach, incorporates components 
such as functional analyses, self-management planning, use of a significant other 
(i.e. early warning system), refusal training, problem solving, and cognitive 
modification. A functional analysis identifies triggers of potential high-risk situations 
and pleasurable non-substance using behaviors (Meyers & Smith, 1995). 
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Additionally, the procedure refers also to problem solving skills to introduce 
pleasurable activities that may replace substance-using behavior (Smith & Meyers, 
2001, p. 35). From that perspective, there is an overlap with self-management 
planning, which focuses also on replacement of high-risk situations, by rearranging 
the environment into low-risk or safe situations (Budney & Higgins, 1998). 
Behavioral skill training (Meyers & Smith, 1995) covers a variety of components 
such as self-management planning, refusal training, problem solving, 
communication training, and cognitive modification. 
Some components were not considered to be part of usual CRA per se (e.g. 
urine analysis review, i.e. progress graphs; Budney & Higgins, 1998; independence 
training; Meyers & Smith, 1995).  
Unraveling the descriptions and reviewing the manuals and protocols resulted in 
the identification of the following 18 more or less discrete CRA components: 
 
1. A functional analysis primarily examines the antecedents (external 
stimulus, cognitive reaction and concomitant affect) and consequences of 
a specific behavior of interest, such as substance abuse or the 
consumption of alcohol in specific potential high-risk situations (Azrin, 
1976). In addition, CRA also focuses on a secondary functional analysis, 
which attempts to analyze pleasurable non-substance related behaviors 
(Meyers & Smith, 1995). Two CRA functional analysis forms have been 
developed: for drinking behavior (Meyers & Smith, 1995, p. 34-35) and for 
non-drinking behavior (Meyers & Smith, 1995, p. 38-39). 
2. The self-management planning (Budney & Higgins, 1998, p. 63) or the 
related stimulus control procedure (e.g. Azrin et al., 1994; see also Azrin 
et al., 2001) addresses external stimulus situations that are precursors to 
drug use and high-risk social situations, to increase the amount of time 
spent engaging in drug incompatible and pro-social activities.  A 
comprehensive Risk-List, regarding situations, persons and places 
associated with substance abuse and similarly situations incompatible or 
non-associated with drug use is created (Safe-List). Subsequently, a 
Daily Planner Recording Form is utilized to schedule these non-drug-
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associated activities for the next day. In addition, the treatment plan is 
governed by assessment through the Happiness Scale and the Goals of 
Counseling Form (Smith & Meyers, 2001, p.44-47). 
3. The contingency management with vouchers (Higgins et al, 2003) 
encompasses a reinforcement procedure in which points can be earned 
as rewards for non-using. Evidence is presented by examining the urine 
specimens collected. Earned points can be exchanged for retail items or 
services in the community. 
4. Involvement of the significant other (Azrin 1976, Azrin et al., 1982), often 
a partner, spouse or friend to enhance compliance and adherence in 
treatment including pharmacological support, e.g. medication assurance 
procedure (Azrin 1976), and to create a monitoring system, e.g. early 
warning/mood monitoring (Azrin, 1976). Additionally, assistance can be 
obtained from the significant other to promote non-substance related 
activities, session attendance, providing transportation, reminders, and 
supervising assigned home practice (Azrin et al., 1994). 
5. To address the adherence of a medication regime, CRA studies used a 
disulfiram or medication assurance procedure (Azrin, 1976, Azrin et al., 
1982). Azrin added motivational procedures and psycho-education to 
improve adherence. Meyers and Smith (1995) enumerate ten advantages 
of being on disulfiram. A monitor ensured that daily doses of the 
prescribed medication were dispensed and used, to establish an 
antabuse habit (Azrin, 1976). The study of Azrin et al. (1982) added 
techniques by assisting the participant specifically to take a dose during 
the session. More recent studies incorporate agents including 
methadone, naltrexone and buprenorphine. 
6. To observe subjects’ vocational, recreational activities, and social 
interactions with spouses, partners and family to generate and improve 
existing environmental contingencies, home visits (Hunt & Azrin, 1973) can 
be made. 
7. Job-finding or vocational counseling (Azrin, 1976; Hunt & Azrin, 1973) is 
employed to realize a satisfying, gainful employment or career activity, 
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which might be important to achieve and maintain abstinence. The 
procedures are based on those outlined in Azrin and Besalel’s Job Club 
Counselor’s Manual (1980). An early study on job-finding (Jones & Azrin, 
1973) demonstrated that offering financial incentives to the public to 
report job openings that resulted in placement produced substantially 
more job placements than using employment agencies and other 
standard services, at about 20% of the cost.  
8. The goal of a social club, including social counseling (Hunt and Azrin, 
1973) or social club component of CRA (Meyers & Smith, 1995, p. 5) is to 
increase subjects’ skill in handling interpersonal situations so they 
experience more positive reinforcement and less negative, aversive effect 
from social interactions (Monti et al., 1989). The social club (Azrin, 1976) 
gives subjects a practical opportunity to develop and practice new social 
skills and to create recreational activities in a non-threatening drug or 
alcohol free environment, similar to the one outlined by Mallams et al. 
(1982). 
9. A related intervention, although not per se applied in a formal created 
context such as a social club, is social/recreational counseling to develop 
satisfying social and recreational activities that compete with alcohol use 
and support sobriety. The development of potentially reinforcing activities 
that subjects are interested in pursuing and creation of a list of persons 
who might participate in these activities is pivotal. Specifically, finding at 
least one safe (non-substance using) person has priority. However, some 
individuals have impaired access to recourses associated with non-
substance related activities. Therefore Reinforcement-Access Counseling 
(Hunt & Azrin, 1973) was implemented to facilitate engagement (Priming) 
into positive, rewarding behavior (see also Budney & Higgins, 1998, p. 
42). Also a buddy (Azrin, 1976), an abstinent former patient as a peer-
advisor, can be implemented for participants with an impaired social 
network. Time management is introduced to plan and schedule events 
and activities so that little high-risk time is available. Planning and 
scheduling activities increase the likelihood that subjects will follow 
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through with treatment goals and activities. Azrin et al. (1994) added 
Behavioral Contracting to stimulate reinforcement contingent on drug 
incompatible activities (Azrin et al., 1994). Behavioral contracting or direct 
reinforcement (see also Contingency management) consisted of 
establishing responses such as focusing on employment (e.g. Azrin & 
Besalel, 1980, 1983), money management, and accompaniment to social 
activities by the spouse (i.e. specified on a Safe-List). The amount of time 
spent in Safe-Activities is monitored and reinforced.  
10. In a specially devised form of relaxation training (Urge Control Procedure; 
Azrin et al., 1994; see also Azrin et al., 2001) subjects are taught to 
interrupt proprioceptive sensations (internal stimuli), urges, thoughts, and 
incipient actions associated with substance using behavior, and to 
replace these thoughts and sensations by competing thoughts and 
relaxation (e.g. Azrin, Nunn & Frantz, 1980). 
11. Drink or substance refusal training (Azrin et al., 1982), is considered as a 
form of communication training in which participants are trained to be 
consistent about refusing alcohol or drugs, without making it into an issue 
(Sisson & Azrin, 1989).  
12. Problem-prevention rehearsal (Azrin, 1976) or problem solving (D’Zurilla 
and Goldfried, 1971) is employed to teach strategies for handling daily 
hassles related to substance abuse (c.f. Azrin et al., 1994).  
13. According to Miller (2001, p.22) motivational counseling was introduced 
by Azrin et al. (1982) to promote treatment retention. Motivational 
counseling encompassed an interview (Inconvenience Review Checklist) 
to capture salient reasons for treatment engagement and enhancement of 
self-motivation (i.e. Annoyance Review; Azrin et al., 1994) and to set 
positive expectations in social interactions with the participants. 
14. To foster abstinence for an agreed-upon, limited time period, sobriety 
sampling (Azrin et al., 1982) was introduced. The process of negotiating 
is to settle upon an intermediate goal that appears to be a challenge, but 
one that is obtainable (see Miller & Page, 1991).  
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15. To increase positive communication between family members and to 
improve family relationships, communication training can be applied. The 
Perfect Relationship Form (Smith & Meyers, 2001, p. 57) is designed to 
explore the individuals' skill level. Another way to re-establish a 
relationship that favors pleasant events is to utilize the Daily Reminder to 
be Nice Form (Sisson & Azrin, 1989, p. 254-255; Meyers & Smith, 1995, 
p. 179). Three main communication procedures, to be used in family 
communication at home, were also modeled and practiced during session 
(Azrin et al., 1994; see also Azrin et al., 2001). These interventions 
include Reciprocity Awareness, Annoyance/Anger Prevention and 
Positive Request Procedure (Azrin et al., 1994). 
16. Related to communication training, techniques to resolve marital conflicts 
arising from unrealistic expectations or attempts to control a partner's 
behavior through aversive means and inadequate communication were 
also developed. This focus is designated as relationship counseling 
(Budney & Higgins, 1998) or reciprocal relationship counseling (Azrin, 
Naster, Jones, 1973; Stuart, 1969) or behavioral marital/family therapy 
(Azrin, 1976; Hunt & Azrin, 1973) and also includes an early warning 
system (Azrin, 1976). This technique aims to enhance functioning as a 
marital partner, and makes substance abuse incompatible with the 
relationship. To explore the current state of happiness with the partner a 
Relation Happiness Scale (Azrin, Naster & Jones, 1973, p. 370) and a 
Perfect Relationship Form is used (Smith & Meyers, 2001, p. 57). To 
provide couples with examples of types of 'Relationship-Related Activities' 
a specific form developed by Azrin et al (1973, p. 371) can be 
administered. To resolve disagreement between the couple, a Reinforcer 
Sampling Principle (Ayllon & Azrin, 1968) can be employed. 
17. Through cognitive modification the sampling of a rewarding lifestyle can 
be promoted (Miller & Meyers, 2001, pp.168). Cognitive modification is 
mentioned in the manual of Meyers and Smith (1995). Negative cognitive 
patterns lead to strong mood disturbances and anxiety, which in turn 
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compromise lifestyle development (see Meyers & Smith, 1995, p. 117-
119). 
18. To counter the increasing prevalence of HIV and Hepatitis B and C 
among injection drug users, interventions have been developed aimed at 
the reduction of risk-taking behavior (HIV/ AIDS prevention) such as 
injection drug use and high-risk sexual behavior (Abbott, 1998a). 
 
2.3.5. Evolution of CRA 
This study was not intended to evaluate the methodology and outcome of 
CRA. Elsewhere we concluded from such a review that CRA is more effective 
than treatment as usual when related to number of drinking days in subject with 
an alcohol use disorder. Moderate evidence is available that CRA with disulfiram 
is more effective related to number of drinking days and there is no difference for 
continuous abstinence. Furthermore, there is strong evidence that CRA with 
preferably abstinence-contingent incentives is more effective with regard to 
cocaine abstinence. Finally, there is limited evidence to support that CRA with 
incentives is more effective for opioid detox programs, and in methadone 
maintenance programs (Roozen et al., 2004). 
In Table 2.1 the six identified CRA treatment protocols are ordered according 
to their year of publication and according to the CRA components they contain. 
The number of components of each protocol has been counted and is summated.  
There is an increase in the number of components in the three seminal alcohol 
studies from 7 through 11 to 15, respectively, followed by an increase to 12, 15 
and 17 in the last three groups of studies (Table 2.1). 
In general, CRA is combined with a broad variety of pharmacological 
interventions (e.g. disulfiram, naltrexone, buprenorphine and methadone) in the 
treatment of a wide range of (multiple) substance use disorders. The first studies 
were aimed at stable abstinence, but CRA is currently also being employed in 
pursuit of stabilization and harm minimization (Abbott et al., 1998a,b). CRA has 
for the most part been applied in an outpatient setting. 
 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































This conceptual and historical analysis of the components of CRA demonstrates 
that there has been a gradual increase in the number and content of treatment 
components applied in CRA-studies. The underlying operant reinforcement 
approach has been expanded to include new components over time, such as 
sobriety sampling, motivational counseling, cognitive modification, and skills 
training. 
In general, CRA encompasses interventions aimed at behaviors that can be 
strengthened or weakened by their consequences (e.g. by having a subject 
participate in a rewarding activity) and interventions addressing the environment, 
such as an important significant other. Although CRA does not a priori endorse 
skills training, the CRA philosophy may assess the lack of necessary behavioral 
strategies and can govern the development of these coping-skills chosen from a 
menu of options or toolbox (Miller & Meyers, 2001, p. 169). The core and unifying 
principle is operant reinforcement (Skinner, 1938) and entails rewards that are 
consistently implemented contingent on defined stimuli in a broad variety of life 
areas. 
Several reviews have shown that CRA packages are effective (Miller et al., 
1995, 1998 and 2003; Miller & Wilbourne, 2002; Roozen et al, 2004). 
Nevertheless, the content of the included CRA studies varies substantially. The 
identified protocols sometimes use different terms (e.g. reciprocal relationship 
counseling or behavioral marital/family therapy) to cover comparable 
components. Consequently, it seems viable that the complexity, diverse content, 
and different terms used within CRA may have caused confusion, which 
negatively affects the likelihood of adopting CRA in routine practice. 
This lack of consistency has also obscured the isolation of active components 
of CRA, resulting in a dearth of evidence about how CRA actually works. Some 
components have been highlighted individually or have been the subject of 
dismantling research. Some examples include a social-club with social / 
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recreational activities (Mallams et al., 1982), reinforcement of non-drug-related 
social, vocational, and recreational activities (Schottenfeld et al., 2000), 
reciprocity counseling (Azrin et al., 1973), Job club (Azrin, Flores & Kaplan, 1975; 
Azrin & Philips, 1979; Azrin et al., 1981), concerned other involvement and CRA 
pharmacotherapy–compliance procedure (Azrin et al., 1982; Sisson & Azrin, 
1986), role of disulfiram within CRA (Miller et al., 2001ab) and incentives (Higgins 
et al., 2003; Jones & Azrin, 1973). Evidence about which components, and under 
which condition may be crucial to efficacy, let alone the differential weight of the 
combined components, is scant. There is an urgent need to establish a simplified 
and economical CRA, defined and driven by a unifying operant reinforcement 
framework. 
In several trials, CRA has been employed in concert with a formal contingency 
management (voucher) component. The program was designed to maintain the 
power of contingencies, by managing the sampling, frequency and accuracy of 
administered and implemented contingencies in the patients' own community 
(Higgins, 2003). The success of operant reinforcement principles in the treatment 
of substance use disorders has been extensively illustrated (Higgins & Silverman, 
1999; Higgins et al., 2003, Higgins, Heil & Plebiani Lussier, 2004). Nevertheless, 
the effects of voucher-based incentives often slowly dissipate after 
discontinuation. The effectiveness in the long term is probably dependent on the 
degree of non-substance abuse related reinforcement that occurs naturally in the 
community. 
Studies of CRA show an increase in the inclusion of pharmacological agents. 
Agents such as buprenorphine, disulfiram, methadone and naltrexone directly 
compete with positive reinforcement induced by the use of alcohol and illicit 
substances. For instance, disulfiram therapy acts as a punisher of drinking and 
punishment is a behavioral process. “The efficacy of disulfiram appears to be at 
least as much behavioral as pharmacological” (Higgins, 2002). Another example 
is the prescription of naltrexone in alcoholics and opioid addicts, resulting in a 
reduction of the reinforcing properties of alcohol and heroin. 
The present analysis has several limitations. The first limitation concerns the 
accuracy of the study details provided in Table 2.1. These details were derived 
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from the treatment descriptions explained in the method section of the published 
CRA papers. In general, these descriptions are brief, whereas a few components 
are explicitly mentioned, followed by a reference to one of the CRA manuals. 
Moreover, the differential weight of each component in the program was unclear. 
Furthermore, treatment descriptions might refer to procedures that were not 
necessarily attached to the CRA philosophy. 
A second limitation of this study is the fact that several protocols used different 
terminology to classify more or less the same interventions. Based on 
interpretation we translated the interventions used in each protocol into 
discernible components as listed in Table 2.1. This might have led to some broad 
interventions such as CRA’s relapse prevention becoming difficult to recognize in 
the list of components as reflected in Table 2.1. 
A third limitation is that we omitted family-focused interventions, such as 
Community Reinforcement and Family Training (CRAFT), which are conceptually 
in alignment with the original CRA program. These interventions were developed 
with respect to the belief that family members can make helpful contributions to 
engage resistant substance abusers into treatment (Meyers, Miller & Smith, 2001; 
Meyers et al., 2002; Miller et al., 1999). Because of the primary focus on a 
concerned significant other (such as domestic violence prevention), instead of the 
focus on the individual with a substance use disorder, CRAFT studies were not 
considered within the scope of this conceptual analysis. However, several Azrin 
studies included compatible compliance procedures, and CRAFT studies have 
been also subject of updates and modifications. In our opinion this development 
related to CRAFT legitimizes it’s own conceptual analysis. 
A fourth limitation encompasses the notion that more recent version(s) of CRA 
have technically more components available. But technical availability does not 
necessarily mean that they were all being employed to treat each client. It 
depends on how the components are tailored to individual or population needs.  
It is noteworthy that the evolution of CRA has not highlighted recent influences 
derived from operant research such as behavioral economics (e.g. delay 
discounting; see Bickel & Vuchinich, 2000). Clinical findings, derived from 
behavioral economics, should be incorporated into the CRA approach (Higgins, 
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2003). Studies of discounting or delayed consequences provide a scientific 
account in the prevention and treatment of substance use disorders (Higgins, Heil 
& Plebiani Lussier, 2004, p. 441).  
Based on variables such as addiction severity and treatment stage, the core 
behavioral premises of CRA might be complemented with newer ones and which 
pharmacological agents from a menu of options, under the condition that the core 
CRA treatment remains uniform and parsimonious. The core CRA should be 
established by research aimed at the identification of CRA components, which are 
actually delivered in CRA, and based on whether or not they are having the 
postulated effects on in vivo contingencies. After clarifying the active components, 
research should focus on the mechanisms and mediators of behavioral outcomes 
(Pantalon et al., 2004). Therefore, further studies, which tease apart the 
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A systematic review of the effectiveness of the 
Community Reinforcement Approach in alcohol, 
cocaine and opioid addiction 





The Community Reinforcement Approach (CRA) has been applied in the 
treatment of disorders resulting from alcohol, cocaine and opioid use. The 
objectives were to review the effectiveness of (1) CRA compared with usual care, 
and (2) CRA versus CRA plus contingency management. Studies were selected 
through a literature search of RCTs focusing on substance abuse. The search 
yielded 11 studies of mainly high methodological quality. The results of CRA, 
when compared to usual care: there is strong evidence that CRA is more effective 
with regard to number of drinking days, and conflicting evidence with regard to 
continuous abstinence in the alcohol treatment. There is moderate evidence that 
CRA with disulfiram is more effective in terms of number of drinking days, and 
limited evidence that there is no difference in effect in terms of continuous 
abstinence. Furthermore, there is strong evidence that CRA with ‘incentives’ is 
more effective with regard to cocaine abstinence. There is limited evidence that 
CRA with ‘incentives’ is more effective in an opioid detoxification program. There 
is limited evidence that CRA is more effective in a methadone maintenance 
program. Finally, there is strong evidence that CRA with abstinence-contingent 
'incentives’ is more effective than CRA (non-contingent incentives) treatment 
aimed at cocaine abstinence 
 
 





The Community Reinforcement Approach (CRA) is a biopsychosocial 
multifaceted approach to change a lifestyle of substance abuse. CRA 
acknowledges the role of environmental events and influences in habitual abuse, 
and focuses on alternative positive resources in the social environment (e.g. 
Meyers & Smith, 1995). CRA is based on the theoretical view that substance-
related reinforcers and the relative lack of alternative reinforcers unrelated to 
substance abuse maintain dependence. In this view, the development of 
alternative rewarding social activities that are incompatible with substance use is 
essential to initiate and maintain abstinence (Schottenfeld et al., 2000). 
Emphasis is placed on changing environmental contingencies in the aspects of 
life, such as labor, recreation, family involvement etc., to promote a lifestyle that is 
more rewarding than substance abuse. CRA integrates not only cognitive 
behavioral interventions, but also pharmacological interventions (e.g. disulfiram). 
Another operant method, which is widely applied in CRA research, involves 
voucher-based incentive programs to promote abstinence (Budney and Higgins, 
1998). These vouchers are exchangeable for retail items or services, and can be 
obtained by an individual who has submitted substance-free urine samples.  
Despite promising reports of early research (Azrin, 1976; Hunt & Azrin, 1973) 
on alcohol, CRA has not been widely implemented (Kadden, 2001). Possible 
reasons for this are the labor intensity and the relatively high costs (Barber, 
1992). In spite of these reasons, the cost-effectiveness of CRA (Wolfe & Meyers, 
1999) has placed it high on the list of strongly supported methods for the 
treatment of alcohol problems that are identified in structured reviews of the 
literature on treatment outcomes (Finney & Monahan, 1996; Holder et al., 1991; 
Miller et al., 1995, 1998, and 2003; Miller & Wilbourne, 2002). However, in 
general, these reviews contain only limited number alcohol studies involving CRA, 
mainly based on the early work of Azrin, which compromises assessments of 
effectiveness. Although the most recent review (Miller et al., 2003) contains also 
recent CRA trials. In addition, there seem to be no systematic reviews or meta-
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analyses available in which the effectiveness of CRA, with or without voucher-
based contingency management, is compared with usual care.  
The objective of this systematic review was to evaluate the effectiveness of 
CRA in the treatment of alcohol, cocaine and opioid addiction. Comparisons that 
were made included: 
1. CRA versus usual care; 
2. CRA versus CRA plus voucher-based contingency management; 
3. CRA versus CRA plus pharmacological support. 
 
3.2. Method 
3.2.1. Criteria for considering studies for this review 
Types of studies Only (matched) randomized controlled trials (RCTs) were 
included.  
Types of participants Subjects with alcohol, cocaine and opiate abuse or 
dependence (DSM-IV) between 18 and 65 years of age were included. RCTs with 
subjects whose substance dependence was not the main diagnosis, or whose 
addiction was not seen as a reason for contact, were excluded (e.g. subjects with 
a diagnosis of schizophrenia who also have a substance dependency). 
Types of interventions Only RCTs that applied a behavioral approach based 
on CRA principles were included. RCTs in which only one component of CRA 
was investigated were excluded. RCTs in which a pharmacological agent (e.g. 
disulfiram) was administered, combined with psychosocial treatment based on 
CRA, were also included, as were RCTs based on CRA with pharmacological 
maintenance treatment (e.g. methadone). 
Types of outcome measures Effectiveness was defined in terms of (1) 
(continuous) abstinence, determined by urine samples, blood samples or self-
reports. When data on continuous abstinence were not available, abstinence 
percentages that imply abstinence percentages within a follow-up assessment 
period were included. Abstinence was regarded as a primary outcome measure in 
CRA review  
 
 77 
maintenance treatment (e.g. methadone) pertaining to the cessation of illegal 
drug use (heroin). RCTs were included if at least one of the following outcome 
measures was used; (2) addiction severity, measured for example according to 
the ASI, a semi-structured interview that gives a multidimensional profile of the 
addicted individual and an indication of the addiction severity (McLellan et al., 
1980). The ASI contains seven life domains (medical, employment, alcohol, 
substance, legal, psychiatric, family and social). The composite scores 
subsequently reflect the severity of each of the seven domains over the previous 
30 days; (3) frequency of substance abuse, measured for example according to 
the number of (heavy) drinking days and time spent drinking; (4) time to relapse.  
 
3.2.2. Search strategy for identification of studies 
Relevant RCTs meeting the inclusion criteria were identified by: 
1. A computer-aided search using two search engines: OVID and WebSPIRS. 
WebSPIRS was used for a search in the following databases: Biological 
Abstracts, ERIC, LISA, OSH, Periodical Abstracts, PsycINFO, SERFILE and 
Sociological Abstracts. OVID includes EMBASE, MEDLINE and CINAHL. All 
databases were searched from the date of commencement. The search was 
conducted in March 2002, using the highly sensitive search strategy of the UK 
Cochrane Centre (October 1996), based on the first two stages of the Medline 
search strategy recommended in the Cochrane Handbook (Appendix V of 
Section V) and published by Dickersin et al. (1994). This was run in 
conjunction with a specific search that included combinations of the following 
keywords: alcohol abuse, substance abuse, drug abuse, alcohol(-)related 
disorder(s), opioid(-)related disorder(s), opiate(-)related disorder(s), cocaine(-
)related disorder(s), community reinforcement approach, community 
reinforcement, CRA, disulfiram, acamprosate, methadone, heroin, naltrexone 
and buprenorphine. Only RCTs that were published in the English language 
were included. 
2. Screening references given in relevant identified trials and reviews. 
3. Screening the Cochrane Library, 2002 issue 1. 
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3.2.3. Methods of the review 
Study selection 
Two reviewers (HGR and JJB) independently selected the trials to be included 
in the systematic review. As the reviewers were acquainted with the studies, 
these were not blinded with regard to author, journal or research center. 
Disagreements concerning the inclusion of RCTs were resolved by consensus. A 
third reviewer (MvT) was consulted if consensus was not achieved. 
 
Methodological quality assessment 
Two reviewers independently assessed the methodological quality of the 
RCTs. The criteria list (Table 3.1) that is recommended in the guidelines for 
systematic reviews issued by the Cochrane Back Review Group (van Tulder et 
al., 2003) was used, but adapted for this CRA review. The full criteria list with 
operationalization is available on request from the first author. The original 
criterion “blinding of care-providers” was omitted, because care-providers in the 
CRA studies could not be blinded for the treatment they provided. Two new items 
were added (items 9a and 9b in Table 3.1) in order to assess potential information 
bias. With regard to the primary effect measure, the results obtained by using 
standardized and valid measuring instruments, such as blood samples or urine 
samples give a higher validity of abstinence than self-reports. Furthermore, highly 
relevant assessments provide more information concerning the primary effect 
measure than secondary measurements, such as depression questionnaires.  
Several external validity items were also added (Table 3.1). The items 10a, 
10b and 10c were added, because a description of the content of the CRA 
program provides more clarity about what is actually tested and the extent to 
which the results can be compared to the findings of other studies. Furthermore, a 
clear explanation of the theoretical background of the experimental program was 
evaluated positively. ‘Treatment integrity’ influences the extent to which the 
results can be generalized and replicated. Item 12a indicates the level of 
experience of the therapists, and 12b indicates whether the therapists have been 
trained in the application of CRA. Specific training for the experimental program, 
CRA review  
 
 79 
together with tape/video-recording to determine adherence (12c), increases the 
external validity of the study. Moreover, the effects of the administration of an 
experimental treatment can be improved when a protocol is used (12d). 
An item was scored "positive"(+) if the criterion was fulfilled, "negative" (-) if it 
was not fulfilled, or "unclear" (?). A total score was computed by counting the 
number of positive scores, and high quality was defined as fulfilling 6 or more of 
the 11 internal validity criteria. If the article did not contain information about the 
methodological criteria, i.e. if one or more criteria were scored "unclear", the 
authors were contacted for additional information. Scores on the external validity 
criteria were considered as supplementary information, to give an indication of the 
extent to which the results of the studies could be generalized. 
 
Data extraction 
Two reviewers independently extracted the data concerning the following: 
study population (disorder, setting, gender and age, Addiction Severity Index 
composite scores, sample-size and dropouts), interventions (frequency and 
duration CRA and control group, interventions CRA) and results (follow-up results 
per outcome measure). 
 
Data analysis 
The data from the included studies were merged in a meta-analysis to quantify 
the effect. Separate meta-analyses were performed for the short (≤ 4 weeks), 
intermediate (> 4 and ≤ 16 weeks) and long-term (>16 and ≤ 24 weeks) effects of 
treatment (Van Tulder et al., 2003). When available, other and longer follow-up 
periods, up to one year are provided in Table 3.2 in the result section. The pooled 
Relative Risks (RR) were computed with 95% Confidence Intervals (CI) using the 
random effects model. 
A qualitative analysis was also performed using a four-level rating system for 
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1. Strong evidence: provided by generally consistent findings in multiple high 
quality RCTs. 
2. Moderate evidence: provided by generally consistent findings in one high 
quality RCT and one or more low quality RCTs or by generally consistent 
findings in multiple low quality RCTs. 
3. (A) Limited evidence: only one RCT (either high or low quality). (B) Conflicting 
evidence: inconsistent findings in multiple RCTs. 
4. No evidence: no RCTs. 
 
Generally, consistent findings were defined as 75% or more of the studies having 
statistically significant findings in the same direction. 
 
3.3. Results 
3.3.1. Study selection 
The search resulted in 66 references via PsycINFO, 90 references in 
MEDLINE, 24 in EMBASE and 2 in CINAHL. After consulting the additional 
databases, Biological Abstracts, ERIC, LISA, OSH, Periodical Abstracts, 
SERFILE and Sociological Abstracts, the search yielded 97 different references. 
After deleting duplicates from all the databases consulted, the search finally 
resulted in 167 different references. 
The first selection was based on titles, keywords and abstracts, and resulted in 
both reviewers selecting 26 empirical CRA studies and rejecting 141 studies. Of 
the rejected studies, 83 were non-CRA and 49 discussed and reviewed CRA but 
were not RCTs.  
Furthermore, another five empirical studies (e.g. Meyers et al., 1998) reported 
on Community Reinforcement and Family Training (CRAFT) or interventions 
aimed at the involvement of family members (e.g. Sisson & Azrin, 1986) and an 
additional four were CRAFT reviews (e.g. Meyers, Miller & Smith, 2001). CRAFT, 
which is related to CRA, was developed on the basis of the belief that family 
members can make contributions in helping to persuade resistant substance 
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abusers to seek treatment (Meyers, Miller & Smith, 2001). Many skill-training 
strategies used in CRAFT are similar to those used in CRA, but are mainly 
focused on family members. It was therefore decided that CRAFT studies were 
not within the scope of this review. 
Three additional studies were identified through reference checking (Azrin et 
al., 1994, 1996; Mallams et al., 1982). After reading the full papers, six of the 
selected 29 CRA studies were excluded because they were not RCTs.  
One study (Mallams et al., 1982) was excluded because it did not evaluate a 
CRA program as defined by the inclusion criteria, and the intervention consisted 
of one component only (“Social club”).  
Another study (Schottenfeld et al., 2000) that was excluded investigated the 
number of alternative activities as main research objective in a population with an 
opiate as well as a cocaine addiction. 
A CRA study to reduce AIDS risk behavior in an opioid-dependent population 
(Abbott et al., 1998a) did not focus on one of the outcome measures of interest, 
and was therefore excluded.  
One study of sociopathic alcoholics was excluded because it investigated 
drinking outcomes in three treatment arms: (1) CRA, (2) individually focused 
cognitive behavioral treatment and (3) usual care (Kalman et al., 2000). However, 
no data on subjects receiving usual care were available (Kalman, 2002).  
The study carried out by Abbott et al. (1999) was excluded because the data 
set, which was based on Abbott et al. (1998b), compared subjects who had 
entered a program with or without methadone as transfers from other community 
methadone programs. 
Two studies carried out by Azrin et al. (1994, 1996) included subjects with 
different diagnoses of psychoactive substances, so they were excluded. 
Two studies (Higgins et al., 1995; 2000b) were follow-up studies of previously 
published research (Higgins et al., 1993; 1994; 2000a), and Higgins et al. (1997) 
is a reprint of Higgins et al. (1995). 
Four studies reported on the same two alcohol trials (Miller et al., 1992; Miller 
et al., 2001a,b) and homeless people (Smith et al., 1998; Smith & Delaney, 2001). 
Miller et al. (2001a,b), consisted of two complementary chapters (two search hits) 
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and is therefore considered as one trial in this review. Finally, a total of 11 trials 
were included (see Tables 3.1 and 3.2). 
 
3.3.2. Methodological quality 
The final results of the methodological quality assessment are presented in 
Table 3.1. For the critical appraisal of each individual study, 11 internal and 10 
external validity criteria were assessed. The percentage of agreement, to assign a 
positive score, between the two reviewers (HGR and JJB) was 88 % for the 
internal validity criteria and 94 % for the external validity criteria. Subsequently, all 
authors were consulted to check this assessment and to provide relevant 
information. Three authors responded to the request and provided additional 
information on 8 studies. As a result, 23 of the "unclear" scores were changed to 
“positive”. The additional information from the authors also resulted in 25 of the 
“negative” scores being changed to “positive”. 
In general, the methodological quality of the studies included in this review 
was high (see Table 3.1). Ten studies had 6 (> 50%) or more positive scores on 
the internal validity criteria, which was the pre-determined threshold for high 
quality (Abbott et al., 1998b; Azrin, 1976; Azrin et al., 1982; Bickel et al., 1997; 
Higgins et al., 1993, 1994, 2000a; Hunt & Azrin, 1973; Miller et al., 2001a,b; 
Smith et al., 1998). 
Most of the studies did not include a blinded observer (item 5), and it was often 
unclear whether or not the researcher who performed the treatment allocation 
was aware of the treatment to which the subject was allocated (item 1b). With 
regard to the external validity criteria, several studies did not provide the CRA 
intervention according to a protocol (item 12d) and did not determine the 
adherence through tape/video-recording (item 12c). Many studies also had a 
small sample size (item 13). 
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3.3.3. Data extraction and study characteristics 
Characteristics of the identified studies that were included (n = 11) are shown 
in Table 3.2. Five studies dealt with CRA in alcohol treatment (Azrin, 1976; Azrin 
et al., 1982; Hunt & Azrin, 1973; Miller et al., 2001a,b; Smith et al., 1998). The 
first two studies, which were the seminal studies for the entire CRA treatment, 
were inpatient studies and compared CRA versus usual care based on Jellinek 
(1960). Azrin’s study (1976) added a disulfiram compliance-enhancing program to 
CRA. The first outpatient study (Azrin et al., 1982) compared CRA consisting of 
behavioral therapy plus a disulfiram assurance program with a disulfiram 
assurance program and disulfiram alone. The alcohol study carried out by Miller 
et al. (2001a,b) included two sub-groups: (1) disulfiram-eligible and (2) disulfiram-
ineligible clients. The subjects were randomized to six-subgroups. Comparisons 
were made between usual care (with disulfiram) and (single) CRA (with 
disulfiram). Finally, one alcohol study dealt with a special population of homeless 
alcohol-dependent subjects (Smith et al., 1998). In this study, subjects were 
allocated to various conditions, such as eligible and ineligible for disulfiram. 
However, this study is based on a simplified two-condition collapsed design with 
the primary focus on comparing CRA with usual care. A minority of the CRA 
subjects was assigned to a disulfiram condition, so the CRA condition was 
considered to be single. 
Four studies (Higgins et al., 1991, 1993, 1994, and 2000a) examined the 
effects of CRA with abstinence-contingent ‘incentives’ in the treatment of cocaine. 
In two studies (Higgins et al., 1991, 1993) the control group received “12-step 
counseling” as usual care, which is based on the disease model that is commonly 
used by community substance abuse clinicians in the U.S. One study compared 
CRA versus CRA with abstinence-contingent ‘incentives’ (Higgins et al., 1994), 
and one study (Higgins et al., 2000a) compared elaborate CRA, with abstinence-
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Furthermore, two opioid studies were identified. One (Bickel et al., 1997) 
evaluated the effect of a 160-day buprenorphine dose-taper combined with either 
usual care or a behavioral treatment based on CRA with ‘incentives’. The other 
study (Abbott et al., 1998b) compared the effects of CRA and usual care in a 
methadone maintenance program. 
Three early studies reported their results in such a way that it was not possible 
to include them in the statistical pooling with respect to continuous variables, 
because they only provided means and no standard deviations (Azrin, 1976; Azrin 
et al., 1982; Hunt & Azrin, 1973). Data pertaining to time to relapse was not 
provided by the included studies, so no further considerations could be made. 
 
3.3.4. Effectiveness of CRA in alcohol treatment aimed at abstinence 
Single CRA versus usual care 
Three high quality studies that were identified compared single CRA with usual 
care without disulfiram (Hunt and Azrin, 1973; Miller et al., 2001a,b; Smith et al., 
1998).  
The first study, which is the first CRA study, showed the effectiveness of CRA in 
treating alcohol-dependence in an in-patient setting, focusing on several aspects 
of life such as employment and time spent away from home (Hunt and Azrin 
1973). At 6 months follow-up the CRA group showed a significantly lower 
percentage of ‘time drinking’ than the usual care group (14% versus 79%; P < 
0.005). One limitation concerns the CRA treatment package. The early version(s) 
of CRA had technically fewer components available, and gradual decreased the 
number of counseling hours. Despite this, the number of treatment sessions of 
more recent CRA studies might depend on the type (severity) of target population 
being treated. 
In the out-patient study carried out by Miller et al. (2001a,b) no difference was 
found between single CRA (22.2%) and usual care (24.0%) with regard to 
abstinence during 1-6 months and 16-24 months follow-up periods in subjects 
who were disulfiram-ineligible. The same was found with regard to the number of 
drinking days per week. There was also no statistically significant difference in 
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abstinence between the usual care group and the CRA group in disulfiram-eligible 
subjects (41.9% versus 32.3%). However, the CRA group performed much better, 
than the usual care group, with regard to the number of drinking days per week 
(0.22 versus 1.35). 
A critical statement must be made concerning the 'contamination' of the 
research groups; 51.3 % of the subjects in the usual care group and 18.4 % of the 
subjects in the CRA group accepted disulfiram, despite ascertainment of the 
treatment condition. Subjects in the usual care group were encouraged to take 
disulfiram, in contrast to subjects in the CRA group. 
In the third high quality RCT involving homeless alcoholics (Smith et al., 1998), 
participants in the CRA program had statistically significantly higher continuous 
abstinence rates, ranging from 2 months to 1 year after intake [at 8 weeks: (χ2(1) 
= 10.61, P = 0.001; at 16 weeks: χ2(1) = 8.47, P = 0.004; at 36 weeks: χ2(1) = 
7.16, P = 0.01)]. The same significant findings applied to the number of drinking 
days. However, some critical comments should be made: the study included a 
specific population, and only a minority of the subjects (disulfiram eligible and 
motivated to comply) took disulfiram. In the analyses, the subgroups were 
combined and in this review they are considered to have received no disulfiram.  
The number of drinking days (continuous variable) reported by Miller et al. 
(2001a,b) and Smith et al. (1998) were merged into a meta-analysis. The data 
from the proximal follow-up (Miller et al., 2001a,b) and the 6-month follow-up data 
(Smith et al., 1998) were considered as long-term effects (16 < weeks ≤ 24). 
Using the random effects model, the number of drinking days was [WMD (95% 
CI) = -0.94 (-1.60 to –0.27, Q=2.75, df 2)] in favor of CRA. With respect to this 
statistical pooling, the potential source of heterogeneity regarding the follow-up, 
population and disulfiram eligibility affects the interpretation of this robust finding 
and should be considered with caution.  
Overall, there is strong evidence (level 1) that single CRA is more effective 
than usual care with regard to number of drinking days, and there is conflicting 
evidence (level 3) with regard to continuous abstinence. 
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CRA with disulfiram versus usual care with disulfiram 
Three of the studies that were included (Azrin, 1976; Azrin et al., 1982; Miller 
et al., 2001a,b) compared CRA with disulfiram versus usual care with disulfiram. 
The in-patient study carried out by Azrin (1976), which was of high quality, 
showed significant results at 6 months follow-up in favor of CRA with disulfiram in 
terms of time drinking (2% versus 55%, P < 0.005), employment, time spent away 
from home and time institutionalized. These benefits were maintained for at least 
2 years following discharge from the hospital. 
The high quality study carried out by Azrin et al. (1982), which included three 
treatment conditions, also compared CRA with disulfiram versus usual care with 
disulfiram. At 6 months follow-up, the percentage of time drinking was significantly 
lower in the CRA with disulfiram group than in the control group (3% versus 55%, 
P < 0.01). The CRA with disulfiram group also showed a statistically significant 
difference with regard to amount of alcohol consumed and ethanol intoxicated 
moments. 
A limitation concerns the acceptance of disulfiram. In the group receiving usual 
care, based on Jellinek (1960), disulfiram use was encouraged. However, 
compliance in the usual care and in the disulfiram condition was extremely poor 
(Azrin et al., 1982): the mean number of days of disulfiram consumption was 0 in 
the usual care with disulfiram group versus 24.8 in the CRA with disulfiram group 
(P < 0.001). The total CRA therapy program was reduced from an average of 30 h 
(Azrin, 1976) to 6.4 h (Azrin et al., 1982), which also complicates comparison of 
the two studies. 
In a high quality study, Miller et al. (2001a,b) found some evidence in favor of 
usual care: 58.8% of the subjects receiving usual care with disulfiram, were still 
abstinent at 1-6 months of follow-up, compared to only 34.4 % in the CRA with 
disulfiram group. This result was not statistically significant. At long-term follow-up 
(16-24 months) this difference had dissipated. There was also no statistically 
significant difference in drinking days per week (0.20 in the CRA group versus 
0.25 in the usual care group). A critical comment can be made with respect to 
treatment integrity. The usual care with disulfiram used a compliance procedure 
(Sisson & Azrin, 1986), which can also be regarded as a part of a CRA-program. 
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This may have reduced the contrast. In the usual care group, 90 % of the subjects 
accepted disulfiram, and over 80% were rated by the therapist as compliant. In 
the CRA with disulfiram group 56.4% accepted disulfiram and 44.1% were 
compliant. All subjects treated in these two groups were disulfiram-eligible. The 
study carried out by Miller et al. (2001a,b) also shows that when data is combined 
during follow-up (1-6 months), the subjects in the disulfiram-eligible group, who 
received CRA were drinking on significantly fewer days (3% versus 19%, P < 
0.001) than the subjects in the usual care group. 
In summary, there is moderate evidence (level 2) that CRA with disulfiram is 
more effective than usual care with disulfiram in terms of number of drinking days, 
and limited evidence (level 3) that there is no difference in effect between CRA 
with disulfiram and usual care with disulfiram in terms of continuous abstinence. 
 
3.3.5. Effectiveness of CRA in cocaine treatment aimed at abstinence 
Single CRA versus usual care 
No RCTs were identified that examined the effects between single CRA and 
usual care, so there is no evidence (level 4). 
 
CRA with abstinence-contingent’ incentives’ versus usual care 
A meta-analysis was conducted on two studies (Higgins et al., 1991, 1993), 
the latter of which was of high quality, to determine the effect of CRA with 
‘incentives’ versus usual care (details are presented in Table 3.2). Using the 
random effects model, the pooled relative risk for cocaine abstinence in a CRA 
treatment program with a duration of 4 weeks or less was 3.75 [(95% CI) 1.79 to 
7.87, Q = 0.31, df 1], and for a CRA treatment program with a duration between 4 
and 16 weeks it was 5.09 [(95% CI) 1.63 to 15.86, Q = 0.44, df 1].  
There is strong evidence (level 1) that CRA with ‘incentives’ is more effective 
with regard to cocaine abstinence than usual care.  
 
CRA with abstinence-contingent ‘incentives’ versus CRA (non-contingent 
incentives) 
CRA and NTX in the treatment of addiction 
 
 92 
Two studies (Higgins et al., 1994, 2000a), both high quality RCTs, determined 
the effect of CRA with abstinence-contingent ‘incentives’ versus CRA (non-
contingent incentives). Higgins et al. (1994) examined the difference between 
CRA versus CRA with abstinence-contingent ‘incentives’, and Higgins et al., 
(2000a) compared CRA both with and without abstinence-contingent ‘incentives’. 
In the latter study all patients received CRA and the experimental condition 
depended on whether it was combined with cocaine abstinence-contingent 
vouchers or vouchers provided independent of cocaine use (details are presented 
in Table 3.2). For the purpose of statistical pooling, the CRA with non-contingent 
‘incentives’, which attenuates clinical homogeneity, was considered to be single 
CRA. The results of this pooling were calculated for an intermediate term, as no 
short-term data were available. The pooled effect size for cocaine abstinence in a 
CRA treatment program with duration of 4-16 weeks was 1.73 [(95% CI) 1.04 to 
2.88, Q = 0.48, df 1].  
There is strong evidence (level 1) that CRA with abstinence-contingent 
'incentives’ is more effective than single CRA (non-contingent incentives) 
treatment aimed at cocaine abstinence. 
 
3.3.6. Effectiveness of CRA in opioid treatment aimed at abstinence 
CRA with ‘incentives’ versus usual care in a detoxification program 
One identified RCT (Bickel et al., 1997) compared a 160-day buprenorphine 
dose-taper combined with either usual care or a behavioral treatment based on 
CRA with ‘incentives’. Fifty-three percent of the subjects receiving CRA with 
‘incentives’ completed the treatment, versus 20% receiving usual care [χ2 (1, N = 
39) = 4.5, P = 0.03]. In the short-term (≤4 weeks) the CRA with ‘incentives’ was 
more effective (68%) in terms of continuous abstinence than usual care (55%), 
but this was not statistically significant. In the intermediate term, more participants 
in the CRA with ‘incentives’ (47%) achieved at least 8 weeks of continuous 
abstinence [χ2 (1, N = 39) = 4.8, P = 0.03], compared to usual care (15%). In the 
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long term (> 16 and ≤ 24 weeks) there was still a difference (11% versus 0%), but 
this was not statistically significant. 
Hence, there is limited evidence (level 3) that CRA with ‘incentives’ is more 
effective than usual care in a detoxification program. 
 
CRA with ‘incentives’ versus single CRA in a detoxification program 
No RCTs were identified that examined the effects of CRA with ‘incentives’, 
either separately or versus usual care, so there is no evidence (level 4). 
 
CRA versus usual care in a relapse prevention program 
No RCTs could be identified, so there is no evidence (level 4). 
 
Single CRA versus usual care in a methadone maintenance program 
One RCT (Abbott et al., 1998b) was identified, with three treatment arms: 
usual care, CRA, and CRA with relapse prevention (CRA/RP). We considered 
methadone maintenance to substitute and prevent illegal drug use. In the long 
term  (> 16 weeks) CRA was significantly more effective than the usual care, 
based on the consecutive (3 weeks) opiate-negative urine analysis (84% versus 
78%) and the 6-month ASI composite scores. However, there might be some 
limitations in this study. Firstly, with regard to the design: combining treatment 
arms 2 (CRA) and 3 (CRA with relapse prevention). Nevertheless, by the time of 
6-month follow-up the mean number of RP sessions was 1.06. When this number 
is contrasted with the attended 20 CRA sessions, one could say that these 
conditions are essentially the same and legitimatize collapsing. Secondly, in the 
follow-up: 29% of the urine samples were missing. 
Hence, there is limited evidence (level 3) that single CRA is more effective 
than usual care in a methadone maintenance program. 




3.4.1. Clinical implications 
In general, there is limited to moderate evidence for the efficacy of CRA with or 
without medication or contingency management in various substance-related 
disorders, including alcohol, cocaine and heroin. It can be argued that the 
collapsing of alcohol, cocaine and opioid findings might cause a misinterpretation 
of this meta analysis. For instance, the voucher approach is often used in the 
CRA drug treatment (via dichotomous variable) and is, in general, absent in the 
alcohol treatment. Also the support for the effectiveness on CRA with alcohol 
abusers is rather bit stronger than for the drug populations. Additionally, the 
reported findings vary substantially depending on the type of variable are 
reviewed (e.g. alcohol outcomes with respect to dichotomous and continuous 
variables). 
On the other hand the combining of the meta-analysis' findings seems 
legitimate, because one could ask why to distinguish studies on the basis of the 
drug of dependence? CRA addresses the behavior of addiction; not the 
physiological basis derived from the drug that is being used. It seems viable that 
the focus on the outcome of abstinence is comparable across various substance 
types (Gowing, 2003).  
Due to the course of the progression of addiction, which is similar to that of 
chronic diseases (O'Brien, 2003), there is a cumulating of evidence to view 
addiction as a chronic, relapsing brain disease (Leshner, 1997; McLellan, 2002; 
Van den Brink et al., 2003). In general, this view has generated a variety of 
treatment goals, such as crisis intervention, stable abstinence, stabilization of 
substance use and improving quality of life (harm-minimization) and palliation 
(Van den Brink et al., 2003). These different treatment goals determine the type of 
defined outcome measures, which in turn, correspond with the different treatment 
goals such as abstinence (e.g. Azrin, 1976; Higgins et al., 1993) and harm-
minimization (e.g. Abbott et al., 1998a). This view of chronic disease legitimizes a 
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focus on the choice of continuous outcome variables rather than dichotomous 
variables. Although we defined outcome measures such as addiction severity, 
frequency of substance abuse and time to relapse, data was often not provided. 
In addition, analogue to these treatment goals, the use of a pharmacological 
agent such as disulfiram is solely associated with abstinence in the treatment of 
alcohol abuse and renders also the goal of a concomitant psychosocial therapy 
such as CRA. Nevertheless, with respect to the palette of treatment goals the 
choice to focus on abstinence can be argued. The more sensitive nature of 
continuous measures might provide a better outcome perspective for CRA. But 
abstinence is the outcome measure that is most easily assessed objectively and 
hence becomes the obvious primary outcome indicator, as identified in the 
methods section (Gowing, 2003). 
Currently, there are 3 dominant researchers conducting studies in the CRA 
area: Nathan Azrin, Stephen Higgins and Robert Meyers. In nearly all included 
studies Azrin, Meyers and Higgins are directly involved as (co) authors.  
Most of the included studies were of high methodological quality. Only a few 
studies could be identified within each type of comparison, i.e. CRA versus usual 
care and CRA versus CRA with contingency management for alcohol, cocaine 
and opioid abuse. 
With respect to the alcohol studies, it was demonstrated that there is limited 
evidence (level 3) that single CRA with or without disulfiram is more effective, in 
terms of continuous abstinence, than usual care. However, there is moderate 
evidence (level 2) that single CRA with or without disulfiram is more effective than 
usual care in terms of number of drinking days. Furthermore, these results that 
favor CRA support the findings that CRA is also effective in the treatment of 
alcohol abuse in specific populations, some of which have severe life-problems, 
such as homeless (Smith et al., 1998; Smith & Delaney, 2001). Other specific 
populations have also been the subject of research on CRA: Dine’ (Navajo) 
people (Miller et al., 1999b) and sociopathic alcoholics (Kalman et al., 2000). 
It is noteworthy that significantly more disulfiram-eligible clients than disulfiram 
ineligible subjects were completely abstinent during 1-6 months of follow-up 
(Miller et al., 2001a,b). However, as previous noted, the treatment integrity of 
CRA and NTX in the treatment of addiction 
 
 96 
Miller (2001a,b) study was affected, because the usual care condition with 
disulfiram used a CRA compliance procedure (Sisson & Azrin, 1986). From its 
inception, it seems important to advocate procedures in CRA (i.e. via significant 
others) to increase acceptance and compliance with the medication regime (e.g. 
Sisson & Azrin, 1986). An important finding was the interaction between 
effectiveness of disulfiram-compliance procedure and marital status of the 
subjects [F (2,41) = 6.12, P < 0.006]. For married subjects who participated in the 
full CRA program, the therapy outcome showed no improvement (Azrin et al., 
1982).  
Higgins and his co-workers investigated two operant-oriented programs for the 
treatment of cocaine dependence: community reinforcement and contingency 
management via 'incentives’. There is strong evidence that the combination 
package (CRA with contingency management) is superior to usual care (level 1) 
or CRA with non-contingent 'incentives' (level 1). In every study, CRA with 
abstinence-contingent 'incentives' is significantly more effective than usual care in 
cocaine-dependent subjects. 
However, the fact that this treatment package consists of two combined 
operant-oriented methods is a limitation. These cocaine studies do not address 
single CRA, so there is no evidence that single CRA is more favorable than usual 
care. A recent RCT demonstrated that there is no evidence that CRA produces 
larger effect sizes than vouchers in cocaine abusers. Nevertheless, with regard to 
alcohol use, employment, and other outcomes, CRA produced greater effects 
than vouchers (Higgins et al., 2003). 
Furthermore, on base of urinalyses, it seems clear that the effect of incentives, 
as a part of a larger CRA intervention, dissipates slowly after discontinuation. The 
collapsing of the data provided by Higgins et al. (1994, 2000a) should be 
interpreted with caution. In a certain degree the collapsing seems 
understandable, however, we don’t know how it affected other variables; the 
clients experience. Another critical comment that can be made regarding external 
validity concerns the relatively low ASI composite scores. This is possibly 
associated with the enrolment of the participants, who were mainly recruited 
through advertisements in newspapers and via public service announcements on 
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different media channels. This might affect the generalizability of the results to 
different study populations. In general, the severity of the symptoms worsens the 
prognoses (McLellan et al., 1983). Furthermore, it should be noted that the same 
research team conducted all the RCTs that were identified.  
The literature search revealed that small naturalistic studies have also been 
conducted to assess the efficacy of CRA with contingent management in cocaine 
and marijuana abuse (Budney et al., 1991; Vick and Houden, 1991), and even in 
an individual with a dual diagnosis (Fix, 2001). A larger study has also been 
conducted to examine the power of CRA in a population with mainly cocaine and 
marijuana abuse (Azrin et al., 1994). This study demonstrated that CRA, even 
when a worst-case analysis was conducted, was superior to supportive 
counseling in reducing the mean number of days of drug use at the end of 8 
months of treatment (49.1% versus 78.3%, P < 0.003) and the effect sustained 
after 9 months of follow-up (52.8 versus 80.4%, P < 0.004; Azrin et al., 1996). 
Urine analysis supported this outcome in the last month of treatment [χ2(1) = 6.05, 
P = 0.014). At follow-up there was a statistically non-significant trend in favor of 
CRA [χ2(1) = 3.38, P < 0.066]. 
There were no RCTs that determined the effect of single CRA in an opioid 
detoxification or a relapse prevention program to treat opioid dependency. 
Nevertheless, one naturalistic study that was identified examined the role of CRA 
during a rapid opioid detoxification process and, additionally, CRA in a naltrexone 
maintenance program aimed at abstinence, which showed promising results 
(Roozen et al., 2003).  
Hence, with respect to the CRA programs focussing on opioid substitution 
(Abbott et al., 1998b), detoxification (Bickel et al., 1997) and abstinence (Roozen 
et al., 2003), it seems that, there is limited evidence and optimistic and promising 
research findings. Abbott et al. (1998a) examined the role of CRA in risk-
behavior, including injection drug use and high-risk sexual behavior, to prevent 
AIDS. These types of behavior were significantly, although comparably reduced in 
all treatment groups (Higgins & Abbott, 2001). In the treatment of opioid 
dependence, CRA could be an option to realize further optimization of the 
treatment outcome. 
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Based on the results of a variety of cocaine and opioid studies it becomes 
clear that abstinence-contingent incentives are an effective approach. This 
reinforcement principle is also a basic premise of CRA, and is supported by Azrin 
et al. (1996) who stated: "the favorable results appear attributable to the inclusion 
of a significant other in therapy and the use of reinforcement abstinence 
contingent ‘incentives’". Problems might be encountered in the implementation of 
abstinence-contingent incentives in clinical routine practice, but pertaining to the 
token economy, there might be options that could make this approach feasible (cf. 
Franco et al., 1995). 
CRA is associated with relatively intensive and time-consuming treatment 
(Barber, 1992). The initial study (Hunt & Azrin, 1973) took an average CRA time 
of 50 h. This was reduced to 30 h in the next study (Azrin, 1976) and was 
completed in approximately 6 h in the Azrin study in 1982. These data suggest 
that claims about the high treatment and labor intensity can be refuted. It has 
recently been demonstrated that CRA treatment can improve many aspects of life 
in approximately 5 sessions over a period of in 4-6 weeks. Subsequently, the 
CRA treatment can be tailored and adapted to individual goals, varying from life-
long abstinence to moderation of substance use (Miller, 2001c). 
As previously discussed, a limitation of this review is the absence of 
dependent measures such as the amount of alcohol consumed, blood alcohol 
concentrations or the number of non-drug related activities. The inclusion of such 
continuous measures might be considered as direct measures of the 
effectiveness of CRA.  
Another limitation concerning the conducted analyses is the elimination of the 
early CRA studies from the statistical pooling due to insufficient data available. 
 
3.4.2. Research implications 
Most studies included in this systematic review evaluated a cognitive 
behavioral ‘treatment package’. A CRA manual for the treatment of alcohol abuse 
that has been published describes the appropriate CRA elements for clinical use 
(Meyers & Smith, 1995). A treatment manual is also available for the combined 
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approach in the treatment of cocaine dependence (CRA and vouchers, Budney & 
Higgins, 1998), which was used as a guideline in nearly all of the identified 
cocaine studies. 
One limitation is that we know little about the actual or comparative value of 
the different elements within CRA. Although we have underlined some critical 
elements, it is still unclear which element within the CRA framework is the most 
effective, and which components of CRA are necessary and which are 
superfluous. A conceptual analysis appears to be necessary. This seems 
especially relevant now that the biopsychosocial model has been widely accepted 
and multidimensional approaches are gaining terrain in the treatment of addiction. 
Among the possible key elements of CRA that have been suggested is a CRA 
pharmacotherapy–compliance procedure (Sisson & Azrin, 1986), to encourage 
taking pharmacological agents under supervision in order to prevent omissions of 
medication intake and to increase adherence to treatment. This, in turn, results in 
a reduction in therapy time, thus reducing costs and increasing benefits (e.g. 
Azrin et al., 1982; Miller et al., 2001a,b). In several studies CRA outperformed 
other treatment modalities in terms of participation in non-drug-related activities 
(i.e. Higgins et al., 2003; Schottenfeld et al., 2000). The latter authors suggested 
that reinforcement of non-drug-related social, vocational, and recreational 
activities are a crucial component of CRA. This is also supported by Mallams et 
al. (1982), who suggested that a peer-group social reinforcement (i.e. community 
social club) should be arranged to improve therapy outcome. These non-
substance-related reinforcement activities seem to be an important element of 
CRA to maintain a long-term substance-free lifestyle. 
Future RCTs should aim at identification of the most effective components of 
CRA programs. In addition to maintaining high internal validity, efforts should be 
made to conduct RCTs with a high(er) external validity. Considerable attention 
should be paid to training therapists in the application of CRA, and making tape 
recordings or similar procedures to assess treatment integrity. It is therefore a 
prerequisite that CRA procedures are protocol-based. Additionally, a clear 
description of the control program (usual care) should also be given.  
We recommend: 
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1. More high quality RCTs of CRA in the treatment of alcohol, cocaine and 
opioid addiction.  
2. RCTs conducted by other research groups in different countries and/or 
different settings to confirm the most promising findings. 
3. RCTs focusing on the severity of addiction. 
4. RCTs with a larger sample size, which is determined by a power analysis.  
5. RCTs including CRA treatments that are protocol-based and adherence 
determined through tape/video-recording. 
6. More RCTs with a follow-up of one year or longer.  
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A systematic review of the effectiveness of 
naltrexone in the maintenance treatment of opioid 
and alcohol dependence 





This systematic review summarises evidence of the effectiveness of 
naltrexone (NTX) and the added value of psychosocial treatment in the 
maintenance treatment of opioid and alcohol dependence. 
Studies were selected through a literature search, conducted in March 2004. 
Seven opioid and seventeen alcohol studies were identified. Where possible, 
meta- (regression) analyses were performed. There is lack of evidence about the 
effectiveness of NTX in the treatment of opioid dependence. There is evidence for 
the effectiveness and applicability of NTX in the management of alcohol 
dependence. The opioid studies combined NTX with a variety of psychosocial 
interventions, which plagued the evaluation of their value. Concomitant 
psychosocial interventions used in the alcohol studies were mainly cognitive 
behavioral, which seems to be more favourable than NTX combined with 
supportive therapy.  In general, the auxiliary therapies fail to ameliorate dropout 
and NTX's non-compliance. 
 
 





Naltrexone (NTX), an opioid antagonist, blocks intrinsic properties of psychoactive 
substances that act on the μ, κ, and δ opioid receptor sites by competitive 
occupation. It is ascertained that alcohol acts on the opioid receptor sites. By 
blocking these sites, NTX prevents the reinforcing effects of alcohol consumption 
(O’Brien, Volpicelli & Volpicelli, 1996).  
The metabolic pattern of NTX predominantly involves the reduction of NTX into 
6-β-hydroxy naltrexone (6-β-naltrexol; Wall et al., 1981). The long acting 
properties of NTX are mainly due to this metabolite, which has an elimination half-
life (T1/2) of approximately 13 hours compared to the parent drug with a T1/2 value 
of 4 hours. The dose-related antagonism on both subjective and objective 
responses has been subject to some research, although these findings are based 
on small samples (Resnick et al., 1974; Verebey, 1981). NTX and 6-β-naltrexol 
are dose proportional (linear increase) in terms of AUC and Cmax over the range of 
50 to 200 mg. A bio-equivalence was demonstrated after 100-mg single doses 
(Meyer et al., 1984). Despite the excellent pharmacological (blocking) properties, 
in practice NTX treatment is often hampered by dropout, non-compliance and 
consequently relapses into opioid or alcohol abuse (Rothenberg et al., 2003; 
Tucker et al., 2004).  
In general, pharmacological interventions suffer from poor compliance (O’Brien 
and McLellan, 1996; Weiss, 2004). To promote adherence to NTX regimes and to 
initiate and maintain lifestyle changes, behavioral and psychosocial interventions 
have been developed (Miller & Wilbourne, 2002). However, evidence is scant 
regarding the question whether and which type of psychosocial intervention 
should be combined with NTX treatment in order to optimise its effectiveness. 
Recently, several systematic reviews and meta-analyses have been published 
regarding the effectiveness of NTX in the treatment of alcohol dependence (Bouza 
et al., 2004; Fiellin et al., 2000; Garbutt et al., 1999; Kranzler & Van Kirk, 2001; 
Miller & Wilbourne, 2002; Sinclair, 2001; Srisurapanont & Jarusuraisin, 2004; 
Streeton & Wheelan, 2001; Swift, 1999). In general, these studies conclude that 
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NTX is more favourable in terms of abstinence, percentage of drinking days and the 
number of drinks than a placebo in the treatment of alcohol dependence. 
In contrast to the alcohol literature, only a few reviews could be identified, which 
have assessed the effectiveness of NTX maintenance in opioid dependent 
participants (Kirchmayer et al., 2002; O’Connor & Fiellin, 2000; Van den Brink & 
Van Ree, 2003). These studies conclude that the evidence on the surplus value of 
NTX over placebo is minimal and conflicting at best. 
First and foremost, the current study was conducted to unfold and update the 
effectiveness of NTX, because the previously mentioned reviews did not include 
several recent studies on NTX maintenance. To summarise the available (recent) 
evidence on the effectiveness of NTX, in the maintenance treatment of alcohol 
and opioid dependence, a systematic (meta-analytic) review was conducted with 
the following aims: 
1. to study the effects of  NTX compared to placebo in the maintenance 
treatment of opioid and alcohol dependence; 
2. to study whether combining NTX with psychosocial treatment is more 
effective than treatment with NTX alone. 
 
4.2. Experimental procedures 
4.2.1. Criteria for considering studies for this review 
Randomised (placebo) controlled trials (RCTs) and controlled clinical trials 
(CCTs) with NTX maintenance treatment were included. When group allocation in a 
trial was determined randomly, the study could be labelled as an RCT. If the 
randomisation procedure was unclear, but considered as randomised (e.g. double-
blind study), the trial was assumed to be a CCT. 
RCTs and CCTs had to include participants with alcohol or opiate abuse or 
dependence (DSM-III-R or DSM-IV) between 18 and 75 years of age. Only RCTs 
and CCTs in outpatient settings were included to diminish clinical heterogeneity. 
Specific populations (populations such as federal probationers, prisoners and 
healthcare professionals) were omitted as the outcomes may be biased.  RCTs and 
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CCTs had to report data on at least one of the following outcome measures: (1) 
relapse rates, with relapse defined as drinking at least four alcoholic drinks for 
women, five for men on an occasion or single day; and (2) (continuous) abstinence, 
confirmed by urine samples, blood samples or self-reports. When data on 
continuous abstinence was not available, abstinence percentage (i.e. the proportion 
of participants abstinent during the follow-up period) was included; (3) frequency of 
substance abuse (percentage of drinking days or days using drugs); (4) time to first 
relapse and (5) time to first drink. It must be noted that relapse is the most sensitive 
outcome measure linked to the assumed mechanisms of NTX's action, which is the 
reduction of the reinforcing pleasure when drinking alcohol (Volpicelli, 1997; 
Littleton & Zieglgansberger, 2003) or when using opioids. 
 
4.2.2. Search strategy for identification of studies 
Relevant RCTs meeting the inclusion criteria were identified by: 
1. A computer-aided search using the following databases: Pubmed, 
EMBASE, PsychINFO and the Cochrane Controlled Trials Register 
(CCTR). All databases were searched from the date of commencement. 
The search was conducted in March 2004, using the first two stages of the 
search strategy recommended in the Cochrane Handbook (Appendix V of 
Section V) and published by Alderson, Green and Higgins (2004). This 
strategy was run in conjunction with combinations of the following 
keywords: naltrexone, alcohol abuse, substance abuse, drug abuse, 
alcohol(-)related disorder(s), opioid(-)related disorder(s), opiate(-)related 
disorder(s), alcohol dependence and opioid dependence. Only RCTs that 
were published in the English language were included. 
2. Reference checking of identified trials and reviews. 
 
4.2.3. Methods of the review 
Two reviewers, (RdW and HGR) independently assessed the methodological 
quality and extracted the data from the included trials. The criteria list for 
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experimental studies (RCTs and CCTs), issued by the Cochrane Drugs and 
Alcohol Group was used to assess the methodological quality (Ferri, 2003). The 
full criteria list with operationalisations is available on request from the 
corresponding author. The guidelines of the Cochrane Drug and Alcohol Group 
consider six criteria including randomisation (range 0-2), allocation concealment 
(range 0-6), blinding (range 0-3), inclusion of all patients in the analysis (range 0-
3), similarity of baseline characteristics (range 0-1) and equal treatment of groups 
(range 0-1). A total score was computed by summing the scores of all six criteria 
(range 0-16). Low quality was defined by a 0-8 score, and high quality by 9 (> 
50%) or higher.  
Statistical pooling was performed for subsets of studies that were clinically 
sufficient homogeneous with respect to population, interventions and outcome 
assessment. Statistical heterogeneity was assessed by visually inspecting forest 
plots, and quantified with the Q-test (χ2). Study results were considered 
heterogeneous when P ≤ .05. Meta-analyses were performed for medium term 
(>4 and ≤16 weeks) and long term (>16 and ≤ 32 weeks) treatment effect  (Van 
Tulder et al., 2003, adapted). Pooled Risks Differences (RD) were computed for 
dichotomous outcomes (relapse rate, abstinence) and Weighted Mean 
Differences (WMD) for continuous outcomes (percentage drinking days per time 
period, time to first relapse and time to first drink), along with 95% Confidence 
Intervals (CI) using the random effects model. For dichotomous outcomes the 
number needed to treat (NNT) was also computed. 
A qualitative analysis was also performed using a four-level rating system for 
the strength of the scientific evidence (Van Tulder et al., 2000): 
1. Strong evidence - provided by generally consistent findings in multiple 
high quality RCTs. 
2. Moderate evidence - provided by generally consistent findings in one high 
quality RCT and one or more low quality RCTs or by generally consistent 
findings in multiple low quality RCTs. 
3. A. Limited evidence - only one RCT (either high or low quality); 
B. Conflicting evidence - inconsistent findings in multiple RCTs.  
4. No evidence - no RCTs. 




Generally consistent findings were defined as 75% or more of the studies having 
statistically significant findings in the same direction. 
 
Subgroup analyses were carried out to analyse the potential influence of the 
type of co-intervention on the efficacy of NTX: individual or group psychotherapy. 
Meta-regression analysis was used to determine the statistical significance of 
subgroup effects. Weighted and unweighted linear regression analyses were 
carried out using individual RCTs as the unit of analysis (dependent variable). The 
inverse of the variance (1/SE2) was used to weigh effect estimates of individual 
RCTs. The type of co-intervention was introduced in the model as independent 
variable. 
To estimate the effect of (non-)compliance on outcome we calculated, where 
possible, the magnitude of the linear relationship between effect size (RD for 
dichotomous outcomes and WMD for continuous outcomes) and treatment 
retention by Spearman’s non-parametric correlation. 
 
4.3. Results 
4.3.1. Study selection: NTX in opioid studies 
After consulting Pubmed, EMBASE, PsychINFO and CCTR 119, 275, 149 and 
65 publications, including duplicates, were identified respectively. Only seven 
placebo-controlled trials on maintenance treatment of opioid dependence met the 
selection criteria and were included in the review (Brahen et al., 1977; Guo et al., 
2001; Hollister et al., 1978; Lerner et al., 1992; Mello et al., 1981; San et al., 1991; 
Shufman et al., 1994). 
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4.3.2.  Study selection: NTX in alcohol studies 
The search via Pubmed, EMBASE, PsychINFO and CCTR yielded 136, 461, 
101 and 165 publications, including duplicates, respectively. The first selection 
was based on titles, keywords and abstracts. Initially, 27 studies were selected.  
After reading the full articles, three studies were excluded because the studies 
encompassed experiments such as cue reactivity assessment during the study 
(Monti et al., 1999; Monti et al., 2001; Rohsenow et al., 2000). One study did not 
report on at least one of the outcome measures of interest and was therefore 
excluded (Monterosso et al., 2001). Another study was excluded, because it used 
an inpatient treatment of 21 days (Knox & Donovan, 1999). A recent study by Oslin 
et al. (2003) used participants of three aggregated studies containing one included 
study (Kranzler et al., 2000), an excluded study (Monterosso et al., 2001) and 
unpublished data, and was left out. Furthermore, a study used a nested sequence 
of 3 randomised trials and was excluded because the first ten months were not 
placebo-controlled (O’Malley et al., 2003). Three studies were excluded because 
the studies reported data from an earlier published parent trial: Cramer et al., 2003 
derived data from Krystal et al., 2001; Oslin et al., 2002 used data from Oslin et al., 
1997a and Monterosso et al., 2001; Pettinati et al., 2000, used data from the study 
of Volpicelli et al., 1992. 
Finally, a total of seventeen discrete placebo-controlled trials on alcohol 
dependence were included (Ahmadi & Ahmadi, 2002; Anton et al., 1999; Balldin et 
al., 2003, Chick et al., 2000; Gastpar et al., 2002; Guardia et al., 2002; Heinälä et 
al., 2001; Kiefer et al., 2003; Kranzler et al., 2000; Krystal et al., 2001; Latt et al., 
2002; Lee et al., 2001; Morris et al., 2001; O’Malley et al., 1992; Oslin et al., 1997b; 
Volpicelli et al., 1992; Volpicelli et al., 1997). Furthermore, two follow-up studies 
were included, Anton et al., 2001, a follow-up study of Anton et al., 1999, and 
O’Malley et al., 1996, a follow-up study of O’Malley et al., 1992. Finally, the study of 
O’Malley et al., 1995 was also included, which used data from two trials (O’Malley 
et al., 1992, and Volpicelli et al., 1992). 
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4.3.3. Methodological quality 
The results of the methodological quality assessment are presented in Table 
4.1. The percentage of agreement between the two reviewers was 89.5 % (κ = 
.848, P < 0.0001) for the validity criteria. In general, the methodological quality of 
the studies included in this review was high; 21 out of the 24 trials were assigned 
scores of 9 points or higher (M = 9.74, SD = 1.63, range 7-13). The methodological 
quality of the alcohol studies was somewhat higher (M = 10.00, SD = 1.69) than the 
opioid studies (M = 9.00, SD = 1.29), but this difference was not statistically 
significant. Frequently encountered problems were a lack of (information about) 
concealment of the randomisation, and the fact that in many studies not all patients 
who were randomised were included in the (ITT) analysis. 
 
4.3.4. Opioid studies: effectiveness of NTX 
The seven studies on opioid dependence showed wide heterogeneity in 
population, intervention, and outcome assessment. Therefore statistical pooling 
was not legitimate. Four studies reported on abstinence rates verified by urinalysis 
(Guo et al., 2001, Lerner et al., 1992, San et al., 1991; Shufman et al., 1994). 
On the medium term, two studies reported no statistically significant difference 
on abstinence between NTX and placebo (Lerner et al., 1992; San et al., 1991). 
Two other studies reported differences in abstinence rates in favour of NTX (Guo et 
al., 2001 and Shufman et al., 1994), but in only one trial this difference was 
statistically significant (Guo et al., 2001). 
Long-term effects of NTX were only reported in two studies (Guo et al., 2001 
and San et al., 1991). One study showed a statistically significant difference in 
favour of NTX regarding abstinence rates (Guo et al., 2001). One study reported no 
significant difference on the long term (San et al., 1991). 
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4.3.5. Opioid studies: compliance of NTX 
There was no statistically significant or relevant relationship between the effect 
size, which was calculated for each included study and treatment retention over the 
studies. 
 
Table 4.1. Methodological quality assessment of seven studies in the treatment of opioid dependence 
and seventeen studies in the treatment of alcohol dependence. 
First author, year 1 2 3 4 5.1 5.2 Total 
Opioid studies        
Brahen, 1977 1 3 3 0 0 1 8 
Guo, 2001 2 3 3 0 1 1 10 
Hollister,1998 1 3 3 0 0 0 7 
Lerner, 1992 2 3 3 0 0 1 9 
Mello, 1981 1 3 3 2 1 1 11 
San, 1991 1 3 3 0 1 1 9 
Shufman, 1994 1 3 3 0 1 1 9 
Alcohol studies        
Ahmadi, 2002 1 3 3 0 1 1 9 
Anton, 1999 2 3 3 2 1 1 12 
Balldin, 2003 2 6 3 0 1 0 12 
Chick, 2000 1 3 3 0 1 0 8 
Gastpar, 2002 1 3 3 0 1 1 9 
Guardia, 2002 1 3 3 3 1 1 12 
Heinälä, 2001 1 3 3 2 1 0 10 
Kiefer, 2003 2 6 3 0 1 1 13 
Kranzler, 2000 1 3 3 0 1 1 9 
Krystal, 2001 1 3 3 0 1 1 9 
Latt, 2002 2 3 3 0 1 1 10 
Lee, 2001 1 3 3 0 1 1 9 
Morris, 2001 1 3 3 0 1 1 9 
O’Malley, 1992 1 3 3 3 0 1 11 
Oslin, 1997 1 3 3 0 1 1 9 
Volpicelli, 1992 1 3 3 2 1 1 12 
Volpicelli, 1997 2 6 3 0 1 1 13 
Note: the following Cochrane quality criteria were defined: 1. Randomisation (score: 2,1 or 0); 2. 
Allocation concealment (score: 6,3 or 0); 3. Blinding (score: 3,1 or 0) 4. Inclusion of all patients in the 
analysis (score: 3,2 or 0) 5. Other criteria: 5.1 Similarity of the groups at the start of the trial (score: 1 or 0) 
5.2, Groups were treated equally (aside from the experimental intervention (score: 1 or 0)). Two follow-up 
studies (Anton et al., 2001, and O’Malley et al., 1996) and the study of O’Malley et al., 1995 were 
excluded from methodological quality assessment. 
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4.3.6. Opioid studies: concomitant psychosocial treatments 
The co-interventions in the treatment of opioid dependence widely varied, which 
complicated the evaluation of the additional effect of these co-interventions. In four 
studies only NTX was provided (Brahen et al., 1977; Guo et al., 2001; Hollister, 
1978; San et al., 1991). In one study operant analysis through reinforcement 
combined with NTX was analysed (Mello et al., 1981). In some other studies a 
psychosocial treatment, such as individual counseling, (supportive) group therapy 
and behavioral therapy was provided as a co-intervention (Lerner et al., 1992; 
Shufman et al., 1994). In sum, it was not possible to analyse the benefits of the 
included co-interventions for the opioid studies. 
 
4.3.7. Alcohol studies: effectiveness of NTX (medium term) 
Relapse rates were reported by almost all studies (except for Ahmadi and 
Ahmadi, 2002; Balldin et al., 2003; Lee et al., 2001). Fourteen studies provided 
sufficient data regarding relapse rates. Studies showed sufficient clinical 
homogeneity. The Q-test showed statistical heterogeneity [χ2 = 21.25, df 12, P = 
0.05 (Figure 4.1)], but the forest plot did not show a wide variation in effect sizes 
and confidence intervals. Therefore, we calculated an overall effect estimate. The 
pooled difference in relapse rate was 13% in favour of NTX [(95% CI) 7% to 18%; 
NNT = 8; (Figure 4.1)].  
Seven studies reported on continuous abstinence (Anton et al., 1999; Chick et 
al., 2000; Gastpar et al., 2002; Kranzler et al., 2000; Lee et al., 2001; O’Malley et 
al., 1992; Oslin et al., 1997). Both the forest plot and Q-test showed no significant 
statistical heterogeneity. The pooled difference in the proportion of participants 
remaining abstinent was 6% and not significant [(95% CI) –2% to 15%, P = 0.12, Q-
test: χ2 = 8.90, df 6, P = 0.18 (Figure 4.2)]. 
Percentages of drinking days were provided by four studies. The forest plot and 
Q-test both demonstrated considerable heterogeneity (Q-test: χ2 = 36.59, df 4, P < 
0.00001). Three studies reported a statistically significant difference in favour of 
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NTX, with differences in percentage of drinking days ranging between 2.7 and 6.7 
(O’Malley et al., 1992; Volpicelli et al., 1992; Volpicelli et al., 1997). However, 
Krystal et al (2001) showed no significant differences in percentage of drinking 
days. 
Time to first relapse was a study outcome provided in nine studies. Only two 
studies reported the standard deviation (SD) needed for pooling a continuous 
outcome (Anton et al., 1999; Krystal et al., 2001). Therefore statistical pooling was 
not possible. Five studies reported a statistically significant difference in favour of 
NTX (Anton et al., 1999; Guardia et al., 2002; Latt et al., 2002; Morris et al., 2001; 
Volpicelli et al., 1992). Four studies showed no statistically significant difference 
(Chick et al., 2000; Gastpar et al., 2002; Kranzler et al., 2000; Krystal et al., 2001).  
Six studies reported on time to first drink, but only two studies reported the 
outcome with SDs, needed for statistical pooling (Anton et al., 1999; Guardia et al., 
2002). Consequently, statistical pooling was not endorsed. In five of the six studies 
no significant difference was observed (Anton et al., 1999; Chick et al., 2000; 
Guardia et al., 2002; Kranzler et al., 2000; Morris et al., 2001). Only one study 
reported a statistically significant difference in favour of NTX (Kiefer et al., 2003).  
We conclude that there is strong evidence that NTX is superior to placebo 
regarding medium term relapse rates. There is strong evidence that that there is no 
difference in terms of continuous abstinence. Based on a qualitative analysis, there 
is strong evidence in favour of NTX regarding percentage of drinking days, 
compared to placebo. There is conflicting evidence regarding time to first relapse, 
and there is strong evidence that there is no difference in time to first drink. 
 
4.3.8. Alcohol studies: effectiveness of NTX  (long term) 
Six studies reported follow-up or long-term results (Anton et al., 2001, a follow-
up study of Anton et al., 1999; Balldin et al., 2003; Heinälä et al., 2001; Krystal et 
al., 2001; O’Malley et al., 1996, a follow-up study of O’Malley et al., 1992; Oslin et 
al., 2002). Two studies were excluded from this analysis as they did not include a 
comparison between NTX and placebo comparison (Oslin et al., 2002) or targeted 
irregular NTX use, instead of maintenance (Heinälä et al., 2001). 
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Of the four remaining studies, two studies (Balldin et al., 2003; Krystal et al., 
2001) reported no significant differences regarding time to first relapse and 
percentage drinking days. Two studies showed a significant difference in relapse 
rate in favour of NTX (Anton et al., 2001, and O’Malley et al., 1996). 
The pooled weighted mean difference in percentage drinking days (Balldin et al., 
2003; Krystal et al., 2001) was not statistically significant [2.75 (95% CI) -2.36 to 
7.86; Q-test: χ2 = 5.19, df 3, P = 0.16 (Figure 4.3)]. 
In sum, there is moderate evidence in favour of NTX concerning relapse rate. 
There is also moderate evidence that there is no difference in the long-term effects 
of NTX on percentage of drinking days and time to first relapse in alcohol 
dependent patients. 
 
4.3.9. Alcohol studies: compliance of NTX  
Partly due to a lack of available data, there was no statistically significant 
relationship between the effect sizes of the defined outcome measures as reported 
in Figure 4.2 and 4.3, and treatment retention over the studies. Nevertheless, 
several studies individually reported a significant interaction effect of NTX 
compliance on the relations between treatment condition and outcome (Chick et al., 
2000; Kranzler et al., 2000; Krystal et al., 2001; O’Malley et al., 1992; Volpicelli et 
al., 1997). Volpicelli et al (1997) demonstrate a firm relationship between the 
beneficial effects of NTX in reducing alcohol relapse and compliance. Moreover, 
less compliant subjects do not show any effect from NTX treatment. This finding 
was supported by Kranzler et al (2000), who ascertained a link between NTX 
compliance and a decline in frequency of drinking, heavy drinking and average 
alcohol consumption. According to Chick et al (2000), a NTX compliant subgroup 
yielded greater reductions in total alcohol consumption, improvements in serum 
GGT activities, improvement in physicians’ global rating of alcoholism severity and 
by greater reduction of craving compared to the less compliant subgroup. Krystal et 
al (2001) found that, independent of treatment assignment (NTX versus placebo), 
there is evidence that patients who are more compliant with prescribed medication, 
in general, attended more counseling sessions, and participated in more AA 
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meetings and in turn had better treatment outcomes. Despite the absence of a 
statistically significant correlation between treatment retention and effect size, we 
conclude that within several studies a specific relationship between NTX 
compliance and successful treatment outcome was observed, and that this finding 
may explain some of the negative findings and some of the heterogeneity in the 
findings regarding the effectiveness of NTX in the treatment of alcohol dependence.  
 
4.3.10. Alcohol studies: concomitant psychosocial treatment  
An overview of the co-interventions (frequency and interventions) used in the 
treatment of alcohol dependence is presented in Table 4.2. Almost all studies 
provided some form of additional psychosocial treatment. In general, the description 
of the psychosocial intervention was not detailed, although cognitive behavioral 
oriented treatments, including relapse prevention and coping skills, were used in 
most studies. In general, cognitive behavioral therapy (CBT) aims to reduce the 
chance that a slip or lapse may turn into a relapse (Anton et al., 1999). Studies 
generally referred to published manuals (e.g. Gorski & Miller, 1986; Kadden et al., 
1992; Marlatt & Gordon, 1985; McCrady et al., 1985; Monti et al., 1986). Some 
other studies used supportive psychosocial treatments, designed to support the 
patient's own efforts at abstinence without teaching specific coping skills (e.g. 
O'Malley et al., 1992). The frequency of the co-interventions varied between once a 
week and daily. Types of treatments were individual counseling, group therapy, or a 
combination of both. 
Several studies reported the surplus value of auxiliary psychosocial treatment 
(Anton et al., 1999; Balldin et al., 2003; Chick et al., 2000; Gastpar et al., 2002; Latt 
et al., 2002; O’Malley et al., 1992; Volpicelli et al., 1997). It was demonstrated that 
the cumulative rate of abstinence was highest for patients treated with NTX and 
supportive therapy (O'Malley et al., 1992). Conversely, NTX combined with CBT 
prevented slips from becoming relapses and produced the lowest cumulative rates 
of relapse if drinking occurred (O'Malley et al., 1992).  
 
 







 Figure 4.1. Statistical pooling of the relapse rates for alcohol dependence (medium term). 
 
Figure 4.2. Statistical pooling of the abstinence rates for alcohol dependence (medium term). 
Figure 4.3. Statistical pooling of the percentage drinking days for alcohol dependence (long term). 
Note: Four comparisons were extracted from two studies, due to the 2x2 factorial design 
Review: Naltrexone and alcohol
Comparison: 02 Abstinence                                                                                                 
Outcome: 02 Abstinence                                                                                                 
Study  Naltrexone  Placebo  RD (random)  Weight  RD (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
 Anton 1999                32/68              21/63         15.52      0.14 [-0.03, 0.30]       
 Chick 2000                16/90              16/85         23.69     -0.01 [-0.13, 0.10]       
 Gastpar 2002              43/80              42/82         17.15      0.03 [-0.13, 0.18]       
 Kranzler 2000             18/61              22/63         15.77     -0.05 [-0.22, 0.11]       
 Lee 2001                  16/24               7/15          5.73      0.20 [-0.12, 0.52]       
 O'Malley 1992             22/52              10/52         14.86      0.23 [0.06, 0.40]        
 Oslin 1997                15/21              15/23          7.27      0.06 [-0.21, 0.34]       
Total (95% CI) 396                383 100.00      0.06 [-0.02, 0.15]
Total events: 162 (Naltrexone), 133 (Placebo)
Test for heterogeneity: Chi² = 8.90, df = 6 (P = 0.18), I² = 32.6%
Test for overall effect: Z = 1.58 (P = 0.12)
 -1  -0.5  0  0.5  1
 Favours placebo  Favours naltrexone
Review: Naltrexone and alcohol
Comparison: 06 Relapse rates                                                                                              
Outcome: 01 Relapse: naltrexone vs. placebo                                                                            
Study  Placebo  Naltrexone  RD (random)  Weight  RD (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
 Anton 1999                38/63              26/68          6.87      0.22 [0.05, 0.39]        
 Chick 2000                51/85              55/90          8.17     -0.01 [-0.16, 0.13]       
 Gastpar 2002              50/80              51/82          7.89      0.00 [-0.15, 0.15]       
 Guardia 2002              19/101              8/101        12.30      0.11 [0.02, 0.20]        
 Heinälä 2001.             50/58              50/63          8.92      0.07 [-0.07, 0.20]       
 Kiefer 2002               30/40              19/40          5.21      0.28 [0.07, 0.48]        
 Kranzler 2000             31/63              29/61          6.43      0.02 [-0.16, 0.19]       
 Krystal 2001              83/187            143/378        12.89      0.07 [-0.02, 0.15]       
 Latt 2002                 27/51              19/56          6.02      0.19 [0.01, 0.37]        
 Morris 2001               45/56              30/55          6.84      0.26 [0.09, 0.43]        
 Oslin 1997                 8/23               3/21          3.96      0.20 [-0.04, 0.45]       
 Volpicelli 1997           26/49              17/48          5.61      0.18 [-0.02, 0.37]       
 O'Malley 1995             48/93              23/93          8.89      0.27 [0.13, 0.40]        
Total (95% CI) 949                1156 100.00      0.13 [0.07, 0.18]
Total events: 506 (Placebo), 473 (Naltrexone)
Test for heterogeneity: Chi² = 21.25, df = 12 (P = 0.05), I² = 43.5%
Test for overall effect: Z = 4.60 (P < 0.00001)
 -1  -0.5  0  0.5  1
 Favours placebo  Favours naltrexone
Review: Naltrexone and alcohol
Comparison: 07 Long-term percentage drinking days                                                                         
Outcome: 01 Long-term percentage drinking days                                                                         
Study  Placebo  Naltrexone  WMD (random)  Weight  WMD (random)
or sub-category N Mean (SD) N Mean (SD)  95% CI  %  95% CI
Krystal I 2001         195     18.00(25.00)        190     15.10(23.00)     40.93      2.90 [-1.90, 7.70]       
Krystal II 2001        195     18.00(25.00)        196     19.40(26.00)     39.35     -1.40 [-6.46, 3.66]       
Balldin I 2003          30     47.00(31.00)         25     32.00(24.00)     10.34     15.00 [0.45, 29.55]       
Balldin II 2003         32     50.00(35.00)         31     44.00(27.00)      9.38      6.00 [-9.41, 21.41]      
Total (95% CI)    452                         442 100.00      2.75 [-2.36, 7.86]
Test for heterogeneity: Chi² = 5.19, df = 3 (P = 0.16), I² = 42.2%
Test for overall effect: Z = 1.06 (P = 0.29)
 -10  -5  0  5  10
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This finding was confirmed by Balldin et al. (2003), in which the time to first 
relapse was longer for the group treated with CBT when compared to supportive 
therapy. Similar outcomes were observed in the study of Heinälä et al. (2001), 
where NTX combined with CBT was better than NTX combined with supportive 
therapy. In this respect it is suggested that cognitive behavioral treatments 
improve NTX treatment effectiveness (Anton et al., 1999, Balldin et al., 2003, 
Heinälä et al., 2001; O’Malley et al., 1992). 
 
4.3.11. Alcohol studies: subgroup analyses 
Subgroup analyses were performed addressing the surplus value of NTX in 
combination with different types of psychosocial treatment. Four studies used 
individual treatment such as relapse prevention or cognitive behavior therapy 
(Anton et al., 1999; Kranzler et al., 2000; Krystal et al., 2001; Volpicelli et al., 1997), 
and four studies applied group psychotherapy (Kiefer et al., 2003; Morris et al., 
2001; Oslin et al., 1997; Volpicelli et al., 1992). The pooled difference in relapse 
rate for NTX in combination with individual treatment was 13 % [(95% CI) .05 to .20; 
NNT = 8; Q-test: χ2 = 12.18, df 7, P = 0.095] and the pooled difference of NTX 
embedded in group therapy was 20 % [(95% CI) .09 to .30; NNT = 5; Q-test: χ2 = 
4.91, df 3, P = 0.18]. Meta-regression analyses showed that these subgroup effects, 
the comparison between individual and group treatment, were not statistically 
significant. Further subgroup analyses were not possible due to a lack of available 




We conducted a review on the effectiveness of NTX in the maintenance treatment 
of opioid and alcohol dependence. Where possible, studies were statistically pooled 
using the random effect model. This model takes into account the within-study 
sampling error and between-studies variation. 
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4.4.1. Opioid dependence: effectiveness of NTX maintenance 
The small number of available opioid studies showed wide variation regarding 
population and interventions. Consequently, the studies could not be statistically 
pooled. Overall, treatment with NTX may be slightly more favourable when 
compared to placebo, but due to clinical heterogeneity, there is insufficient evidence 
to confirm of refute the effectiveness of NTX in the treatment of opioid dependence. 
This result is in concordance with other reviews (Kirchmayer et al., 2004), despite 
one added recent study (Guo et al., 2004). We did not find a meaningful 
relationship between treatment retention and effect size in the included opioid 
studies. Furthermore, it was not possible to evaluate the additional effect of 
psychosocial therapy in the opioid studies. Often NTX was provided as a mono-
therapy. The other included studies used different sets of techniques to assist the 
participant. 
 
4.4.2. Opioid dependence: NTX in combination with psychosocial 
interventions 
Several studies, not included in this review, have suggested that NTX combined 
with psychosocial interventions is superior to NTX alone (Callahan et al., 1976; c.f. 
Carroll et al., 1997; Resnick et al., 1979, 1981; Stone-Washton et al., 1982). More 
recent research has demonstrated that the combination of NTX with psychosocial 
treatment may be an effective approach only for specific (highly motivated) groups 
or in controlled settings or conditions (cultural or/and family involvement) to monitor 
compliance, such as health professionals and federal probationers (Cornish et al., 
1997; Fals-Stewart et al., 2003; Kirchmayer et al., 2003; Krupitsky et al., 2004; Ling 
& Wesson, 1984; Washton et al., 1984). 
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4.4.3. Alcohol dependence: effectiveness of NTX maintenance 
This review demonstrated that NTX is effective in the treatment of alcohol 
dependence, especially with regard to the primary outcome parameter, i.e. relapse 
into heavy or uncontrolled drinking. We included seven additional recent studies 
(Ahmadi and Ahmadi 2002; Balldin et al., 2003; Gastpar et al., 2002; Guardia et al., 
2002; Kiefer et al., 2003; Latt et al., 2002; Lee et al., 2001) compared to the most 
recent update of the Cochrane review (Srisurapanont & Jarusuraisin, 2004). Our 
results corroborate the outcomes of the previous reviews on NTX and alcohol 
dependence (Bouza et al., 2004; Fiellin et al., 2000; Garbutt et al., 1999; Kranzler & 
Van Kirk, 2001; Miller & Wilbourne, 2002; Sinclair, 2001; Srisurapanont & 
Jarusuraisin, 2004; Streeton & Wheelan, 2001; Swift, 1999). 
Although most of the pooled estimates were statistically significant (medium-
term: relapse rate, continuous abstinence, percentages of drinking days, time to first 
relapse; long-term: relapse rate), some results showed considerable statistical 
heterogeneity (medium term: relapse rate, percentage of drinking days). This 
heterogeneity may be partly explained by differences in variables such as 
compliance, co-interventions (frequency and type of interventions) and 
characteristics of the study population.  
Although the pooled effect sizes may be considered to be rather modest, they 
are of the same magnitude as other psychopharmacological agents such as TCAs 
and SSRI’s in the treatment of major depression (Lima & Moncrieff 2000; Storosum 
et al., 2001). It should be noted that NTX studies in alcohol dependent patients 
were virtually all supported by non-pharmaceutical sources and thus have a smaller 
likelihood of selective publication of only positive studies.  
 
4.4.4. Compliance with NTX treatment 
To evaluate compliance, we estimated the relationship between effect size and 
treatment retention. In general, studies reported on treatment retention and not 
directly on NTX compliance. In addition, the studies that did report on NTX 
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compliance used a wide variety of methods to measure compliance, such as pill-
count, the inclusion of riboflavin in NTX capsules, and self-reports. Furthermore, the 
reported compliance rates were measured at different follow-up periods and using 
different statistical methods. 
Analyses of compliance measured, as the relationship between treatment 
retention and effect size, yielded no positive results.  These negative findings may 
be due to 'aggregation bias' or 'ecological fallacy' (Morgenstern, 1982), as the 
relationship with participant averages across trials may deviate from the relationship 
for participants within trails, and without individual data cannot be investigated 
(Thompson & Higgins, 2002). Indeed, several individual studies did report 
statistically significant findings (Chick et al., 2000; Kranzler et al., 2000; Krystal et 
al., 2001; O’Malley et al., 1992; Volpicelli et al., 1997). Consequently, we conclude 
that NTX compliance probably is pivotal for successful alcohol treatment. 
 
4.4.5. NTX in combination with psychosocial interventions in alcohol 
treatment 
It is suggested that there is added value of auxiliary psychosocial treatment, and 
therefore NTX treatments should be delivered in concert with psychosocial 
interventions (Srisurapanont & Jarusuraisin 2004). Nearly all studies on NTX 
embedded NTX in a cognitive-behavioral oriented program (Table 4.2). A 
systematic exploration of the influence of psychosocial co-intervention was 
hindered by sketchy descriptions of these treatments. Consequently, the content of 
CBT and supportive therapy was often unclear. Nevertheless, based on the current 
data, there is some evidence that the combination of NTX with CBT is somewhat 
more effective than NTX combined with supportive therapy. NTX and CBT both 
target to prevent slips from becoming relapses and therefore might have synergistic 
effects, but it is not possible to draw firm conclusions on the possible auxiliary 
benefits of these psychosocial interventions. 
Nowadays, cognitive-behavioral interventions, such as teaching coping skills 
and relapse prevention are considered as top-ranked treatment modalities (Miller & 
Wilbourne 2002). It should be noted, however, that some groups, such as older 
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adults, appear to respond well to a medically oriented program that is rather 
supportive and individualised (Oslin, Pettinati & Volpicelli, 2002). 
Subgroup analyses suggested a difference in effect in favour of NTX when 
combined with group therapy. The difference between group therapy and individual 
or other treatment was, however, not statistically significant. The meta-regression 
analysis was hindered by the lack of statistical power (only four studies per 
subgroup). 
 
4.4.6. Long-term effects of NTX 
In general, the studies reported on the medium-term effects (i.e. 12-13 weeks) of 
NTX. Evaluations of placebo controlled NTX maintenance programs on the long 
term are rather scant, especially for opioid studies. Due to insufficient data, no firm 
conclusions can be drawn with regard to the effects of NTX after discontinuation. 
However, it is tempting to argue that NTX, just like other medications such as 
antipsychotics and antihypertensives, does not foster sustained remission after 
discontinuation, as chronic disorders need continuous treatment  (McLellan, 2002). 
This would suggest that NTX should be prescribed over a long period of time. 
 
4.4.7. Methodological quality 
In general, the methodological quality of the included studies just exceeded the 
threshold of 50% (> 8). In most studies the scores regarding methodological quality 
were suppressed due to inadequate description of randomisation, intention-to-treat 
analysis, and allocation concealment criteria. Furthermore, many studies showed 
dropout rates, which exceeded the threshold of 20%. The loss to follow-up and the 
high drop out rates (attrition bias) produce a substantial problem, as retention itself 
is often one of the primary outcomes. 
All included opioid studies fulfilled the criterion of an adequate blinding. It should 
be noted, however, that blinding of patients in an opioid NTX–placebo trial is 
virtually impossible. Participants can easily trace their allocated condition by a 
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heroin challenge test. NTX was approved by the FDA based on its pharmacological 
efficacy without any positive double blind studies because of the above-mentioned 
blinding problems. A third condition (no treatment) can be added to resolve some of 
the methodological issue. 
 
4.4.8. Limitations of this review 
This review has a few important limitations. We did not consult the authors to 
receive either additional information on methodological aspects of their study, or 
additional (statistical) information when it was not reported in their studies. 
Supplementary information on methodological assessment might have resulted in 
(slightly) higher method scores. The number of studies that provided statistical data 
needed to perform quantitative analyses limited the actual performed analyses, as 
we had to eliminate several studies from the meta-analyses due to a lack of 
available data or because the standard deviations (SD’s) were not provided. 
Therefore, the results might be slightly skewed and this might attenuate the validity 
of the conclusions. 
In general, the performed meta-analyses were based on intention to treat (ITT) 
analyses, although several studies did not report ITT data suitable to conduct 
statistical analyses. We often chose to extract reported outcomes based on 
smaller sample sizes than the initial number of randomised participants (Chick et 
al., 2000; Gastpar et al., 2002; Guardia et al., 2002; Krystal et al., 2002). This 
might have resulted in improved outcomes in favour of NTX. Due to inclusion of 
other studies in the analyses this limitation is not substantial and probably does 
not affect the conclusions. 
 
4.4.9. Safety of NTX 
Exploring the literature, we encountered several publications dealing with safety 
issues, which may be important for use of NTX in regular clinical practise. There are 
three remarks to make. 
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 It must be noted that NTX itself has virtually no abuse potentials and is not 
characterised by tolerance. It has been argued that NTX has the capacity to 
produce dose related hepatocellular injury. Nevertheless, there is virtually no 
evidence that NTX causes clinically significant liver disease or exacerbates, even at 
high doses, serious pre-existing liver disease (Brewer & Wong, 2004). 
Currently, there are some reports of serious adverse events and even deaths, 
which are attributed to rapid detoxification procedures (Dyer, 1998; Kaye et al., 
2003; Pfab et al., 1999; Roozen et al., 2002; San et al., 1995). It is important to note 
that NTX has no approval for rapid opioid detoxification in the US and EC, though it 
has been used for that purpose. The method is surrounded with a variety of 
opinions, as there is lack of agreement about the treatment and evidence on the 
long term (Singh & Basu, 2004). 
Warnings have been issued regarding the overdose risk following NTX 
discontinuation in the treatment of opioid dependent patients. Receptor 
hypersensitivity followed by tolerance reduction could increase the risk of a fatal 
heroin overdose (Lesscher et al., 2003). However, a retrospective study showed 
no significant difference in overdose deaths between a NTX-exposed and a non-
exposed group of deaths (Arnold-Reed et al., 2003). Conversely, a recent large 
longitudinal study, based on data from 12 trials, ascertained that individuals who 
leave pharmacotherapies for opioid dependence experience higher overdose and 
death rates compared with those in treatment. Accordingly, NTX treatment 
patients should be warned about heroin overdose risks (Digiusto et al., 2004; 
Ritter 2002). 
 
4.4.10. Options to increase the effectiveness of NTX 
Several strategies and hypotheses have been brought up in the literature, in 
which NTX compliance is subject of debate. Recently, Weiss (2004) suggested 
three strategies to improve the effectiveness of pharmacotherapy in the treatment 
of patients with alcohol and drug dependence: (1) interventions that can be used 
by the clinician in individual sessions, (2) the inclusion of external reinforcements 
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(positive and negative contingencies) and involvement of family members or 
significant others and (3) medication prescribing and dosing strategies. 
Individual sessions should focus on a collaborative approach to create a 
treatment plan that addresses the cost/benefit ratio of improved outcome by NTX. 
Patients who are adherent are considered as acting on a consensual agreed-upon 
plan that they have had a part in designing, or at least as accepting the importance 
of performing the recommended treatment actions (DiMatteo & DiNicola, 1982). In 
this respect interventions aimed at enhancing medication adherence should 
specifically target the patient's beliefs and attitudes concerning the illness and 
medication and should not be in conflict with subjects’ personal goals (Patel & 
David, 2004). 
A second option concerns the inclusion of external reinforcements. Linked to the 
Community Reinforcement Approach (CRA), an adjunctive instructional program for 
improving compliance can be used (Azrin & Teichner, 1998). It can be employed to 
encourage taking NTX under supervision (of significant others) to increase 
treatment adherence (Meyers & Smith, 1995; Roozen et al., 2003). In addition, 
Contingency Management (CM; Higgins et al., 2004) can enhance compliance and 
increase the effectiveness of NTX (Carroll et al., 2001; Carroll et al., 2002; Preston 
et al., 1999). Both CRA and CM are based on the learning theory derived from the 
operant reinforcement approach designated by Skinner (Skinner, 1938). NTX fits 
well in this framework as NTX directly competes with positive reinforcement 
induced by the use of opioids and alcohol. 
A third opportunity is aimed to increase the likelihood of taking NTX. "Pill-count" 
or medication usage skills for effectiveness program (e.g. MUSE-P) can improve 
medication compliance through a feedback system. Feedback is given by 
medication bottles with micro-electronic monitor caps that record the date and time 
of each opening and display the number of hours passed since the previous 
opening (Cramer 1998; Cramer & Rosenheck 1999). A pharmacological route, as a 
dosing strategy, to govern adequate plasma concentrations of NTX seems to be the 
insertion of NTX implants or depots (Carreno et al., 2003; Foster et al., 2003; 
Kranzler et al., 2004) to treat both alcohol and opioid use disorders. 
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4.4.11. Predictors of NTX’ effectiveness 
Recently, there is an increase in interest to predict the effectiveness of NTX, 
which is important to explain the variability in outcome in the current literature. It is 
ascertained that genetic polymorphism programming the μ-opioid receptor might 
play a pharmacogenetic role in the differential response to an antagonist (Oslin et 
al., 2003, Oswald et al., 2004). Other alcohol studies on predictors of clinical 
effectiveness of NTX suggest that participants with an older age, high levels of 
alcohol craving, a strong family history of alcohol use disorders, high levels of 
somatic distress, and low educational level are more likely to benefit (e.g. Flannery 
et al., 2003; O’Mallley et al., 1996; Oslin, Pettinati and Volpicelli, 2002; Monterosso 
et al., 2001; Volpicelli et al., 1995). 
Studies on opioids showed that young participants, a low level of dependence, 
employment, being married, and length of NTX therapy were related to better 
outcome (Greenstein et al., 1983; McGregor et al., 2002). A high score on cluster-B 
personality disorders and polydrug use is associated with relapse in NTX opioid 
treatment (Roozen et al., 2003). 
 
4.4.12. Conclusions and recommendations for future research 
We conclude that NTX, at least based on the pharmacological profile, is a viable 
agent in substance use disorders including opioids and alcohol. Blinding problems 
in the classic way and insufficient data afflict the assessment of effectiveness in 
opioid dependence. Therefore, up to now, there is insufficient evidence to support 
maintenance treatment in opioid dependent patients. In contrast, this review 
confirms the effectiveness of NTX in the maintenance treatment of alcohol 
dependence. 
In general practice, it is crucial that patients take NTX as prescribed in order to 
control safety issues and to evaluate the effectiveness of NTX, properly. Therefore 
it is warranted to pursue avenues of research to prevent drop out and to ameliorate 
treatment compliance. Future studies on both alcohol and opioid disorders ought to 
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seek the identification of the cognitive-motivational rationale (adherence) 
concerning the NTX treatment regimen. In combination with reports on side effects, 
craving and urinalyses on both NTX and its' active metabolite (i.e. 6-β-naltrexol) 
related to alcohol consumption or opioid metabolites (i.e. 6-monoacetylmorphine) 
may provide more awareness into the potential mechanisms of action of NTX, in 
terms of discontinuation, relapse, and resuming alcohol or opioid use. 
More RCTs with longer treatments are recommended, particularly because 
addiction is viewed as a chronic relapsing disease (Leshner, 1997; McLellan, 2002; 
Van den Brink & Van Ree, 2003). Finally, to gain more information on the effects of 
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Experiences with an outpatient relapse program 
(Community Reinforcement Approach) combined 
with naltrexone in the treatment of opioid-
dependence: effect on addictive behaviors and the 
predictive value of psychiatric comorbidity 





There is increasing interest in naltrexone, an opiate antagonist, in the treatment 
of opiate addicts. The effects of naltrexone are often compromised by a lack of 
compliance and drop-out. The effects of this compound are probably more 
favorable when combined with a psychosocial intervention such as Community 
Reinforcement Approach (CRA). To explore the effects of a combination therapy 
(naltrexone plus CRA treatment) and the predictive value of sociodemographic and 
psychopathologic characteristics. Using a before-and-after design, heroin addicts (n 
= 24) receiving a combined naltrexone plus CRA treatment are compared with a 
group (n = 20) on methadone maintenance therapy (reference group). Over a 
period of 6 months, 58% (14/24) did not relapse, after 1 year at least 55% (12/22) 
still met the initial goal of continuous abstinence. At baseline, the treatment group 
and the reference group were similar on nearly all variables except for the number 
of times clients were arrested. Within the treatment group, a comparison was made 
between the continuous abstinent and those who relapsed into frequent opioid use. 
Differences were significant in the cluster-B personality disorders and in polydrug 
users. The combination of naltrexone plus intensive CRA in an outpatient setting 
appears to be promising. A high score on cluster-B and polydrug use is associated 
with relapse. 





In the field of opiate addiction treatment, there has been an increase in the use of 
pharmacological compounds such as naltrexone. After induction, this agent can 
be effective in the prevention of recurrent heroin use. During naltrexone 
maintenance treatment, the effects of heroin will be blocked, leading to lesser 
anticipation of the desired effects and a decrease in the relapse rate. 
Similar to other forms of therapies aimed at abstinence, patient compliance is 
often a problem and many patients relapse after having discontinued taking 
medication (American Psychiatric Association, 1995).  
One study (Washton et al., 1984) showed good results with naltrexone (61% 
abstinence after 6 months) with highly motivated participants, such as business 
people and doctors. In addition, in southern Europe, good results with naltrexone 
(40 % abstinence after 6 months treatment) have been reported (Guiteirrez et al., 
1995). The result is attributed to traditional family structure and other forms of 
social interactions that increase treatment compliance. These findings suggest 
that a combination of naltrexone maintenance and psychosocial therapy may lead 
to an increase in therapy compliance and a decrease in the relapse rate. 
A promising approach is the Community Reinforcement Approach (CRA) 
(Meyers & Miller, 2001). CRA encompasses elements such as social network and 
enhancing motivation and is often supported by a variety of pharmacological 
interventions (i.e. naltrexone) and procedures to enhance compliance with the 
recommended medication regimen. First, there are interventions aimed at 
enhancing the social network (for example interventions including partners and 
parents, aimed at compliance). CRA pays attention to the expectations, motivation, 
coping skills, social, labor and recreational elements.  
However, combined forms of therapy also suffer often from early dropout and 
lack of therapy compliance. An important factor, which effects compliance and 
dropout, is psychiatric comorbidity (Kranzler & Rounsaville, 1998). In general the 
severity of psychiatric symptoms worsens the prognoses (McLellan et al., 1983). 
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Research suggests that the prevalence of psychiatric disorders among heroin 
addicts is high. There is a relationship between drug addiction and depression, 
anxiety and personality disorders (Verheul et al., 2000). Personality disorders are 
seen as negative predictors of treatment outcome (De Jong et al., 1993). 
The aim of this open-label study is to optimize the effects of using a combination 
of CRA and naltrexone.The present study consists of a naturalistic follow-up study 
with before-and-after comparison without a control group. In order to assess a 
possible generalization of the study, a comparison on relevant variables was made 
with a group of heroin addicts participating in a methadone maintenance program. 
The following questions were addressed: (1) is the study population comparable to 
the group of addicts participating in a methadone maintenance program; (2) what is 
the outcome in heroin addicts treated with naltrexone plus CRA, and (3) what is the 
predictive value of sociodemographic characteristics and psychiatric comorbidity in 
patients treated with naltrexone plus CRA?  
 
5.2. Methods 
5.2.1. Study Population 
The treatment group consists of 24 heroin addicts treated with naltrexone in a 
CRA program from February 1996 until evaluation in May 1998. The treatment 
took place at the outpatient treatment center for addiction KENTRON in Roosen-
daal (< 100.000), the Netherlands. Subjects were recruited from methadone 
programs through newspaper articles and via addiction clinics throughout the 
Netherlands. During the research period 60 persons showed interest in 
participating by at least one contact. 24 persons were included (40%). 
All 24 subjects were opiate-dependent and 21 of these were participants in a 
methadone program. Subjects were included during a 24-month period. Table 5.1 
shows that follow-up varied between 6 and 24 months (mean length of treatment 
16.6; SD = 5.3 months). 
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Detoxification of 19 subjects consisted of a rapid detoxification procedure 
(Roozen et al, 1997). In this procedure naltrexone was administered in increasing 
dosage: 12.5 mg/day on day 1, 25 mg/day on day 2, and up to 50 mg/day on days 
3 and 4. To ameliorate withdrawal symptoms clonidine, diazepam, midazolam 
and ondansetron were used as indicated. The other 5 patients were detoxified by 
a methadone-tapering procedure either in a regular clinic or at home. Patients 
from the latter group had to pay a fee of Eur 227.00 (n = 5), and patients from the 
rapid detoxification program had to pay an extra fee of Eur 1,818.00 (n = 19). 
Detoxification was followed by naltrexone maintenance. Subjects were 
stimulated and expected to bring a non-using partner, spouse or good friend to 
assist as a coach during detoxification and aftercare treatment. To check 
selection bias, a reference group of 20 participants randomly drawn from a 
regular methadone program was selected. 
 
5.2.2. Intervention 
After naltrexone induction, all subjects received a maintenance dosage of 
naltrexone of 25 mg/day. The treatment consisted of medical support, psychosocial 
interventions followed by a consistent and strict policy towards compliance 
(naltrexone) and control of substance abuse by urine analysis. The importance of 
the social network was emphasized. CRA implemented: diagnostic interview 
(functional analysis), psycho-education, pharmacotherapy, compliance therapy, 
urine analyses/monitoring, marriage/relation therapy, and support of the social 
network, career orientation, job counseling, education and hobbies, problem 
solving, social skills and cognitive restructuring.  
The therapist (first author) has several years experience in the addiction setting. 
On regular basis, he received supervision from the second author and from 
multidisciplinary coworkers. The CRA program was tailored to the work of Meyers 
and Smith (1995). Treatment integrity was guarded on the basis of monitoring forms 
and stored in files. Data collection, extraction and interviewing was done by an 
independent researcher. 
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During the first month of treatment, counseling sessions averaged 2-3 sessions 
of 45 min/week, which was reduced to 1 weekly session of 45 min after 3-6 months, 
and, during the last phase, to monthly sessions. After 9 months the dosage of 
naltrexone was reduced to 12.5 mg/day. Abstinence was verified by means of 
controlled urine analyses. 
 
5.2.3. Assessment Procedure 
Subjects in the treatment group were interviewed prior to detoxification regarding 
baseline characteristics. The reference group was assessed in the same way. 
 
5.2.4. Instruments 
The following questionnaires and tests were included in this study: (1) SCL-90 
(Symptom Check List; Derogatis, Lipman & Covi, 1973); (2) ABV (Amsterdamse 
Biografische Vragenlijst; Wilde, 1970); (3) VKP Questionnaire on Personality Traits 
(Vragenlijst Kenmerken van de Persoonlijkheid; Duijsens et al. 1993), and (4) the 
VGIT, the shortened version of the GIT (Groningse Intelligentie Test; Luteijn & 
Kooreman, 1987); 
1. The SCL-90 is a multidimensional self-report on mood and somatic com-
plaints. This list has been translated into Dutch (Arrindell & Ettema, 1981). 
There is a relationship between the scales of depression and anxiety in the 
SCL-90 and relevant categories in the DSM-III(R) (Koeter, 1992). The SCL-
90 has proven to be a reasonable indicator of the severity of 
psychopathology among psychiatric patients (Koeter, Ormel & Van den 
Brink, 1988).  
2. The ABV is a personality questionnaire measuring the dimensions: N = 
neurotic instability; NS = neurotic somatic complaints; E = social 
extravertism, and T = test attitude. The T dimension ranges from a self-
criticizing attitude (low score) to a self-defending attitude (high score) in 
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answering the questionnaire. The N and NS scales are highly inter-
correlated. The test-retest index is satisfactory (De Zeeuw, 1986).  
3. For the presence and severity of personality pathology the VKP was used. 
This self-reporting questionnaire is based on the International Personality 
Disorder Examination (IPDE) of the WHO (World Health Organization, 
1993). The VKP provides severity ratings on all 13 DSM-III-R (American 
Psychiatric Association, 1987) personality disorders. An important 
advantage of the VKP (next to cost-effectiveness) is the fact that during 
testing there is no systematic bias or interview tendencies (Zimmerman, 
1994). Compared to an interview, the VKP has a high sensitivity and a low 
specificity. 
4. VGIT: in this study intelligence was tested by using the short version of the 
GIT (Luteijn & Kooreman, 1987) consisting of the 3 subtests: numerical, a 
card lay puzzler and a word puzzler. The short version correlates 0.91 with 
the complete version (10 subtests) of the GIT. The results can be 
translated into an IQ score (De Zeeuw, 1986). 
 
5.2.5. Statistical Analysis 
To assess the predictive value of psychiatric co-morbidity comparisons were 
made between the abstinent and relapsed group concerning sociodemographic 
background, intelligence, juridical conflict, psychopathology and personality 
disorders. Differences in the means of continuous variables were tested by using 
the Student’s t test. χ2 statistics and Fisher’s exact test (two-sided) were used to 
test differences in categorical data. Because of the small sample size and the 
explorative nature of the study, the significance level was set at P < 0.05. 




5.3.1. Comparison of treatment group with regular methadone clients 
Table 5.1 shows that the 2 groups are similar on all variables except for the 
number of times clients were arrested (96% naltrexone versus 57% methadone P < 
0.05). 
 
Table 5.1. Characteristics and psychopathology among naltrexone- and methadone population. 
 
 Population P 
 naltrexone (n=24) methadone (n=20)  
 Mean SD Mean SD  
Age, years 30.5 6.4 29.9 7.1 NS 
Age onset opiate addiction, year 21.7 4.5 23.0 5.3 NS 
Duration addiction, years 8.8 6.0 7.0 8.0 NS 
Daily amount heroin, g 0.6 0.7 0.8 0.8 NS 
Daily amount methadone, mg  24.8 10.6 25.7 9.0 NS 
Mean IQ  102 10.6 90 13.5 NS 
Polydrug users, % 67  91  NS 
Women, % 13  18  NS 
Min. once arrested, % 96  57  < 0.05 
Min. once detention, % 58  43  NS 
Min. once suicide attempt, % 35  29  NS 
Clients with partner, % 63  57  NS 
Clients with occupation, % 43  57  NS 
Subscale SCL-90 (n=24) (n=16) NS 
   Anxiety  15.3 5.5 17.1 6.6 NS 
   Agoraphobia 8.7 3.0 10.6 4.7 NS 
   Depression 33.0 12.7 34.9 13.4 NS 
   Som. complaints 21.6 8.6 22.9 9.0 NS 
   Insufficiency 16.5 5.1 17.4 6.0 NS 
   Sensitivity 31.2 11.0 31.6 11.6 NS 
   Hostility  10.3 3.9 9.3 4.6 NS 
   Insomnia  6.9 3.3 7.2 3.8 NS 
   Other 14.3 4.9 14.8 5.6 NS 
Total 157.6 47.8 165.8 54.1 NS 
Subscale ABV (n=24) (n=16)  
   N 69.5 31.6 55.3 27.8 NS 
   NS 24.3 9.1 23.3 8.9 NS 
   E 60.8 16.9 52.3 17.5 NS 
   T 32.7 7.9 37.3 8.3 NS 
Note: Displayed are numbers, percentages, mean scores, standard deviations and significant levels (P < 
0.05) for subscales and total scores of the SCL-90 and ABV. 
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5.3.2. Treatment outcomes of the naltrexone group 
After a 6-month treatment period, 14 of 24 clients were still abstinent (58%). 
After 1 year, 12 of 22 were still abstinent (55%). One client used heroin incidentally 
after detoxification without relapse into frequent opiate abuse. All 10 clients, who 
relapsed into frequent opiate abuse, did so within 7 months after the start of 
treatment (Table 5.2). 
 
Table 5.2. Retention characteristics of the treatment population. 
Naltrexone plus CRA population 
Number of clients who relapsed 10/24 (42%)  
Number of clients who were abstinent after:  
    Mean ≥ 6 months 14/24 (58%)  
    Mean≥ 12 months 12/22 (55%)  
Mean length of treatment 16.6 (months) SD = 5.3; min 6, max 24 
Mean time to first relapse  3.8 (months) SD = 2.4; min 1, max 7 
Note: Displayed are numbers, percentages, means, standard deviations, minimal and maximal values. 
 
Of 11 frequent cocaine users, 9 used cocaine a couple of times during treatment. 
One of them had a period of some weeks of extensive cocaine use. In that scenario 
the treatment was intensified and adapted to cocaine use, which ceased. Three 
clients who regularly used amphetamines ceased using this drug. One of them 
started taking drugs again after 5 months in treatment, but ceased using the 
substance again after 9 months. Of 8 benzodiazepine users, 6 stopped their 
benzodiazepine use. One of them persisted in irregular use of benzodiazepines, 
another slowly decreased his use to a stable maintenance level. The use of 
cannabis remained the same for almost all clients. 
 
5.3.3. Predictive value of sociodemographic characteristics and 
psychiatric comorbidity 
The abstinent (n = 14) and relapsed clients (n = 10) were compared with regard 
to sociodemographic background, intelligence, social integration, juridical conflict, 
psychopathology and personality disorders. Of the 43 different comparisons made, 
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only three showed statistical significance: (1) 90% of the relapse population were 
poly-drug users compared to 50% in the abstinence group; (2) the T score of the 
ABV showed a small but significant difference, a highly critical self-evaluation 
indicates a risk of relapse, and (3) those who relapsed had a higher total score on 
the B-cluster personality disorder measured at a dimensional level (Table 5.3). 
 
Table 5.3. Personality pathology according to DSM-III(R) axis II as measured by VKP, among naltrexone 
plus CRA group both in abstinent- and relapsed population. 
Disorder Dimensional score P 
 abstinent (n=14) relapsed (n=10)  
 Mean SD Mean SD  
Cluster A 5.2 3.8 5.6 4.7 NS 
   Schizoid 1.1 1.3 1.2 1.3 NS 
   Schizotypal 2.1 2.1 2.1 2.3 NS 
   Paranoid 2.1 1.3 2.3 1.6 NS 
Cluster B 9.7 5.0 15.8 6.4 < 0.05 
   Borderline 2.4 1.8 3.7 2.1 NS 
   Antisocial 5.1 2.7 7.1 2.8 NS 
   Histrionic 0.9 1.4 2.0 2.1 NS 
   Narcissistic 1.4 1.6 3.0 2.4 NS 
Cluster C 7.7 7.0 9.5 7.9 NS 
   Dependent 1.8 1.9 2.8 2.4 NS 
   Avoidant  1.8 2.2 1.8 2.4 NS 
   Obsessive-compulsive 1.9 2.1 2.4 2.3 NS 
   Passive-aggressive 2.2 2.1 2.5 1.6 NS 
Appendix A    
   Sadistic 0.7 0.7 1.1 1.2 NS 
   Self-defeating 1.9 1.9 2.7 2.1 NS 
Note: Displayed are means, standard deviations and significance levels (P < 0.05) of the dimensional 




The results of this pilot study, 55% drug free for a period of at least 12 months, are 
promising considering that this group of heroin addicts had a long addiction history 
and a long-term history of failed attempts to become abstinent. These results were 
achieved by rapid detoxification and by means of psychosocial outpatient treatment 
with naltrexone support. For the interpretation of these results it is important to 
investigate the selectivity of the treatment group. A comparison with a reference 
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group of methadone patients showed that both groups were similar. There was no 
difference as to drug abuse history and the amount and severity of (comorbid) 
psychopathology were not less in the naltrexone group. The only difference was the 
fact that the subjects participating in naltrexone treatment had been arrested more 
frequently than the subjects of the regular methadone program. 
It is, however, likely that those subjects who applied for participation in the 
naltrexone group were more motivated than those participants following regular 
programs. Patients, in the treatment group could afford to pay a fee, or had a 
person in their network willing to pay for the treatment. Probably only a limited and 
selective proportion of heroin addicts maintain good contacts with non-addicts in 
order to find a non-drug using partner, spouse or friend willing to assist as a coach 
during treatment. In sum, participants in the naltrexone treatment group were 
probably better motivated and integrated in the community.  
However, this can hardly be used as an objection against the study results, 
because motivating subjects is one of the key elements of the treatment as a whole.  
When the fee was a problem, or when the patient or the network was incapable of 
financing the treatment (objective information supporting their claim), there was a 
possibility of raising the complete amount of money from a charity foundation, 
from the municipality or from social benefits as a gift. Prior to acceptance, potential 
candidates and their coaches took part in a couple of informative meetings where 
they were motivated and prepared for treatment. It is the experience of the authors 
that this preparation prior to detoxification should not be underestimated.  
As to any connection between the type of addict and success rate, we found that 
the risk of dropout was greatest among polydrug users, although even here 7 of the 
16-polydrug users (44%) benefited from the treatment. In addition, cluster-B 
personality disorder was found to be an indicator for dropout, but was insufficient to 
be a contraindication for participation (c.f. Verheul, 1997).  
Considering a 55% abstinence rate covering an average period of 12 months 
and comparing these results with other studies we find the results promising. 
Although it is tempting to credit the results to the applied intervention (naltrexone 
plus CRA), this is not possible until a randomized experimental design is followed. 
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High abstinence rates in heroin addicts by a new 
comprehensive treatment approach 





The objective of this study was to determine the effectiveness of a new 
combination of naltrexone maintenance combined with the Community 
Reinforcement Approach (CRA) in detoxified, opioid dependent patients. The 
design consisted of an open, naturalistic study following a RCT on the 
effectiveness of two methods of rapid detoxification. Four outpatient addiction 
treatment centres in the Netherlands participated. 
272 detoxified patients were recruited from methadone maintenance programs. 
The intervention encompassed an outpatient treatment during 10 months, 
consisting of 13 sessions focusing on naltrexone compliance and 10 sessions 
according to CRA. The main outcome measures were abstinence for opioids and 
cumulative abstinence duration at 1, 10 and 16 months after detoxification. 
Secondary outcomes included health status, use of other psychoactive 
substances, addiction severity, craving, and general psychopathology. Follow-up 
data were available for 86% of the participants at 16 months. With intention-to-
treat analysis, treatment yielded abstinence rates of 28% and 32% at 10 and 16 
months. The cumulative abstinence rate at 16 months was 24%. Health related 
quality of life significantly improved more in the continuously abstinent group than 
in the relapsed group. In the abstinent group craving, general psychopathology, 
use of other psychoactive substances and addiction severity decreased 
significantly. An abstinence-oriented approach consisting of rapid detoxification 
followed by a combination of naltrexone and CRA is a clinically significant 
alternative for long-term methadone maintenance treatment for opioid dependent 
patients.  




An estimated 25,000 heroin dependent patients live in the Netherlands 
(16,000,000 inhabitants).  About three-quarters are served by addiction treatment 
centres, particularly by means of methadone maintenance treatment. About 4,500 
of the opioid dependent patients are involved in drug free treatment.  
Interventions directed at abstinence are regarded as problematic in terms of high 
drop-out and high relapse rates and prove to be effective only in a minority of 
motivated patients under stable living conditions with adequate social support 
(Van den Brink & Van Ree, 2003). Given the difficulty of achieving sustained 
abstinence (Amato et al., 2003), there is a tendency to focus on stabilisation and 
harm-minimisation (Krantz & Mehler, 2004). 
Recent developments in the treatment of opioid dependent patients aiming at 
abstinence are promising. In general, detoxification in opioid dependent patients 
is not a substitute for treatment, but it is regarded as the first prominent 
component in a comprehensive treatment strategy (Kasser et al., 1997). 
Detoxification strategies based on antagonist-induced withdrawal seem to be 
associated with higher initial abstinence rates and with a guaranteed start of 
naltrexone maintenance treatment (Gowing, Ali & White, 2002a). Naltrexone 
blocks the euphoria induced by opioids and prevents the incentive property of 
sustained use. Studies on naltrexone maintenance show a clear effect in highly 
educated and socially well-integrated groups (Kirchmayer, Davoli & Verster, 
2003). Pharmacotherapy of opioid addiction is more effective in combination with 
behavioral and psychosocial approaches (Kleber, 2003; Roozen, Kerkhof & Van 
den Brink, 2003), although innovative approaches to encourage medication 
adherence are needed (Weiss, 2004).  
In the Community Reinforcement Approach (CRA) adherence to medication 
can explicitly be stimulated. CRA regards behavior as modifiable by positive 
reinforcement from the individual’s real-life community context (Meyers & Smith, 
1995). In general, there is evidence for the efficacy of CRA, with or without 
medication, in various substance-related disorders, including alcohol, cocaine and 
heroin (Roozen et al., 2004).  
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The objectives of this study were to determine whether such a comprehensive 
approach results in high, long-term abstinence rates after successful 
detoxification in opioid dependent patients and whether continuously abstinent 
patients do better than relapsing patients in other domains.  
 
6.2. Methods 
6.2.1. Study design and setting 
From four addiction treatment centres in the Netherlands (Novadic, Jellinek, 
Parnassia and Kentron), 296 participants were recruited for this naturalistic study. 
Twenty-four did not meet the inclusion criteria (n = 5) or refused to participate (n = 
19). After a standardized inpatient detoxification program of one-week (De Jong, 
Laheij & Krabbe, 2005) all 272 patients started treatment with naltrexone 
maintenance and CRA in an outpatient condition. Follow-up was conducted at 1, 
10 and 16 months after detoxification. 
 
6.2.2. Participants 
All patients were recruited from the standard methadone maintenance 
programmes on a voluntary basis. They attended these programmes at least 
during the previous year, were at least 18 years old and met the diagnostic 
criteria for opioid dependence according to Diagnostic and Statistical Manual of 
Mental Disorders (American Psychiatric Association, 1994). They underwent 
several unsuccessful attempts to become abstinent, expressed their clear wish to 
become abstinent, and were familiar with the Dutch language. Exclusion criteria 
were: severe somatic diseases or psychiatric disorders, pregnancy, AIDS, doubts 
about the patient’s willingness to co-operate and contraindications regarding 
general anaesthesia. Patients were not excluded because of dependence on 
other drugs or drug abuse.  However, because of the unpredictable effects of 
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cocaine on the cardiovascular system during anaesthesia, treatment was 
postponed for 48 hours if a patient had used cocaine shortly before detoxification.  
 
6.2.3. Treatment 
The CRA protocol (Roozen et al., 2000) encompassed twenty-three sessions. 
Physicians and psychosocial therapists administered the sessions. This protocol 
was tailored on the CRA manual of Meyers and Smith (1995). In 13 sessions, a 
physician administered and monitored compliance with naltrexone (50-mg dd.), 
addictive behaviors, craving, and the occurrence of adverse events. Subjects had 
to be accompanied by a non-drug using coach during treatment as for example a 
partner, spouse or good friend, who specifically assisted the patient with taking 
naltrexone. Concurrently, in 10 psychosocial sessions, the lifestyle of the patient 
was assessed and discussed. In these sessions attention was paid to drug refusing 
behavior, relational issues, social counseling, recreational counseling, vocational 




Independent research assistants assessed participants at baseline and during 
follow-up. The primary outcome measure was defined as self-report of no heroin 
and/or methadone use in the last 30 days verified by urine analysis for opioids at 
follow-up. The Cumulative Abstinence Duration (CAD) was defined as the period 
starting after detoxification until the first use of opioids. At baseline and at 16 
months the European version of the Addiction Severity Index (Kokkevi & 
Hartgers, 1995) was used to assess the severity of seven areas of functioning: 
medical, employment, alcohol, substances, legal, family and social, and 
psychiatric. At all assessment points health domains were measured with the SF-
36 (Ware & Sherbourne, 1992). The health related quality of life, based on 
societal preference values (index) and from the patient perspective (visual 
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analogue scale: VAS), was measured with the EuroQol-5D (Brooks, 1996). Use of 
other psychoactive substances and addiction severity was measured with the 
EuropASI and urine analyses. Craving was measured with a VAS and general 
psychopathology with the Symptom Checklist-90 (Derogatis, 1983). 
 
Table 6.1. Baseline characteristics of the 272 patients. 
 Mean baseline (SD) 
Age (years) 35.9 (6.4) 
Male (%) 82.0 
Ethnic Dutch (%) 82.9 
Fully employed (%) 50.2 








Regular Drug use (years):  
Heroin 12.1 (5.9) 
Methadone 7.4 (5.7) 
 Age at first heroin use 20.8 (5.1) 
 Age at first methadone use 24.1 (7.2) 
 Number of Previous detoxifications 7.9 (8.0) 
 EuropASI Severity scores (0-9):  
   Physical Health 1.2 (1.5) 
    Work, education, income 2.2 (2.3) 
   Alcohol .9 (1.7) 
   Drugs 6.2 (1.1) 
   Justice/police 1.6 (1.9) 
   Family/social relations 2.7 (1.8) 
   Psych/emotional problems 2.1 (1.9) 
   Gambling .12 (.6) 
Note: Figures are percentages, means and standard deviations. 
 
6.2.5. Data management and statistical methods 
An intention-to-treat analysis was performed. To test differences for 
continuous variables the general linear model with repeated measures was 
conducted on continuous variables with baseline levels as covariate. Missing data 
considering continuous variables were systematically replaced through analysis 
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provided by the expectation maximisation imputation algorithm. χ2 tests were 
applied for dichotomous outcomes and the independent t-test for continuous 




After one, ten and sixteen-month follow-up, data were available for 78, 74 and 
86% of the study population. Table 6.1 shows details of the patient population at 
inclusion. Participants attended an average of 6.6 sessions (SD = 3.8) from a 
physician and 4.3 (SD = 2.7) sessions of psychosocial CRA therapy. 
Figure 6.1 shows the point prevalence of abstinence and the CAD slope. After 
one-month follow-up 46% of the patients were abstinent for opioids. After 10 and 
16 months of follow-up the point prevalence was 28% and 32% respectively. The 
cumulative abstinence duration (CAD) shows a decline in abstinence rates. After 
10 months 27% and after 16 months 24% were continuously abstinent. 
Table 6.2 shows the changes over time for the secondary outcome measures. 
 
Figure 6.1. Point prevalence and cumulative abstinence duration (CAD) in opioid dependent patients  








Measurement after detoxification (months)
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Table 6.2. Secondary outcome measures in detoxified opioid dependent patients. 
 Baseline Month 1 Month 10 Month 16 
Health perception     
   General health perception SF-36* 57.4 (20.1) 63.9 (22.0) 65.4 (22.0) 61.9 (22.8) 
Quality of Life     
   EuroQol Index (range 0 – 1) .74 (.23) 
 
.72 (.25) .76 (.21) .76 (.22) 
   EuroQol VAS (range 0 -100) 68.6 (17.7) 
 
73.6 (18.6) 74.4 (18.3) 74.1 (18.7) 
EuropASI Severity scores (range 0-9)     
   Physical Health 1.2 (1.5)   1.0 (1.6) 
   Work, education, income 2.2 (2.3)   1.5 (2.1) 
   Alcohol 0.9 (1.7)   0.5 (1.3) 
   Drugs 6.2 (1.1)   3.0 (2.4) 
   Justice/police 1.6 (1.9)   .7 (1.6) 
   Family/social relations 2.7 (1.8)   1.1 (1.7) 
   Psych/emotional problems 
 
2.1 (1.9)   1.7 (2.1) 
Craving     
   VAS 
 
22.9 (26.5) 7.8 (16.8) 21.7 (30.6) 22.1 (30.1) 
SCL-90     
   Total score (range 90-450) 154.9 (49.5) 139.7(43.4) 140.2(50.3) 137.4(49.5) 
Note: Figures are means and standard deviations; *(range 0 – 100) 
 
There was a slight improvement in the general health perception of the SF-36 
during the follow-up periods (F = 9.67, P < 0.001). The EuroQol-5D index showed 
a significant beneficial effect during follow-up (F = 9.05, P < 0.001). An overall 
improvement during follow-up was also observed for the EuroQol VAS (F = 8.48, 
P < 0.001). The ASI severity scores showed a significant improvement on all 
domains except for physical health (Table 6.2). With respect to craving, Table 6.2 
shows a minor but statistically significant improvement on the VAS during the 
follow-up period (F = 27.0, P < 0.001). There was a difference between the VAS 
at intake and month 1 (P < 0.001). Mental health, as measured by the sum score 
of the SCL-90, showed a significant improvement over time (F = 9.90, P < .001).  
All participants had declined in the number of substance-using days during the 
most recent 30 days, compared to baseline levels (Table 6.3). There were no 
significant differences in baseline characteristics between the continuously 
abstinent and the relapsing group. Table 6.4 shows the comparison of the 
secondary outcomes between abstinent and non-abstinent patients at 16-month 
follow-up. Compared with the non-abstinent patients the abstinent patients had a 
better health-related quality of life, lower severity scores on the EuropASI, except 
for the alcohol score, lower levels of craving and lower general psychopathology. 
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The opioid abstinent group used significantly less days cocaine (1.9 versus 6.3; P 
< 0.01) days) and benzodiazepines (3.6 versus 7.0; P < 0.01) compared with the 
relapsed patients. 
 
Table 6.3. Substances used in the past 30 days, according to ASI self-report. 
Substance Baseline Month 1 Month 10 Month 16 F P 
Alcohol 6.3 (10.3) 6.0 (8.1) 6.5 (9.1) 6.9 (9.4) 0.42 .74 
Heroin 18.4a (12.1) 3.0b (7.5) 8.3c (12.0) 10.3c (13.0) 53.88 .00 
Methadone 22.9a (11.0) 2.9b (8.1) 8.2c (12.5) 10.6c (13.4) 75.73 .00 
Opiates (other) 0.1 (1.7) 0.1 (.4) 0.4 (3.1) 0.3 (2.1) 0.79 .50 
Medicines 6.0 (11.1) 8.4a (11.7) 5.2b (10.1) 5.7b (10.7) 4.40 .01 
Cocaine 4.1 (7.4) 2.3 (5.8) 3.5 (7.7) 4.53 (8.8) 0.83 .48 
Amphetamines .1 (.4) .0 (.2) .0 (.2) .0 (.0) 1.72 .16 
Cannabis 7.5 (11.6) 6.8 (1.6) 7.8 (11.7) 8.5 (12.4) 0.65 .58 
       
>> 1 substance 18.1a (11.9) 4.9b (9.0) 8.7b (13.2) 10.7b (12.6) 39.26 .00 
Note: Figures are means and standard deviations. Means with different superscripts differ in pair-wise 
comparisons (SIDAK) at P < 0. 05. 
 
 
Table 6.4. Comparison of secondary outcome measures between abstinent and non-abstinent 
patients at 16-month follow-up. 
 Abstinent Non-abstinent P 
Health perception    
General health perception SF-36 (range 0 – 100) 71.8 (21.2) 55.5 (21.5) .030 
Quality of Life    
EuroQol Index (range 0 – 1) .84 (.17) .74 (.23) .010 
EuroQol VAS (range 0 -100) 81.6 (15.4) 68.9 (19.2) .013 
EuropASI Severity scores (range 0-9)    
   Physical Health .8 (1.5) 1.2 (1.6) .06 
   Work, education, income .8 (1.5) 2.0 (2.4) < .001 
   Alcohol .5 (1.2) .06 (1.3) .46 
   Drugs .7 (1.3) 4.5 (1.7) <. 001 
   Justice/police .5 (1.3) .8 (1.8) .07 
   Family/social relations .7 (1.2) 1.4 (1.8) <. 001 
   Psych/emotional problems 
 
1.1 (2.0) 2.1 (2.3) .001 





This study explored the long-term outcome of opioid antagonist induced 
withdrawal in opioid dependent patients, followed by a comprehensive treatment, 
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in which naltrexone maintenance was combined with the Community 
Reinforcement Approach. Twenty-four percent of participants were persistently 
abstinent over a 16 months follow-up period.  
These positive results can be attributed to the use of the opioid antagonist 
precipitated withdrawal techniques, which facilitate the likelihood of successful 
induction into maintenance naltrexone treatment (Gerra et al., 2000; McGregor et 
al., 2002). The results are in line with the contemporary literature that 
demonstrates the value of integrating pharmacological agents and cognitive 
behavioral oriented therapies that have been widely promulgated to achieve and 
maintain long-term abstinence in opioid abuse or prevent relapse (Carroll et al., 
2001; Roozen, Kerkhof & Van den Brink, 2003; Weiss, 2004). 
The degree of success is much higher than that which could be expected from 
regular treatment approaches, such as methadone tapering (Amato et al., 2003). 
Most studies have reported upon follow-up periods ranging from one week to one 
month (O'Connor & Kosten, 1998). More recent reviews suggest that it may not 
be possible to draw conclusions concerning the long-term effectiveness or cost-
effectiveness of withdrawal induced by opioid antagonists with minimal or heavy 
sedation or anaesthesia (Gowing, Ali & White, 2002a,b). Several recent studies 
report on long-term outcome, yielding (continuous) abstinence rates ranging from 
13 to 80% (Albanese et al., 2000; Bochud Tornay et al., 2003; Cucchia et al., 
1998; Hensel & Kox, 2000; Lawenthal, 2000; Rabinowitz et al., 1997, 1998 and 
2002). It is impossible to draw general conclusions from these reports because of 
the wide variation in study design, objectives, data assessment, sample size, 
variety in populations and treatment modalities. Naltrexone may be an efficacious 
adjuvant in the therapy. This is especially so for (highly) motivated patients who 
fear the severe consequences of not stopping taking opioids. Such patients may 
include health-care professionals who may be dismissed or parolees who may be 
returned to prison (Kirchmayer et al., 2003). The population in this study 
comprised a regular group of patients in a methadone maintenance programme 
who were mostly single, and had a low educational level and a fifty percent 
unemployment rate. These characteristics contrast with the aforementioned 
beneficial effects only for selected groups of opioid dependent patients. 
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Considering their low level of social, psychological and physical problems the 
study group could be considered a more hopeful category of methadone 
maintenance patients.  It is noteworthy that abstinence was associated with an 
improvement in health. Those who did not relapse showed improvements in 
addictive behaviors, craving, health, and health-related quality of life. Even those 
who were only temporarily abstinent showed improvement on these outcomes.  
No differences in baseline characteristics were found between the group who 
remained abstinent for 16 months and those who relapsed. No significant 
predictors for continued abstinence were found among the large number of 
characteristics included in the study. Consequently, abstinence as a goal of 
treatment is attainable for a larger proportion of opioid dependent patients than 
has been assumed to date. We would conclude that all patients who are 
motivated for an abstinence-oriented approach would be suitable for the 
comprehensive series of interventions described in this paper. 
The design chosen for the add-on effect of general anaesthesia in rapid 
induction of withdrawal was that of a randomised controlled trial. Because no 
differences were found between the two treatment groups, they were aggregated. 
This resulted in a naturalistic design with a non-randomised evaluation as major 
limitation, even though it was performed following recent guidelines for such 
studies (Caetano, 2004). The study aimed to follow detoxified opioid dependent 
patients over a follow-up period of 16 months. This meant that no conclusions 
could be drawn concerning the causal relationship between the combination of 
naltrexone and CRA and abstinence in opioid dependent patients nor for the 
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Effects on smoking cessation: naltrexone combined 
with a cognitive behavioral treatment based on the 
Community Reinforcement Approach 





A promising option in substance abuse treatment is the Community 
Reinforcement Approach (CRA). The opioid antagonist naltrexone (NTX) may 
work in combination with nicotine replacement therapy (NRT) to block the effects 
of smoking stimuli in abstinent smokers. Effects of lower doses than 50 mg/dd. 
have not been reported. A study was conducted in Amsterdam in 2000/2001 with 
the objective to explore the effects of the combination NTX (25/50-mg dd.), NRT, 
and CRA in terms of craving and abstinence. In a randomized open label, 2 x 2 
between subjects design, 25 recovered spontaneous pneumothorax (SP) 
participants received 8 weeks of treatment. Due to side effects, only 3 participants 
were compliant in the 50mg NTX condition. Craving significantly declined 
between each measurement and there was a significant interaction between 
decline in craving and craving measured at baseline. The abstinence rate in the 
CRA group was nearly double than in the non-therapy group (46% versus 25%; 
NS) at three months follow-up after treatment. 




Naltrexone (NTX), which is traditionally used to prevent alcohol and opioid abuse, 
recently emerged in the tobacco literature (e.g. Krishnan-Sarin, Meandzija, & 
O'Malley, 2003). It is suggested that there may be a link between opiates and 
nicotine (Krishnan-Sarin, Rosen & O'Malley, 1999). Under controlled laboratory 
conditions, where habitual smokers smoked cigarettes, an increase in beta-
endorphin levels co-occurred with increases in plasma nicotine concentrations 
(Pomerleau et al., 1983). It is conceivable that nicotine stimulates endogenous 
opioid release, which provides positive reinforcement for smoking.  
Subsequently, an opioid antagonist, such as NTX, may (partially) block these 
rewarding effects. In a study of Sutherland et al. (1995), it was suggested that 
NTX reduced the perceived difficulty of abstaining during 24-h cigarette 
withdrawal. Some additional support for the use of NTX came from a study of 
King & Meyer (2000) who demonstrated that NTX in controlled conditions 
significantly reduced the total number of cigarettes smoked. In a study conducted 
by Wewers et al. (1998) it was demonstrated that plasma nicotine levels, number 
of cigarettes smoked daily and self reported satisfaction with smoking were 
significantly lower among those treated with NTX.  
A review of David et al. (2002), however, shows that short-term trials of NTX 
yield conflicting results with regard to effects on ad libitum smoking, withdrawal 
symptoms, mood states, subjective and physiological responses to smoking. In 
addition, several placebo-controlled studies ascertained no support for NTX on a 
variety of biochemical and behavioral measures of nicotine intake or even 
produced negative effects on mood (e.g. Brauer et al., 1999; Wong et al., 1999; 
Sutherland, 1995). Thus at best it remains unclear whether NTX helps smokers 
quit (David et al., 2002).  
However, as to our knowledge, all NTX studies on smoking cessation 
examined the effects of the 50-mg daily dose. Only one study could be identified 
by using 100-mg dd. of NTX (Sutherland et al., 1995). This study demonstrated 
no dose response effect between 50 and 100 mg NTX per day (Sutherland et al., 
1995) and no other studies could be identified with lower dosages.  
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In a review, Silagy et al. (2002) concluded that all forms of Nicotine 
Replacement Therapy (NRT) are effective as part of a strategy to promote 
smoking cessation. Consequently, it has been demonstrated that the concurrent 
use of NTX and NRT is beneficial for smoking cessation (Hutchison et al., 1999; 
Krishnan-Sarin, Meandzija, & O'Malley, 2003), for instance because it may 
ameliorate withdrawal symptoms, dysphoria and sedation (Hutchison et al., 
1999). Additionally, it is suggested that NTX augments the efficacy of NRT in 
terms of craving (Hutchison et al., 1999; Krishnan-Sarin, Meandzija, & O'Malley, 
2003). Also the single use of NTX may reduce craving (Houtsmuller et al., 1997; 
King & Meyer, 2000). Craving is thought to play an important role in maintaining 
regular smoking patterns in smokers, and in leading to relapse in smokers 
attempting to quit (Houtsmuller & Stitzer, 1999). Although still ill understood, 
craving mostly is referred to as a compulsory desire to use (c.f. Robinson & 
Berridge, 1993, 2001). In addition, craving is considered as a complex, dynamic, 
multi-dimensional phenomenon (Barabási, 2003; Buscema, 1998), consisting of 
biological, psychological and social components.  
With respect to psychosocial treatments, the Community Reinforcement 
Approach (CRA) is a promising option, which ascertained evidence in favor of 
CRA in the alcohol-, cocaine- and opioid treatment (Roozen et al., 2004). CRA 
has also been mentioned in relation to smoking cessation (Poldrugo et al., 2002). 
CRA is a comprehensive cognitive behavioral oriented treatment package that 
focuses on environment (community)-organism interactions to rearrange a 
substance abusing lifestyle (Meyers & Smith, 1995). It is based on the view that 
substance-related reinforcers and the relative lack of alternative reinforcers 
unrelated to substance abuse maintain dependence. Development of alternative 
rewarding activities that are incompatible with substance use is essential to 
initiate and maintain abstinence (Schottenfeld, et al., 2000). CRA integrates 
concomitant administration of pharmacological agents with psychosocial aspects. 
It seems likely that CRA, as a novel multi faceted approach, is appropriate to 
foster abstinence in a smoking cessation therapy. In the present study this 
expectation was addressed. The objective of this study was to explore (1) the 
effects of CRA in terms of abstinence, therapy retention and treatment 
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Twenty-five participants were recruited from a database of 181 recovered 
spontaneous pneumothorax (SP) patients treated at the VU medical center (22 
participants) and Slotervaart hospital (3 participants) in Amsterdam, the 
Netherlands. SP is considered as a smoking related disease, because tobacco 
use enhances the chance of having peripheral airway inflammation (Snider, 
1992), which has a role in the pathogenesis of idiopathic SP (Schramel et al., 
1997; Smit, 1999). The chances of contracting SP is 8-22 fold higher when people 
smoke (Bense, 1987) and smoking cessation reduces this chance (Sadikot et al., 
1997). All participants were contacted by telephone to enquire if they wanted to 
participate. Participants were included if they were between the ages of 18 and 
65, smoked at least 15 cigarettes daily for a minimum of five years, and 
expressed the wish to stop smoking. Participants should have performed at least 
three unsuccessful attempts to stop smoking in the past five years. They should 
not simultaneously participate in another smoking cessation treatment and they 
should have the collaboration of a non-smoking concerned significant other to 
assist the participant in his attempt to stop smoking. Participants were excluded if 
they were dependent on opioids, cannabis or alcohol. All participants gave written 
informed consent. 
7.2.2. Procedure 
The treatment (T1-T9) was provided for eight weeks (Figure 7.1). Prior to the 
treatment, participants and their significant other (e.g. supportive partner or friend) 
were invited for an information visit (T0) to collect socio-demographic, medical 
history data (Table 7.1), and to explain the rationale and procedure. Participants 
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were consecutively randomized by a using a block design and allocated to four 
treatment groups (Figure 7.1).  
 
Figure 7.1. Treatment plan and flowchart of the visits (T0 to T10). 
Note: T10 and T11 are follow-up contacts. T11 was only a telephone contact.  I = Intake, S = 
Selection, R = Randomization and F = Follow-up. The detoxification encompassed a gradual increase 
of NTX from 5 mg (day 1 & 2), 10 mg (day 3 & 4), 15 mg (day 5), 20 mg (day 6) to 25 mg (day 7). The 
NRT administration was tapered down by applying 21 mg/24h (day 1& 2), 14 mg/24 h (day 2 – 5) and 
7 mg/ 24 h (day 6 & 7). For particpants allocated to both 50-mg NTX conditions, NTX was further 
increased from 25 mg to 50 mg at T2.  * Only for participants allocated to the CRA condition. 
 
 
In the week following the first treatment visit (T1) the administration of NTX 
(Antaxone®), which was administered in oral solution, was gradually increased 
from 5 mg up to 25 mg. NRT (Nicotinell®) was tapered from 21 mg/24h to 7 mg/ 
24 h (see Figure 7.1). The rationale for this non-standard use of the NRT taper 
procedure was to ameliorate possible withdrawal symptoms and to reduce 





•CRA + 25 mg Naltrexone
•25 mg Naltrexone
•CRA + 50 mg Naltrexone
•50 mg Naltrexone
F
Preparation Week 1 Week 2 - 8 3-18 Months
T0 T1 T3 T4 T5 T6 T7 T8 T11T10T9
5 10105 15 20 25 mg naltrexone
21 21 14 14 14   7   7 mg nicotine
NALTREXONE  + TNP
T2
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alignment with the randomization procedure: 25 mg NTX, 25 mg NTX + CRA 
therapy, 50 mg NTX and 50 mg NTX + CRA therapy. The timing of the clinical 
and laboratory assessments is summarized in Table 7.2. At the weekly visits, data 
was collected and the NTX was administered (HJW/SvB). The participants 
allocated to the CRA condition received concomitant CRA treatment at visit 1, 2, 
3, 5 and 7. The non-treatment group received no additional treatment. Each 
participant was seen at the same time of day at all visits. A follow-up took place 3 
months after the treatment visits, and a second follow-up was conducted 1½ year 
later by telephone to assess continuous abstinence. Only participants who had 
been abstinent at 3 months were contacted for second follow-up. Dropouts were 
considered as smokers. 
 
CRA 
The cognitive behavioral treatment was based on CRA (Meyers & Smith, 
1995) to give support during smoking cessation, and is protocol driven (Roozen & 
Kerkhof, 2000). Masters-level psychology students conducted this therapy, which 
took 5 sessions. Treatment integrity was guided by a three days training course 
and weekly individual supervision (HGR). Sessions were focused on motivation, 
adherence with treatment and NTX administration, skill training, functional 
analysis, and on creating a monitoring system. The 'Stimulus Control' procedure 
(Azrin et al., 1994) was employed to eliminate high-risk social situations that are 
precursors to smoking, and, to increase the amount of time spent engaging in 
smoking-incompatible activities. 
 
Objective and subjective measures 
An overview of the measures used is provided in Table 7.3. The success of 
cessation is measured by abstinence according to self-report. Of the collected 
urine samples, the cotinine values were analyzed to verify self-reported smoking 
status.  
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Table 7.1. Sample characteristics at baseline 
Variable 25mg 25mg & CRA 50mg 50mg & CRA TOTAL P 
No. of cases 6 6 6 7 25 NS 
% Male 50 83 67 86 72 NS 
% Married/living 
together 50 50 33 86 56 NS 
% Min. secondary 
education 83 100 100 83 92 NS 
Age 39.83(4.99) 41.00(3.7) 43.67(6.06) 46.43(3.98) 42.88(2.27) NS 
No. cigs/day daily 21.83(2.99) 21.67(2.11) 25.60(2.11) 20.29(1.97) 22.13(1.34) NS 
No. of quitting 




7.80 (0.84) 7.33 (0.52) 7.80 (0.84) 6.86 (1.21) 7.39 (0.94) NS 
Years recovered 
from SP 
8.83(3.21) 12.33(3.49) 8.50(2.90) 5.57(2.22) 8.70(1.50) NS 
SCL-90 score 120.17(6.12) 114.00(7.44) 126.00(5.91) 135.57(18.55) 124.40(5.76) NS 
No. of concerned 
others 
8.00(4.04) 5.83(1.96) 6.50(1.28) 5.00(1.17) 6.28(1.11) NS 
Alcohol units/day 1.33(0.49) 1.33(0.42) 2.20(0.92) 2.14(0.77) 1.75(0.32) NS 
Note: The type of socio-demographic areas covered items such as age, sex, education level, marital 
status, and number of concerned others. A visual analogue scale (VAS) ranging from 1 (poor health) 
to 10 (excellent health) assessed the perceived (subjective) health status. Displayed are numbers, 
percentages, mean scores, standard deviation and significant-levels (P < 0. 05). 
 
 
Table 7.2. Flow chart of study assessments points of clinical measures/ intervention.  
 T0 T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 
Time (hour)* 1.5 1.0 0.5 0.25 0.5 0.25 0.25 0.25 0.25 1.5 0.5 0.1 
Soc.Demogr. data  ♦            
VAS health status ♦            
Physical examination ♦            
Urine sample ♦ ♦   ♦     ♦ ♦  
Self-report smoking ♦ ♦   ♦     ♦ ♦ ♦ 
VAS (craving) ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦  
VAS (taste) ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦  
VAS (CRA)          ♦   
CSQ-8          ♦   
SCL-90 ♦         ♦   
CRA**  ♦ ♦ ♦  ♦  ♦     
Note: * Average time needed to assess data, administer medication, provide instruction and information 
and advice, document side effects, etc. ** Only for participants allocated to the CRA condition. Each CRA 
treatment session lasted about 60 minutes. 
 
 
Design and statistical analysis 
A 2x2 factorial between-subjects design was utilized. The significance level 
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Table 7.4. Scores on the SCL-90 at baseline and at the end of treatment. 
 Baseline End of treatment P 
Subscale (n=14) (n=14)  
Anxiety 12.79 (2.29) 11.93 (1.94) NS 
Agoraphobia 8.00 (1.24) 7.57 (0.94) NS 
Depression 21.43 (3.90) 20.07 (3.97) <. 05 
Som. complaints 16.43 (2.88) 15.50 (3.08) NS 
Insufficiency 12.43 (2.71) 12.07 (2.73) NS 
Sensitivity 22.79 (3.87) 22.29 (5.31) NS 
Hostility 6.86 (.77) 6.79 (.80) NS 
Insomnia 5.21 (1.67) 4.79 (1.81) NS 
Psychotism 11.07 (1.86) 10.50 (1.51) NS 
Psneur 117.00 (15.61) 111.50 (16.68) NS 
Note: Displayed are numbers, mean scores, standard deviations and significant-levels (P < 0. 05) for 
subscales and total score (Psneur) of the SCL-90. 
 
 
Descriptive statistics, paired sample T-test, Spearman’s rho and one-way 
ANOVA’s were used to compare sample characteristics. Logit analyses were 
conducted to analyze main effects or significant interactions between the 4 
conditions. A General Linear Model (GLM) repeated measures analyses was 
conducted, with as between-subjects factors the NTX doses (25 mg versus 50 
mg) and CRA therapy (therapy versus none), and as the within-subjects factor the 
10 VAS measurements. The baseline VAS was used as covariate. Missing data 
analysis, considering the VAS, was conducted by the expectation maximization 
(EM)-algorithm. After this, a t-test was used to analyze if the craving reduced 
linearly or remained constant. The tests of the within subjects effects were 
analyzed using the univariate approach with Huynh-Feldt correction.  
 
7.3. Results 
7.3.1. General outcomes 
Sociodemographic characteristics, scores on the SCL-90 and alcohol use 
were not statistically different between the four groups at baseline (Table 7.1). 
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The scores on the SCL-90 at baseline and at the end of treatment did not differ 
significantly, except for a decrease in depression (P = 0.026, Cohen’s d = 0.35; 
Table 7.4). One week of nicotine replacement was sufficient to ameliorate 
withdrawal symptoms, but participants preferred a longer use of NRT. Eight 
participants withdrew from the treatment because of self-reported side effects 
induced by NTX (2) or because of relapse (6). The overall dropout was 32%.  
In general, most participants tolerated NTX well, but 73% found the taste of 
the NTX fluid unpleasant. The 50-mg doses NTX-treated participants (13) 
experienced more side effects compared to the 25-mg doses NTX-treated 
participants. Reported side effects were headache, dizziness, nausea, insomnia, 
sleepiness and decrease of taste. Due to this, in the 50 mg NTX condition, five 
participants halved this dose to 25 mg. Three participants refused to continue with 
NTX because of side effects. As previously reported two participants allocated to 
the 50-mg condition dropped-out. This left only 3 participants to be compliant in 
the 50-mg condition. In contrast, only one participant allocated to the 25-mg 
condition decreased the daily dose NTX to 12.5 mg. An intention to treat analysis 
showed no significant difference between the NTX conditions. As a result, the two 
NTX conditions were collapsed. 
 
7.3.2. Treatment attendance, satisfaction and evaluation 
CRA participants did attend a mean number of 4.5 (SD = 1.2, range = 1-5) 
sessions. Participants who received CRA were, in general, satisfied with the 
contents and method of the CRA therapy (Mean = 7.3, SD = 0.90, range = 6.0 - 
9.3). The satisfaction about the received treatment in general, measured with the 
CSQ-8, was high (Mean = 25.8, SD = 4.0, range = 22-32).  
 
7.3.3. Abstinence and treatment  
The correlation between self-report daily smoked cigarettes and the cotinine 
values  (T0, T1, T4, T9, and T10) is 0.68 (P < 0.01), with respect to three 













categories of smokers (Table 7.3). When the categories were collapsed into the 
dichotomous measure abstinent or smoking, the correlation between the cotinine 
values and self-report is perfect (1.00, P < 0.01). At 3 months after the end of 
treatment (T10) the abstinence rate in the CRA group was higher than in the non-
therapy group (46% versus 25%) but this did not differ significantly. At 1½-year 
follow-up (T11), participants were asked by telephone: ”Do you smoke?” Hundred 
percent of the participants gave a self-report. The smoking abstinence rate for the 
non-CRA condition was 17%. In the CRA therapy group the abstinence rate was 
31% (NS). The overall abstinence rate after 1½ year was 24%. Sixty-seven 
percent of the participants who where abstinent after 3 months remained 
abstinent thereafter. 
 
Figure 7. 2. Box plot representing the craving (VAS) distribution (T0-T10). 
 
 
Note: Outliers and extremes are 
suppressed. Black line in the box 
represents the median value. 
Horizontal lines under and above the 
box (whiskers) indicate the range of 
values (excluding outliers and 
extremes). Lenght of box indicates the 
interquartile range (IQR), which covers 
the range between 25th and 75th 
quartile. The IQR is an estimate of the 







7.3.4. Craving outcomes 
Craving significantly declined each weekly measurement with a regression 
coefficient of 0.28 points (SD = 0.24) on the VAS scale of 0 – 10 (t = 5.3, df 20, P < 
0.001; Figure 7.2). There is a significant interaction (F = 2.47, df 6.5 and 104.2, P = 
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0.025) between the sequential time points and baseline craving. The interaction 
effect indicates that the higher the participants’ baseline craving, the stronger the 
decrease in craving. The correlation between baseline level of craving and the 
slope of craving is -0.53 (P = 0.014). The VAS measures pertaining to the taste of 





This study yielded a high agreement between biochemical cotinine values and 
self-reported tobacco consumption. Consequently, the abstinence rates can be 
considered as valid. An effect of CRA therapy is suggested with nearly double the 
amount of abstinence. However, the difference is not statistically significant. This 
lack of a significant effect may be due to the small study sample. To calculate the 
number of participants we would have needed to find a statistically significant 
effect, we merged the data (proportions of abstinence at 3 months; 25% versus 
46%, power .8 and alpha .05) in an Arcsin formula (Lemeshow et al., 1990; 
Lwanga & Lemeshow, 1991). This resulted in 63 participants in each group (one-
sided). Another reason concerns the relatively large amount of time consumed to 
collect data, provide information and give instructions by a researcher. This 
considerable amount of attention may have diluted the CRA effect.  
Due to side effects, a comparison between the 25 mg and the 50 mg NTX 
doses was not meaningful. Non-compliance with regard to dosis contaminated the 
conditions, which impaired the randomization procedure. More than 50 percent of 
the participants in the 50-mg NTX condition reduced the doses to 25 mg or to 
none. Participants were generally satisfied with the treatment in general, and 
NTX, but still suffered side effects, even with 25-mg doses. Side effects after NTX 
induction have also previously been reported (e.g. Sutherland et al., 1995; Brauer 
et al., 1999). However, the severity of the side effect has not caused such a high 
non-compliance in a 50-mg condition in previous studies. Seventy three percent 
of the participants rated the taste of the NTX oral solution (10-ml) as unpleasant, 
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which might have been caused by relative large doses of concomitant additives 
such as saccharine (1 mg) and sorbitol (70%).  
There was a significant decline in craving and a significant interaction between 
baseline craving and decline in craving. Methodological limitations preclude us 
drawing firm conclusions regarding the effect of NTX on craving. But the findings 
do suggest that additional research on NTX related to craving is warranted, as 
analogue results previously have been reported (King & Meyer, 2000). 
The protocol driven cognitive behavioral treatment program based on CRA is 
rather extensive in comparison to many regular smoking cessation programs 
(especially self-help), which could compromise participants’ satisfaction. Results 
indicate, however, that participants were satisfied with the CRA program and 
found the frequency and the duration of the treatment appropriate.  
With regard to methodological limitations, non-blinding of the conditions, small 
sample size, and the necessity for collapsing the two NTX dose conditions, we 
were limited to ascertain an effect between 25 mg and 50 mg NTX condition. 
Further double blind, (placebo) controlled, research in a larger population is 
needed to establish the effects of a low dose of NTX and/or NRT on smoking 
behavior. We recommend in further research the administration of NTX in pill 
form. CRA constitutes an innovative approach in smoking cessation treatment. 
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8. General Discussion 
 
In this dissertation reviews and empirical studies were presented about the 
effectiveness of the Community Reinforcement Approach (CRA), the prescription 
of naltrexone (NTX), and the combination of both interventions for patients with 
substance use disorders. Furthermore, guided by a literature search, CRA 
protocols were unfolded to assess the differences and similarities with regard to 
intervention components. These studies enable conclusions and recommen-
dations and generate topics for future research. 
 
8.1. CRA and NTX in substance use disorders 
 
This thesis focused on CRA combined with NTX in patients with substance use 
disorders. According to the expectations: 
 
1. The CRA review and additional empirical research on this topic asserted that 
CRA is an effective treatment to manage substance use disorders including 
alcohol, cocaine, tobacco and opioid.  
2. NTX is an effective agent under the condition that patients are compliant in 
the treatment of alcohol and opioid use disorders. The problem of early drop-
out and non-compliance suppresses NTX' effectiveness in normal clinical 
practice. 
3. Combinations of the various CRA components and pharmacotherapy 
contribute to successful outcome in the treatment of substance use disorders. 
These components enable subjects to sample rewarding activities in their 
natural environment that are incompatible with, or a valued replacement, of 
substance use. 
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8.1.1. Discussion of the effectiveness of CRA 
An important research question was whether CRA is effective in the treatment 
of patients with alcohol, opioid, tobacco and cocaine use disorders. This topic was 
addressed by a review of the literature (Chapter three) and by collecting new 
empirical data (Chapters five, six, and seven). 
The alcohol studies included in the review yield strong evidence that CRA, 
without additional therapies, is more effective than usual care in terms of reducing 
the number of drinking days. There is conflicting evidence with regard to 
continuous abstinence as the criterion. In addition, there is moderate evidence 
that CRA in combination with disulfiram is more effective than usual care with 
disulfiram in terms of reducing the number of drinking days. 
No difference was found in the review between CRA with disulfiram and usual 
care with disulfiram in terms of continuous abstinence, although the evidence is 
limited. It should be noted that CRA is not focused on abstinence per se: CRA 
identifies and implements positive reinforcers that could perform as incentives to 
change maladaptive behaviors. In addiction treatment, CRA addresses self-
management to regulate alcohol drinking when it occurs.  
The reviewed studies of cocaine dependence provided strong evidence in 
favor of ‘CRA with incentives’ compared to usual care, with regard to cocaine 
abstinence. In addition, the meta-analysis convincingly demonstrated that CRA 
with abstinence-contingent 'incentives’ is more effective than single CRA (non-
contingent incentive) treatment aimed at cocaine abstinence. 
The few studies in opioid dependent patients provided limited evidence for the 
effectiveness of ‘CRA with incentives’ compared to usual care in a detoxification 
program. There is also limited evidence that single CRA is more effective than 
usual care in a methadone maintenance program. Subsequently, empirical 
research was conducted on CRA combined with NTX in the treatment of opioid-
dependence (Chapter five and six). These studies yielded positive results in terms 
of illicit drug use reduction and general health. A relative large subgroup of opioid 
dependent patients was able to achieve sustained abstinence. In this respect 
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abstinence appears to be a feasible goal, and remains an important option next to 
long-term methadone maintenance in the management of opioid dependence. 
Research on smoking cessation yielded a positive effect of CRA therapy, with 
CRA therapy having nearly double the number of participants maintaining 
abstinence compared to the NTX alone condition (Chapter seven). However, the 
difference was not statistically significant. A viable reason for this finding may be 
the small sample size, as CRA appears to constitute an innovative approach in 
smoking cessation treatment. 
These findings corroborate previously conducted meta-analyses on CRA 
(Finney & Monahan, 1996; Holder et al., 1991; Miller et al., 1995, 1998 and 2003; 
Miller & Wilbourne, 2002). “The outcomes achieved with CRA equal or exceed the 
results of any controlled treatment-outcome study in the alcohol literature” (Stitzer 
& Higgins, 1995, p. 1815). In general, as shown by the review (Chapter three), 
CRA is an effective treatment modality and is more effective than most usual 
treatments. 
Therefore, it is recommended to implement CRA in general outpatient routine 
practice. In contrast, there is insufficient evidence for the added value of inpatient 
treatment modalities when compared to outpatient care (Miller et al., 1998 p. 
213). The outcomes following inpatient treatment are strongly related to the extent 
of participation in outpatient aftercare (Miller, 1997). Therefore inpatient programs 
should be geared to pragmatic needs such as treating intoxication, detoxification, 
medical co-morbidity, suicide threats, elevated levels of psychiatric symptoms etc. 
Patients with an absent social network or without housing may also temporarily 
benefit from inpatient treatment that aims on (synthetic) network development. 
But this need does not preclude the outpatient focus of CRA. In this respect Miller 
(1997) suggests that the crucial treatment is the one that occurs while the subject 
is in the natural environment (Miller, 1997, p. 499). 
 
8.1.2. Discussion of the effectiveness of NTX 
The µ-subtype opioid receptor signaling is activated by several drugs including 
morphine, alcohol, and nicotine (Contet, Kieffer & Befort, 2004) and mediates 
General Discussion  
 
 191 
positive reinforcement following the administration of substances. Therefore it 
represents an interesting target for the treatment of a variety of substance use 
disorders (Contet, Kieffer & Befort, 2004). The systematic review on NTX 
(Chapter four) updates and summarizes evidence regarding the effectiveness of 
NTX and the added value of psychosocial treatment in the NTX maintenance 
treatment of patients with opioid and alcohol use disorders. The review shows that 
there is insufficient evidence to refute or confirm the effectiveness of NTX in the 
maintenance treatment of opioid dependence.  
Several studies on NTX have been shown to alter ad lib smoking behavior 
(Sutherland et al. (1995; Rukstalis et al., 2005; Wewers et al. 1998). It is 
suggested that NTX may reduce the relative reinforcing effects of nicotine via 
cigarette smoking in an experimental setting (Rukstalis et al., 2005). The effects 
in other settings than the laboratory and the effects on the medium or long term 
are not clear. More NTX trials are needed to assess the efficacy for smoking 
cessation (David, Lancaster & Stead, 2002). 
Studies on alcohol dependent patients showed varied effects of NTX 
compared to placebo treatment, dependent on treatment duration and outcome 
parameter. On the medium term, there is strong evidence in favor of NTX with 
lower relapse rates compared to placebo [overall risk difference 13% [(95% CI): 7 
to 18%)]. There is also strong evidence in favor of NTX regarding the percentage 
of drinking days, but conflicting evidence regarding time to first relapse. There is 
strong evidence that NTX does not contribute to achieve continuous abstinence 
and the outcome: time to first drink. On the long term, there is moderate evidence 
in favor of NTX concerning relapse rate and moderate evidence for the absence 
of an additional effect on percentage of drinking days and time to first relapse. 
A recent review on NTX in the treatment of alcohol dependence demonstrated 
a short-term increase of nausea, dizziness, and fatigue, when compared to 
placebo (Srisurapanont & Jarusuraisin, 2005). However, these side effects did not 
endorse a greater proportion of treatment discontinuation for the NTX group as 
compared to the placebo group. 
In studies among opioid dependent patients, NTX was combined with a broad 
range of psychosocial interventions, which complicated the evaluation of their 
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added value. Concomitant psychosocial interventions used in the alcohol studies 
were mainly cognitive behavioral. There is some evidence that the combination 
NTX and cognitive behavioral therapy is somewhat better than NTX combined 
with supportive therapy (Agosti, 1995; Sinclair, 2001), as both NTX and cognitive 
behavioral oriented programs may operate synergistically to prevent slips from 
becoming relapses. Meta-regression analysis showed no significant added value 
of either group or individual psychotherapy. In general, the auxiliary psychosocial 
therapies failed to prevent dropout and NTX non-compliance. 
It is reasonable to expect that the effects of NTX dissipate after 
discontinuation. In order to achieve sustained success, and consistent with 
Wiklers’ 'extinction' theory (Wikler, 1976), it has been proposed to administrate 
NTX lifelong (Sinclair, 2001). It has been suggested that pharmacological 
extinction could only be achieved when NTX is paired with alcohol consumption 
and therefore should continue indefinitely (Sinclair, 2001). But, according to 
others (Yoburn et al., 2004), such a continuous opioid receptor blockage can 
produce receptor up-regulation, which has the potential to attenuate the 
pharmacological efficacy of NTX (c.f. Overstreet et al., 1999). An alternative 
strategy would be to employ intermittent or periodical use of NTX (see also 
Sinclair, 2001), which would imply that patients have to carry a NTX pill with them, 
but have to take it only when they are likely to drink (i.e. 'targeted use'; Heinälä et 
al., 2001; Sinclair 1992). Currently, no data are available to choose between 
these two strategies. 
In sum, there is lack of evidence about the effectiveness of NTX alone in the 
maintenance treatment of opioid and nicotine dependence. There is evidence for 
the effectiveness and applicability of NTX in the management of alcohol 
dependence leading to lower relapse rates and a reduction in the number of 
drinking days on the medium term. However, it should be noted that up to 36% of 
the NTX eligible participants discontinue treatment within the first 3 months 
(Srisurapanont & Jarusuraisin, 2005). The treatment attrition hampers the 
evaluation of NTX on the long term. Therefore, new strategies are needed, which 
are designed to improve the effectiveness of NTX, such as sustained release 
preparations (Garbutt et al., 2005). 
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8.1.3. Discussion of the content of CRA 
CRA is a multi-component intervention and most of these components are 
described in the manuals (e.g. Budney & Higgins, 1998; Meyers & Smith, 1995). 
CRA asks for an individualized action-oriented style as CRA is grounded in the 
principles of positive reinforcement; it focuses persistently on opportunities to 
reinforce the patient, even if these opportunities are small. The therapist needs to 
be flexible, directive, energetic and engaging in his treatment approach, and 
should have basic counseling skills, knowledge of the behavioral CRA 
techniques, supportiveness and empathy. It is the combination of compassion 
and skills that make CRA work (Meyers & Squires, 2001).  
Mental health professionals, such as social workers, have been suggested to 
employ CRA treatment programs, because their perspective is compatible with 
CRA in terms of individuals’ social situations and resources (Peele, 2004).   
In the last three decades CRA has been expanded with a wide range of 
interventions to create a “menu” or “toolbox” of options (Meyers & Smith, 1995) 
such as an additional voucher approach, additional social-skill training, self-
control training and motivational enhancement (Chapter two). Unfortunately, the 
incremental value of the different components within CRA is still unclear. Further 
dismantling research on this topic should resolve this issue. 
In the contemporary literature CRA has been successfully combined with 
contingency management by vouchers. Vouchers were included, because the 
efficacy of implementing contingencies via CRA procedures is often compromised 
by lack of consistency, and temporal delays. This might even happen when 
significant others are involved to promote daily routine. Therefore, to maintain the 
power of contingencies, a formal program such as CRA combined with vouchers 
seems favorable to manage the sampling, frequency and accuracy of 
administered and implemented contingencies in the patients' own community 
(Higgins, 2003). 
The dissemination of CRA has been limited and this is not due to high costs, 
as CRA has been associated with medium-low costs (Finney & Monahan, 1996). 
Instead, it could be due to perceived limited additional value to common practice, 
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incompatibility with common practice, or perceived unrealistic levels of clinical 
expertise. For instance, the presence of generally used elements such as coping 
skills and training interventions may give therapists the idea that they already use 
CRA (because of the overlap with concurrent evidence based therapies). On the 
other hand, seasoned health care providers may be reluctant to adopt CRA, 
because of certain incompatibilities with existing treatments. Both claims might 
lead to reluctance to substitute their already embraced therapy assumptions and 
practice (Miller & Meyers, 2001, p.167). Therefore, it should be made clear what 
the differences and similarities of CRA are compared to other therapies. 
In addition, Miller and Meyers (2001, p. 162) state that different therapists 
including novice graduate students were capable of scrutinizing the CRA 
methodology and delivering CRA therapy in several trials. The transfer of CRA 




The studies included in this dissertation contain reviews and empirical studies 
addressing the efficacy of CRA and NTX. The findings yield consistent and similar 
outcomes to outcomes mentioned in the literature. The comprehensive reviews 
applied an elaborate electronic search, which identified recent studies on both 
CRA and NTX. The three empirical studies on CRA and NTX were aimed to foster 
abstinence on two different substance use disorders (i.e. opioid and nicotine). 
However there are some limitations. 
Firstly, despite the effectiveness of CRA, it has not been widely used. At this 
time, there are only three research groups that have studied CRA systematically: 
the groups of Azrin, Miller, and Higgins. More research groups should be involved 
in examining CRA to prevent bias and to increase generalizability. 
Secondly, in the conceptual analysis, in most included protocols, the 
descriptions of the CRA programs are rather brief. In general, the protocols 
yielded insufficient information about the amount and the proportion of time that 
was spent on the various CRA components. Furthermore, only limited attention is 
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paid to treatment integrity. Too few data are available with regard to treatment 
intensity and total treatment consumption, and subsequently there are no data on 
a possible dose-response relationship with the targeted outcome. 
Thirdly, there were only a limited number of subjects in two of the three 
empirical studies. The pilot study on the effectiveness of NTX in opioid dependent 
patients and the NTX study on smoking cessation were underpowered. In 
addition, both studies on the effectiveness of CRA combined with NTX in opioid-
addicted patients did not use a randomized design with adequate concealment. 
Above all, in the pilot study on the effectiveness of NTX in opioid dependence, a 
selection occurred by charging money in order to take part in the treatment with 
NTX. Selection bias was also present in all three empirical studies by the 
inclusion criterion of bringing in a significant other. This selection bias may affect 
the generalizability. 
In the review on NTX it should be noted that the US Food and Drug 
Administration (FDA) approved NTX on the basis of its pharmacological profile, 
without any positive double blind study, because it cannot be effectively blinded in 
heroin dependent patients. Patients can simply take a test dose and discover 
what condition (i.e. NTX or placebo) they are allocated to. Several publications 
show a clear effect of NTX when patients are compliant to the medication regime 
(Kirchmayer et al., 2004). These studies demonstrate that NTX compliance is 
dependent on the population (business executives, physicians and health care 
professionals; Washton et al, 1984), the context of NTX prescription (probation or 
parole; Cornish et al, 1997), and the cultural and therapy setting (family therapy; 
Fals-Stewart & O'Farrell, 2003; Resnick, Washton & Stone-Washton, 1981; family 
involvement; Krupitsky et al., 2004). To increase the efficacy of NTX, further 
research in the identification of subgroups or controlled conditions of drug delivery 
systems seems warranted. 
Fourthly, the smoking study was characterized by side effects of the high dose 
of NTX and a relative high drop-out leading to a collapse of the conditions in CRA 
versus no-therapy. Although not statistically significant, CRA combined with NTX 
produced higher cessation rates than NTX alone. This corresponds with 
outcomes of other studies on CRA (Miller et al., 2001 p. 162). 
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Another limitation concerns the volume of conducted studies included in the 
subgroup analyses of the CRA review. The clinical heterogeneity of the studies 
and the relative scanty number of RCTs hindered the subgroup analyses in a 
variety of substance use disorders. In addition, the inclusion of several 
pharmacological agents and the contingency management program also 
produced heterogeneity. Some of the studies only contained small sample sizes 
and must be considered as pilot studies. 
 
8.3. Clinical and research considerations 
 
8.3.1. Treatment goals in the treatment of substance use disorders 
In general, the primary goal for the treatment of many patients with substance 
use disorders is focused on sustained abstinence. Whilst abstinence is 
considered as the main goal in the alcohol treatment, empirical studies have 
demonstrated that harm reduction approaches, for instance, to alcohol problems 
are at least as effective (Marlatt & Witkiewitz, 2002). Nevertheless, little attention 
has been paid to the advantages of integrating both abstinence and non-
abstinence goals as part of a comprehensive continuum of treatment for patients 
with alcohol problems (Ambrogne, 2002) or other problems related to substance 
use disorders. 
Viewing alcohol problems on a continuum, ranging from abstinence to harm-
reduction, might lead to a reduction of alcohol-related nuisance at the population 
level (World Health Organization, 2001). Providing a continuum of options from 
abstinence to moderation is consistent with stepped-care approaches that offer 
treatment with increasing levels of intensity, restrictions, and cost (Marlatt, 1996; 
Sobell & Sobell, 1993). Furthermore, it provides a useful framework to motivate 
patients in their process of change to reach achievable goals  (DiClemente, 
1999), and might be helpful for individuals encountering decisions regarding their 
alcohol use (Rosenberg & Davis, 1994). The harm reduction approach provides 
low threshold and flexible treatment options with a variety of goals and 
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approaches, tailored to the needs of the individual patient (Marlatt & Witkiewitz, 
2002).  
An important pharmacological option to foster abstinence is acamprosate. It 
has been demonstrated that acamprosate with counseling resulted in more 
abstinent days, reduced drinking days, and lower drop-out rates when compared 
to placebo (e.g. Sass, Soyka, Mann & Zieglgansberger, 1996; Schuckit, 1996; 
Verheul et al., 2005). It should be noted that adding intensive individual 
psychosocial treatments produced no improvement when compared to 
acamprosate and infrequent consultation with a physician (Hammarberg et al., 
2004). Acamprosate is believed to maintain abstinence by blocking the negative 
craving that alcohol dependent patients experience in the absence of alcohol 
(Mann, 2004). From a clinical perspective, acamprosate appears to be especially 
useful in a therapeutic approach targeted at achieving abstinence, whereas NTX 
seems more indicated in treatment focused on controlled consumption (Bouza et 
al., 2004). In addition, NTX is thought to decrease relapse to heavy drinking by 
attenuating the rewarding effects of alcohol (Srisurapanont & Jarusuraisin, 2005).  
NTX has also been compared to acamprosate. NTX produced better effects 
than acamprosate in a sample of moderate alcohol dependent patients in terms of 
relapse rates, cumulative abstinence, number of drinks consumed at one time, 
percentage of heavy drinking days and severity of craving (Rubio et al., 2001). 
The benefit of NTX over acamprosate has been confirmed in a study with four 
treatment arms in terms of time to first drink and time to relapse (Kiefer et al., 
2003). The combination of NTX and acamprosate was significantly more effective 
than acamprosate alone (Kiefer et al., 2003). 
In another comparison, it has been shown that disulfiram was more associated 
with abstinence than was NTX, with twice as many abstinent patients (De Sousa 
& De Sousa, 2004). Conversely, the patients in the NTX condition had 
significantly lower craving scores. Disulfiram has traditionally been used as part of 
abstinence-oriented treatment programs in the treatment of alcoholism, but with 
limited effectiveness due to poor compliance (Fuller & Gordis, 2004). 
 However, in alcohol dependent patients with a co-morbid psychiatric disorder, 
the combination of NTX with disulfiram was not more effective than each 
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medication separately and both separate medication were equally effective 
(Petrakis et al., 2005). 
 
Opioid addiction is a chronic, relapsing disorder with treatment goals including 
crisis intervention, cure, or recovery (detoxification, relapse prevention) and care 
or partial remission (stabilization and harm reduction) (Van den Brink & Van Ree, 
2003), whereas abstinence is often not a feasible goal for all opioid dependent 
persons (American Society of Addiction Medicine, 2001). In contrast to other 
substance use disorders, the management of opioid dependency is currently 
dominated by the harm reduction approach (Van den Brink, Goppel & Van Ree, 
2003).  
Harm-reduction-based treatment with opioid-agonist such as methadone is 
considered as the first choice of treatment. At appropriate doses, methadone 
maintenance is effective in retaining patients in treatment and suppressing heroin 
use (Amato et al., 2005; Sullivan, Metzger, Fudala & Fiellin, 2005). Furthermore, 
methadone treatment is associated with fewer injections and injection-related HIV 
risk behaviors and lower rates of HIV prevalence and incidence (Sullivan, 
Metzger, Fudala & Fiellin, 2005). Most patients require at least 80-120 mg/d of 
methadone to achieve these effects (Joseph, Stancliff & Langrod, 2000). Patients 
may require opioid substitution for many years up to lifelong (Fiellin & O’Connor, 
2002; Goldstein, 1991; Joseph, Stancliff & Langrod, 2000). Consequently, for the 
majority of opioid dependent patients methadone maintenance is considered an 
effective long-term modality (American Society of Addiction Medicine, 2001). Two 
other medications have been used for stabilizing heroin users: buprenorphine and 
levomethadyl acetate (LAAM). The advantage of the pharmacological properties 
of LAAM and buprenorphine over methadone is the possibility of less-than-daily 
doses (Johnson et al., 2000). Due to clinically significant changes in heart 
conduction (prolongation of the QTc interval leading to Torsades de Pointes, a 
distinctive form of polymorphic ventricular tachycardia; Deamer et al., 2001), 
concerns have been raised, eventually resulting in a termination of the distribution 
of LAAM in the Europe in 2001 (Van den Brink & Van Ree, 2003) and the USA in 
2004 (Newcombe et al., 2004). It has been suggested that this issue about QT 
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prolongation with LAAM should be resolved (Ritter et al., 2003). It must be noted 
that at the same time, methadone also has been associated with cardiac 
repolarisation (Kaufman et al., 2002; Krantz et al., 2002; Ritter et al., 2003). 
The other option for substitution treatment is buprenorphine. Because these 
tablets can be dissolved and injected, they can have an abuse potential 
(Varescon et al., 2002). Consequently, a novel tablet has been developed that 
contains a 4: 1 buprenorphine-naloxone ratio, to diminish the abuse potential 
(Stoller et al., 2001). Such a tablet dispensed by sublingual route produces a 
regular expected (partial agonist) effect. In contrast, when this tablet is dissolved 
and injected intravenously it produces an opioid (antagonist) withdrawal 
syndrome. 
A recent comparison between buprenorphine and methadone yielded better 
outcomes for patients who received methadone in terms of treatment retention 
and periods of sustained abstinence from illicit opioids and cocaine (Schottenfeld 
et al., 2005). Thus methadone maintenance is still considered to be the most 
effective treatment in terms of treatment retention and the cessation of illegal 
opioid use (Amato, 2005; Gossop et al., 2001). 
A unique combination is methadone maintenance and the co-prescription of 
heroin. Research has demonstrated that this combination is feasible and more 
effective in reducing physical, mental, and social problems of treatment resistant 
methadone patients than continuation of methadone alone (Van den Brink et al., 
2003). Furthermore, in this specific population, this combination is cost effective 
compared to methadone alone (Dijkgraaf et al., 2005). But these favorable 
outcomes might be partly produced due to accessible methadone maintenance 
programs (Ferri, Davoli & Perucci, 2005). 
It has been argued that stigma and bias directed at the programs and the 
patients have hindered expansion of substitution treatment, which makes the 
treatment system vulnerable to shifting community support and abrupt, politically-
driven changes in policy (Bell et al., 2002). 
Opioid substitution treatments are currently provided in special drug treatment 
settings. In order to make this treatment more available, accessible and attractive, 
the primary care setting seems a valuable option. It has been demonstrated that 
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the physician’s office may be the alternative site for these treatments (Fiellin et 
al., 2001). In addition, the results support the feasibility and efficacy of transferring 
stable opioid-dependent patients receiving methadone (Fiellin et al., 2001) and 
buprenorphine (Fiellin et al., 2002) maintenance to primary care physicians' 
offices for continuing treatment (Fiellin et al., 2001). 
Abstinence oriented treatments should be attempted only when the patient is 
motivated, and with the availability of adequate supervision and support 
(American Society of Addiction Medicine, 2001). Detoxification should be followed 
by psychosocial treatment, otherwise it may lead to rapid relapse and it may not 
be as effective as maintenance (Fiellin et al., 2004). 
Commercial organizations, such as CITA or the Waismann Institute, are 
mainly abstinence focused and are only accessible for a subgroup of patients who 
are capable of financing treatment themselves. Treatments, such as rapid opioid 
detoxification, cost up to $ 8500. It has been reported that 12-18 months after 
initial treatment, 60-65% of patients are still opiate-free (McKey, 1997, p. 20-22; 
Wielenga, 1999). These favorable outcomes were substantiated by a report from 
a study conducted in a private clinic, which was not covered by health insurance. 
In this study on the one-year relapse rate of persons detoxified using this ultra 
rapid method in conjunction with NTX maintenance and counseling, 57% of 
patients had not relapsed (Rabinowitz, Cohen & Kotler, 1998).  
Comparable results were obtained in the pilot study employing rapid opioid 
detoxification and CRA (Chapter five). Although inconclusive, an essential factor 
in this study may have been charging money in order to participate. The robust 
treatment effects might be due to selection (bias) of already motivated subjects 
who are willing to enter the rehabilitation process. As suggested, a NTX treatment 
might be especially effective in highly motivated participants who fear severe 
consequences in case they do not stop taking opioids, for instance health-care 
professionals, who might lose their job or parolees who risk re-incarceration 
(Kirchmayer et al., 2004). Furthermore, these subgroups may be characterized by 
the presence of a social network including non-substance using significant others 
(willing to invest and co-participate in treatment), a relatively moderate addiction 
severity, higher levels of self-efficacy, and the ability to rejoin the community. 
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8.3.2. Improving treatment outcome 
The opioid studies, which employed NTX treatment, asserted that a lack of 
motivation, compliance and a high dropout rate have corrupted the outcomes in 
non-specific samples (Kirchmayer et al., 2004). Recent findings in Australia 
showed that only 4% of the patients in NTX maintenance remained in treatment 
after 6 months (National Drug and Alcohol Research Centre, 2001). Poor 
treatment compliance with pharmacotherapy is a widespread problem for patients 
with substance use disorders. It undermines treatment benefits and produces 
impaired outcomes (c.f. Haynes 2001; O’Brien & McLellan, 1996; Weiss, 2004). 
Moreover, the lack of compliance is considered as a major factor limiting the 
clinical value of pharmacological agents, such as NTX in the management of 
opioid dependence (Rothenberg et al. 2002) and disulfiram in alcohol treatment 
(Fuller et al. 1986; Fuller & Gordis, 2004). Compliance is especially important in 
chronic diseases (DiMatteo et al. 2002) such as substance use disorders 
(Leshner, 1997; McLellan 2002; Van den Brink & Van Ree, 2003), as chronic 
disorders need continuous treatment (McLellan, 2002; O’Brien & McLellan, 1996). 
In general, the effectiveness of pharmacological agents corresponds with the 
degree of treatment adherence (Vergouwen, Bakker & Koerselman, 2003). 
Several alcohol studies demonstrated a relation between NTX compliance (and 
adequate NTX plasma levels) and positive outcomes (Chick et al., 2000; Kranzler 
et al., 2000; Krystal et al., 2001; O’Malley et al., 1992; Volpicelli et al., 1997).  
To improve current treatment outcome there are several potential strategies: 
1. The promise of innovative drug delivery systems (Garbutt et al., 2005); 
2. The development and application of vaccines (Kantak, 2003) 
3. Patient-treatment matching based on clinical variables or via 
pharmagenomics (Oslin et al., 2003); 
4. Combination of pharmacological agents (Kiefer et al., 2003; Besson et al., 
1998; Petrakis et al., 2005); 
5. Combination of pharmacotherapy and psychosocial treatment (Carroll, 
2001). 
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1. Drug delivery systems 
The complexity of dosages and route of administration are important factors that 
trouble treatment effectiveness. In addition, there is evidence that a reduction in 
frequency of administration enhances treatment adherence (Vergouwen, Bakker 
& Koerselman, 2003). A route to govern adequate plasma concentrations of NTX 
seems to be the insertion of (subcutaneous) NTX implants (Carreno et al., 2003; 
Foster et al., 2003), to treat both alcohol and opioid use disorders.  
To mitigate the widely fluctuating NTX plasma levels (often represented by a 
saw tooth pattern of plasma drug concentration), a recent development 
encompasses the use of extended-release formulation of NTX (i.e. naltrexone 
depot, DrugAbuse Sciences (DAS); Vivitrex®, Alkermes). This compound was 
developed by encapsulating NTX into single subcutaneous injectable, 
biocompatible, biodegradable (see Anderson & Shive, 1997) polymer 
microspheres (polylactide-co-glycolide-based) (Bartus et al., 2003).  Basically, the 
polylactide-co-glycolide microspheres establish a depot at the injection site from 
where NTX is slowly released and rejuvenated. Pharmacokinetic analysis 
confirmed that therapeutic levels of NTX could be maintained when injections are 
administered only monthly (Johnson et al., 2004). This long-acting agent seems 
safe and tolerable in the treatment of alcohol dependent patients within 6 months 
follow up (Garbutt et al., 2005; Johnson et al., 2004), but also over an 18-month 
period (Gastfriend, 2005). In addition, the injection of NTX reduced heavy drinking 
among patients during 3 (Kranzler et al., 2004) to 6 months (Garbutt et al., 2005) 
of therapy when compared to placebo. Unfortunately, the effect of a sustained 
release formulation of NTX (depot injection) was not directly compared to the 
effects of the original treatment with NTX tables (Van den Brink, in press).   
To improve patient convenience and while still controlling drug release, new 
innovative drug delivery vehicles are currently under development. Oral delivery is 
the preferred route of drug administration (Tao, Lubeley & Desai, 2003) and the 
efficacy of polylactide-co-glycolide based oral drug delivery systems have already 
successfully been applied (Ain, Sharma, Garg & Khuller, 2002). Recent advances 
encompass non-invasive transmission options, such as oral, pulmonary, and 
transdermal/transmucosal systems, which seem more favorable than injectable 
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release formulations or more invasive forms such as implants to reduce dosing 
regimens. 
On the other hand, there is an emergence of controlled biodegradable 
polymeric implantable microchips (once implanted no removal), which is capable 
of achieving complex drug-release patterns in response to specific stimuli such as 
PH, temperature and enzymes. These devices are currently being developed by 
the use of micro- and nanotechnology (Tao & Desai, 2003). 
These release mechanisms provides on-demand-controlled release of single or 
multiple drugs (Santini, Cima & Langer, 1999). Additionally, pharmacological 
agents are stored in micro reservoirs covered by a thin anode membrane and 
released when the anode membrane is dissolved by means of electrochemical 
dissolution. The development of such a biodegradable controlled-release 
microchip would be advantageous for long-term treatment of conditions when 
sustained drug release is mandatory (Richards Grayson et al., 2003; Tao & 
Desai, 2003). 
Similar to the use of other drug delivery systems, it must be stressed that the 
efficacy is coupled with the motivation of the individual. In addition, it is likely to 
work best as part of a comprehensive treatment program (Garbutt et al., 2005). 
 
2. The development and application of vaccines 
A novel treatment option is the application of vaccines, which is aimed to 
eliminate problematic substance use by altering the pharmacokinetics of the 
substance to prevent substances from entering the brain (Gorelick, 2004). As 
there are currently no effective pharmacological treatments for cocaine 
dependence, immunization treatments may be an interesting option (Gorelick, 
2004; Kantak, 2003). Most work has been conducted with vaccines and 
antibodies targeted against cocaine (e.g. Vaccine TA-CD) and nicotine (e.g. TA-
NIC) (Kantak, 2003). Vaccines operate by inducing drug-specific antibodies in the 
bloodstream that bind to cocaine or nicotine in the blood, resulting in large 
molecules that are incapable of entering the blood barrier. As a result, the 
psychotropic substance is prevented to exert reinforcing actions in the brain. The 
nicotine or cocaine molecules are too small to be antigenic. Consequently, these 
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molecules have to be paired to build a large carrier protein, to mimic the 
psychotropic properties and to serve as an antigen. Two human studies have 
applied succinylnorcocaine covalently bonded to recombinant cholera toxin B 
subunit to create cocaine antigenic (Vaccine TA-CD) (Kosten et al., 2002). These 
vaccines were administered by intramuscular injections of up to three 100-mcg 
doses and five 400 mcg TA-CD vaccine doses, to provoke antibody responses. It 
was shown that the maximum antibody response occurred between 70 and 90 
days after vaccination, with cocaine antibodies persisting for at least six months 
(Martell, 2004). It was concluded that the immunization was well tolerated and the 
peak antibody level was negatively associated with the degree of cocaine use. In 
2003, a clinical trial was started to treat methadone-dependent cocaine using 
persons. In this clinical study up to 132 patients are being recruited to compare 
the efficacy of the vaccine TA-CD to placebo (Xenova group plc, 2005). Other, 
more or less similar, technological innovations are currently developed to treat 
substance use disorders including cocaine, methamphetamine, and nicotine 
dependence (Haney & Kosten, 2004).  
It is expected that this expansion of pharmacological treatment arrangements, 
should be applied in concert with psychosocial programs, just the same as other 
chronic diseases, and should be available only for highly motivated patients 
(Kantak, 2003). 
 
3. Patient-treatment matching 
The search for predictive variables seems an important avenue to select or match 
specific patients to different treatment modalities in order to enhance treatment 
outcome and reduce costs. Large numbers of studies have been conducted into 
the isolation of possible predictors of success in substance abuse treatment (e.g. 
Alterman et al., 2000; Brewer et al., 1998; Ooteman et al., 2005; Siqueland et al., 
1998). In general, reviews reveal that there are very few pre-treatment- or in-
treatment variables that account for a substantial part of the variance in the 
primary outcome variables. Certain variables that are unidentified or unrelated to 
theoretical grounds may be strongly related to successful outcome. In this 
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respect, there is a need for identifying phenotypic indicators of the underlying 
myriad of genetic, psychological and social factors. In order to align specific 
pharmacotherapy to subgroups of alcohol dependent patients, it has been shown 
that specific subgroups, based on variables such as baseline psychopathology 
and a typological differentiation, produced improved outcome with either NTX or 
acamprosate (Kiefer et al., 2005).  Moreover, it has been demonstrated that the 
outcomes of a subgroup of patients with a biological vulnerability, which is 
coupled with overall poor treatment effects, can be improved with NTX treatment. 
Additionally, the type of alcoholism should be assessed before choosing the 
pharmacological strategy (Rubio et al., 2005).  
A new, more specific, way to increase the effectiveness is to determine the 
association between certain genetic polymorphisms and treatment outcomes in 
alcohol-dependent patients (Oslin et al., 2003). Programming the μ-opioid 
receptor might play a pharmacogenetic role in the differential response to an 
opioid antagonist (Oslin et al., 2003, Oswald et al., 2004). More generally, it has 
recently been suggested that genotypes and endophenotypes are more likely to 
be useful matching variables than phenotypicalor clinical characteristics 
(Ooteman et al., 2005). Based on pharmacogenomics, several (new) 
pharmacological agents are currently subject of research, particularly for specific 
types of alcoholism (Kenna, McGeary & Swift, 2004). 
 
4. Combination of pharmacological agents 
Another option to improve outcomes is the combination of available agents, as 
the combination of acamprosate with NTX or disulfiram may lead to improved 
outcomes (Fuller & Gordis, 2004; Besson et al., 1998; Kiefer et al., 2003). NTX 
and acamprosate, especially in combination, yielded better outcomes in term of 
relapse rates than placebo or solely administered acamprosate (Kiefer et al., 
2003). NTX administration is associated with increased plasma acamprosate 
levels (Johnson et al., 2003). It must be noted, however, that this combination of 
medications might produce more side effects (Bouza et al., 2004). The 
combination generated no statistically significant advantage when compared to 
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only NTX, although the combination showed a tendency for a better outcome. For 
that reason, the combination of NTX and acamprosate may be considered as 
somewhat favorable (Kiefer & Wiedemann, 2004; Scott et al., 2005). 
 
5. Combination of phamacotherapy and psychosocial treatment 
The term compliance is associated with a passive patient role (Kristeller and 
Rodin, 1984). In contrast, the term adherence implies an active patient 
participation with autonomy and mutuality in performing treatment actions (Lutfey 
& Wishner 1999; Meichenbaum & Turk, 1987) and is often preferred in the 
literature. Behavioral choices affect adherent behavior and consequently 
determine the course and severity of reoccurrence. These choices can be 
considered as a result of communication between a clinician and a patient, and are 
sometimes defined as shared decision-making (Rasmussen Wilkinson & Williams, 
2002). In this respect, both clinician and patient share responsibilities for adherence 
(Patel & David, 2004).  
Unfortunately, it has been asserted that only a few physicians acknowledge 
that they might contribute to their patients’ non-adherence (Cochran & Getlin, 
1988; Stone, 1979). Besides, several studies have indicated a firm discrepancy 
between physicians’ and patients’ understanding and appraisal of physician-
patient interaction (Dimatteo, Reiter & Gambone, 1994; Frank, Kupfer & Seigel, 
1995; House, Pendelton & Parker, 1986; Merkel, Rudisill, & Nierenberg, 1983). 
This is in stark contrast with the need for a positive patient clinician relationship, 
which is considered to be central to the success of any strategy for improving 
adherence (Heinssen, 2002; Weiss, 2004). It seems plausible that many 
physicians have only limited familiarity with effective strategies and 
recommendations. In this respect it should be stressed that single specific 
strategies such as psycho educational interventions, which focus primarily on 
imparting knowledge, have proved to be largely ineffective (O’Brien & McLellan, 
1996; Patel & David, 2004; Weiss, 2004). 
Because adherence is influenced by multiple factors, a combination of 
strategies is most likely to produce favorable results (Weiss, 2004; Williams et al. 
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1998). Individual interventions should specifically target the patient’s beliefs and 
attitudes concerning the illness and medication by using cognitive motivational 
therapy and behavioral modification approaches (Patel & David, 2004). 
Behavioral therapies, such as voucher management, can be targeted to address 
non-adherence of pharmacotherapies, such as NTX in problematic alcohol using 
patients (Higgins & Petry, 1999; Petry et al., 2000) and detoxified opioid 
dependent individuals (Carroll et al., 2001, 2002; Preston et al., 1999). 
Consequently, targeted behavioral therapies may play a substantial role in 
broadening the utility of available pharmacotherapies (Carroll et al., 2002). 
However, these behavioral regulation techniques may be effective only on the 
short/medium term, as the power of contingency management dissipates after 
discontinuation. Long-term prescriptions are strongly associated with autonomous 
motivation, as autonomous regulation has been found to account for 68% of the 
variance in adherence (Wiliams et al., 1998). A cognitive motivational treatment 
should support patients’ autonomy by addressing initiative, acknowledgment of 
the patients’ feelings, minimizing the pressure to behave in a restricted way, 
offering choices about treatment regimens, and to provide meaningful rationales 
for suggested behaviors (Deci et al., 1994).  
A dilemma to address adherence by physicians is that they do not have the 
function to serve as mental health professionals. Moreover, the interventions 
needed to augment adherence encompass the interplay of psychosocial 
interventions and are part of the professional domain of mental health 
professionals (i.e. psychologists, psychiatrists). Accordingly, due to time 
constraints and lack of skills to employ psychosocial interventions, the role of the 
physicians’ clinical involvement should be concentrated on the prescription of the 
medication, according to professional standards. An alternative is the employment 
of specially trained nurses or care managers, who monitor the patient, implement 
recommended medical management, foster structured coping skills, and closely 
collaborate with the physician and other health and social services (c.f. Roy-Byrne 
et al., 2005; Williams et al., 2004). 
In CRA treatment, this issue is outlined in detail (see Meyers & Smith, 1995, 
pp. 57-77; Sisson & Azrin, 1986, pp. 245-247). The involvement of the subjects’ 
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physician is only to pre-examine eligible patients and when medically cleared, the 
patient can be prescribed the specific medication (e.g. disulfiram). In 
communication between the CRA therapist and physician it should be noted that 
the medication is only a part of the entire treatment and results from a consensual 
agreed-upon plan between the CRA therapist and the patient. In CRA treatment it 
is suggested that a physician monitors the patient only medically and that the 
CRA therapist incorporates adherence within the whole set of CRA interventions. 
In the Netherlands, this procedure to guide the CRA integrity should be reflected 
in the allocation of tasks and warrants dialogs between physicians, health 
professionals, and policymakers to deal with issues such as responsibilities, 
monitoring, and reporting on possible adverse events/side effects. 
 
8.3.3. Principles of behavioral reinforcement  
It has been suggested that repeated exposure to substances results in 
deregulation of brain reward pathways (Koob & Le Moal, 1997; Koob et al., 2004). 
There are qualitative and quantitative differences in increases in dopamine in the 
brain induced by substances and other (natural) reinforcers. Addictive substances 
are more robust in terms of magnitude (five- to tenfold) and duration, when 
compared to naturally induced reinforcers (Wise, 1998, 2002). Due to neural 
adaptations, the individual is more responsive to dopamine as a result of 
addiction and less sensitive to the physiological increase in dopamine produced 
by natural reinforcers (Volkow et al., 2004; Volkow & Li, 2004). As a result there is 
a reduction in the sensitivity of reward circuits in drug dependent individuals to 
natural reinforcers (Mohn, Yao & Caron, 2004; Volkow, Fowler & Wang, 2003), 
but also to monetary rewards (Martin-Solch et al., 2001). 
Substance abuse disorders lead to disruption of several brain regions, which 
may undermine volitional control (Volkow & Li, 2004), or impair the process of 
decision-making (Fellows, 2004). It has been shown that the value of delayed 
reinforcers is considered to be worth less than the value of immediate reinforcers 
in individuals with substance use disorders, when compared to non-substance 
using persons (Bickel & Marsh, 2001). More recent data have confirmed this 
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finding, and have shown that discount rates vary with the preferred substance of 
use (Kirby & Petry, 2004). Therefore it seems evident to consider drug 
dependence as a reinforcement disorder (Higgins, Alessi, & Dantona, 2002). This 
raises the issue whether it is possible to outweigh substance related rewards by 
contrived reinforcers or reinforcement derived from the natural environment. 
First, heritable or genetic factors account for, in general, half of the total 
variability in substance abuse (Uhl & Grow, 2004). In addition, the remaining 
variability is influenced by environmental factors (Lessov et al., 2004). The 
posited genetic risk appears to be represented by a large number of genes, but 
with each of them manifesting small or modest effects (Comings & Blum, 2000; 
Enoch, 2003; Lessov et al., 2004). There is a firm indication that the physical 
development is a process of interaction with the environment and less solely 
determined by genes (Margaron, 2004). However, a subgroup of individuals with 
genetic susceptibility may develop addiction rapidly after initial substance use 
(Hiroi & Agatsuma, 2005). But this genetic risk may be differentially expressed 
depending on the environmental conditions (Lessov et al., 2004). 
Second, owing to micro-array technology, about 100 genes have been 
identified with altered expression after administration of substances (Kuhar, Joyce 
& Dominguez, 2001). Nevertheless, based on the relatively limited prevalence of 
addiction, neural adaptations induced by substance abuse do not fully explain the 
variability in substance dependence. In other words, prolonged exposure is not a 
sufficient condition for addiction (Hiroi & Agatsuma, 2005). Evidence is provided 
by the classic epidemiological studies of Robins, who revealed that only a 
minority of American soldiers who initiated heroin use in Vietnam remained 
addicted after returning to the US. In general, usage decreased to pre-Vietnam 
levels (Robins, Helzer & Davis, 1975; Robins, 1993). 
Hence, the environment plays a fundamental factor in the progression of 
infrequent substance use to substance dependence. Modifying the environment 
of the addicted individual seems essential in treating substance use disorders. 
Although there is an insensitivity in brain regions in patients with substance use 
disorders that are involved in processing reward information, such as monetary 
rewards (Martin-Solch et al., 2001), principles of behavioral reinforcement such as 
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CRA, and the incentive approach with contrived reinforcers, hold consistently 




Despite three decades of research, in which a substantial amount of 
compelling evidence is accumulated, the incentive approach is still not 
implemented in routine clinical practice. Much of the research has focused on 
vouchers as a reward system. In general, the voucher procedure is characterized 
by an escalating pay schedule to promote stable abstinence. When substance 
use occurs, the pay schedule is reset. In this way rewards are provided to initiate 
and to endorse long-term abstinence.  
There is, however, a serious debate on implementing contrived or tangible 
reinforcers. The voucher is often considered as (too) expensive to employ and 
manage (Petry & Smcic, 2002). These costs are considered as an important 
factor, which has hindered its dissemination (Petry et al., 2000). An avenue to 
reduce costs encompasses intermittent reinforcement in which only a certain 
proportion of the target behavior is paired with tangible reinforcers. Several 
studies that applied this system introduced prizes such as CD players, watches, 
etc, to illustrate the power of the incentive approach at low cost (Petry et al., 
2000). Intermittent reinforcement has proven to be effective for treating cocaine 
users at low costs (Petry et al., 2004). 
The effectiveness of the voucher approach is attenuated when the magnitude 
of reinforcement becomes too low (Silverman et al., 1999). Also, the definition of 
a high threshold target outcome (i.e. abstinence), especially for some 
subpopulations (i.e. heroin dependent poly-drug using persons), may result in 
poor sampling of rewards and, as a consequence, reduce the effectiveness 
(Downey et al., 2000; Piotrowski et al., 1999; Schottenfeld et al., 2005; Silverman 
et al., 1996). Possible resolutions encompass defining lower threshold behavior 
for earning a reward, such as reductions in use instead of abstinence, or 
providing high magnitude monetary vouchers (Preston et al., 2001; Dallery et al., 
2001). 
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Costs are probably not the only reason for the lack of dissemination in regular 
clinical practice. There may be other reasons addressing the moral or social 
domain. Paying persons with substance use disorders for not using drugs may be 
considered similar to paying thieves for not to stealing (Van den Brink, 2003). 
Vouchers can be used to acquire reinforcers on a broad variety of items and 
services, and are just like money a conditioned reinforcer. The actual paper bills 
are in themselves not reinforcing, but due to the pairing with preferred goods and 
services they become reinforcers. In this respect, money, instead of vouchers, 
seems a more direct option when it is paired with certain target behaviors. An 
advantage of vouchers over money is that voucher management is associated 
with items and services that are specifically non-substance related. With money 
as the reinforcer this pairing seems uncontrollable.  
This relation between earned items and natural reinforces is considered 
valuable in CRA combined with voucher management. The effectiveness on the 
long term is probably related to the implementation of sufficient non-substance 
related sources of reinforcement that occur naturally in the environment. 
 
CRA 
Reinforcement can also directly be emitted by the sampling of alternative 
rewarding behaviors (e.g. engaging in reinforcing recreational and social 
activities), which can be captured in the natural community to outweigh 
substance-using behavior (Correia, Benson & Carey, 2005; Van Etten & Higgins, 
1998). These reinforcers should consistently be administered contingent on 
clearly defined target behavior or stimuli (e.g. outcome of urinalysis, pre-defined 
social interactions, etc) in a predictable way. It must be noted that alternative non-
substance related behaviors should have a high intrinsic magnitude of 
reinforcement. Additionally, these alternative behaviors should have a high 
density and thus should be closely grouped together in time (Hunt & Azrin, 1973). 
There is a wealth of unexplored opportunities to assess what the patient values in 
terms of items, services, and privileges. The currency can be sampled by means 
of checklists such as the ‘Leisure Interests Checklist’ (Rosenthal & Rosenthal, 
1985) or ‘Pleasant Events Schedule’ (MacPhillamy & Lewinsohn, 1982) and the 
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specifically designed questionnaire for the Dutch addiction treatment services the 
‘Plezierige Activiteiten Lijst’ (Koks & Roozen, 2005) to increase engagement in 
substance-free behaviors. 
 
8.3.4. The role of rewards on intrinsic motivation 
In the past three decades of research on CRA, it has been shown that the 
cognitive behavioral concept has been expanded with elements such as 
motivation enhancing interventions. The creation of cognitive dissonance can 
clearly be distinct within motivational interventions (Draycott & Dabbs, 1998). 
More than four decades of research has shown that cognitive dissonance is an 
important motivator of human action (Aronson, Wilson & Akert, 2002, p. 174). 
According to cognitive dissonance theory (Festinger, 1957), individuals pursue for 
consonance among their cognitions, to avoid discomfort or arousal. As there is 
strong support that dissonance causes physiological arousal (Devine, 1998; 
Zanna & Cooper, 1974). The crucial element is the relationship between cognitive 
elements and what subsequently happens when these elements are inconsistent 
with one another (Kiesler, Collins & Miller, 1969). An inconsistency between 
attitudes or behaviors produces discomfort and enhances the motivation to 
eliminate the dissonance. This is especially the case in situations where a certain 
behavior threatens self-images (Aronson, 1998). In the case of a discrepancy 
between attitudes and behavior, it is most likely that the attitude will change to 
accommodate the behavior.  
Two factors affect the strength of the dissonance: the number of dissonant 
beliefs, and the importance attached to each belief. There are three ways to 
decrease dissonance: (1) reduce the importance of the dissonant beliefs, (2) add 
more consonant beliefs that outweigh the dissonant beliefs, or (3) change the 
dissonant beliefs so they are no longer inconsistent. 
Dissonance theorists point to a number of phenomena that demonstrate 
attitude changes that preserve some harmony between past acts and present 
attitudes. Some involve a cognitive reevaluation that occurs after some 
irrevocable decision has been made. If a person has to choose between two 
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incompatible beliefs or actions, and both options are equally attractive, the final 
decision will lead to dissonance. The option that is finally chosen will seem more 
attractive and the one that was rejected will seem less attractive than it did before 
(Brehm, 1956; Knox & Inkster, 1968). 
People often make considerable sacrifices to attain a goal. According the 
dissonance theory, the goal will be esteemed more highly the harder it was to 
reach (Aronson & Mills, 1959). Derived from the dissonance theory, there is 
evidence for the original suffering-leading-to-liking hypothesis (Cooper, 1980; 
Gerard & Mathewson, 1966). People who have made a great sacrifice to attain 
some goal will value it more than those who achieved the goal with little effort. 
Furthermore, attitude change is more likely in the direction of less incentive (less 
external justification), which in turn produces lower dissonance (Cohen, 1962; 
Festinger & Carlsmith, 1959; Leippe & Eisenstadt, 1994, 1998). In other words, 
the smaller the reward or incentive, the greater the change of attitude. It is 
noteworthy that the dissonance theory is incongruous to behavioral theories that 
predict greater attitude change consistent with increased incentive (i.e. 
reinforcement approach).  
 
Laboratory and clinical research have shown that abstinence reinforcement 
procedures are effective in governing substance-abusing behavior (Higgins, Heil 
& Plebiani Lussier, 2004). According to these studies, reinforcement is crucial to 
the success of behavioral modification. Within this framework, it has been 
demonstrated that contrived reinforcers, such as vouchers, are effective in the 
treatment of alcoholism (e.g. Petry et al., 2000), cocaine dependence (e.g. 
Higgins et al., 2003), opiates (e.g. Silverman et al., 1996) and marijuana (e.g. 
Budney et al., 2000). Although the effects of the reinforcement principles were 
clear for many decades, clinical research on substance use disorders waned after 
the seventies, but resurrected in the nineties (Higgins, Heil & Plebiani Lussier, 
2004 p. 433). 
In the seventies a "cognitive revolution" occurred in the behavior therapy 
(Mahoney, 1974), which exerted a substantial influence on the behavior therapy 
and behavioral science. In this tradition, the importance of motivation has been 
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promulgated. The widely used Transtheoretical Model of Change (Prochaska & 
Diclemente, 1986), characterizes vital variables as psychological mediating 
mechanisms that operate primarily within the subject (Vuchinich & Tucker, 1998 
p. 102). Hence, it seems that motivational interventions focus on self-reevaluation 
and consciousness raising while more behavioral approaches place accent on 
stimulus control and contingency management (Davidson, 1998 p. 33).  
There is a fundamental philosophical and theoretical difference between 
cognitive and contingency oriented treatment modalities (De Mey, 2003), but 
these treatment modalities seem to interact. Behavioral research showed that 
treatment effects remain discernible for months following discontinuation of an 
incentive program. So it seems that there must be changes in "motivation" 
underlying this effect (Higgins, 2003). Nevertheless, this finding seems to conflict 
with results of nearly three decades of research. It has been demonstrated that 
when various types of external rewards, such as money, are administered to 
perform an activity, it discounts intrinsic motivation (Deci, 1971; Deci et al., 1999). 
Similar findings have been observed in detoxified opioid-dependent participants 
who were assigned to contingency management to improve NTX adherence. 
These participants reported significant reductions in readiness to change 
compared with participants assigned to control NTX treatment (Carroll et al., 
2002). 
A review of 128 studies examined the effects of extrinsic rewards on intrinsic 
motivation (Deci et al., 1999). A convergence of findings with previous meta-
analyses (Rummel & Feinberg, 1988; Tang and Hall, 1995; Wiersma, 1992) 
asserted that tangible extrinsic rewards and all expected rewards are detrimental 
to intrinsic motivation under most circumstances (for discussion see Eisenberger, 
Pierce & Cameron, 1999). Intrinsic motivation is defined as a psychological need 
for autonomy and competence. It has been proposed that when rewards are 
interpreted as controllers of behavior, or as indicators of competence, this will 
lead to a decrease in intrinsic motivation. When rewards are viewed as positive 
information (the feedback should be process oriented and address the value of 
the performance) and when they typically occur unexpected, they provide an 
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affirmation of competence (Deci et al., 1999; Ryan & Deci, 2000). But it is not 
always clear how intrinsic motivation affects performance. 
Recent research on opioid dependent patients showed better outcomes for 
contingency management during treatment than for cognitive behavioral therapy 
(week 17). But at distant follow-up points (weeks 26 and 52), the superiority of 
contingency management procedure over the cognitive behavioral procedure 
disappeared (Rawson et al., 2002). More recently, this finding has been replicated 
(Rawson et al., in press). It might be concluded that the external reward system is 
effective on the medium term and, with delayed effect, is crucial to address the 
patients’ autonomy to foster long term changes by means of a cognitive 
motivational treatment (c.f. Williams et al., 1998). Therefore both treatments may 
be sequenced to profit from the immediate effects of contingency management, 
followed by the enduring cognitive behavioral therapy (Rawson et al., 2002). 
It has been argued that the regulation of intentional behavior varies along a 
continuum from autonomous (i.e., self-determined) to controlled (Deci et al., 
1987). The two paradigms are generally considered as complementary, and both 
organism and environment are regarded to be important (De Mey, 2003). 
Analogue to Sabelli’s theory of extended thermodynamics, it may be so that the 
less complex behavioral modality (contingency oriented) must be met first before 
the more complex cognitive systems can be addressed. (Sabelli & Carlson-
Sabelli, 1989). Therefore it may be considered favorable to integrate both 
frameworks (Marlatt, 2001). 
Hence, it might be concluded that cognitive processes mediate stimulus-
response relationships (see also George & Marlatt, 1983). Further research on 
these intrinsic and extrinsic processes, and how these structures interact, is 
needed. 
 
Finally, some comments can be made pertaining to the operant reinforcement 
framework of CRA. The need for pharmacological strategies fit well in the 
behavioral paradigm. Several pharmacological strategies have been outlined and 
agents such as acamprosate, buprenorphine, disulfiram, methadone and NTX 
prevent the positive reinforcement of alcohol and illegal drugs. Even innovative 
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options such as vaccines reduce behavioral effects, by altering the molecular 
structure and thus limiting the amount of active substances that enters the brain. 
Moreover, CRA encompasses strategies that are capable of interfering directly 
with the stimulus-response relationship related to substance use disorders. In 
addition, CRA employs cognitive-motivational elements needed to initiate and 
foster sustained abstinence. In this light, CRA may fulfill the call for a multi-modal 
strategy, which is capable of decreasing the rewarding value of alcohol and drugs 
and of increasing the uptake of natural rewarding activities, weakening the 
conditioned-learned drug responses, and advancing the enhancement of 




Based on this thesis some final recommendations can be made to improve the 
treatment and care for addicted patients: 
 
1. CRA can be regarded as an effective treatment and should be implemented 
more broadly in normal clinical practice. However, to pursue an accumulation 
of evidence on the broad spectrum of CRA in substance use disorders, a 
larger number of studies (RCTs) should be conducted. Other research groups 
should be involved to conduct these studies. These trials should include a 
larger number of subjects, in which the sample size is determined by a power 
analysis. Furthermore, research on CRA should have a follow-up of one year 
or longer, so that the magnitude of the effect of CRA during a longer term can 
be established. 
2. Pertaining to the conceptual content of CRA, dismantling studies should be 
conducted to explore the active components. Furthermore, the amount, 
intensity and mechanisms of these CRA components should be further 
established by means of an expert group. This will enable us to tailor a CRA 
treatment, which is protocol driven and gives the opportunity to assess the 
treatment adherence through tape/video recording. In addition, CRA studies 
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should be conducted with a broad spectrum of pharmacotherapies with and 
without contingency management and with multiple follow-up measurements, 
so that the (auxiliary) value of this program can be evaluated with a higher 
reliability. 
3. To implement CRA in addiction treatment services, far-reaching interventions 
on normative and cultural aspects should be executed. It is rather optimistic to 
assume that training will be enough to get these therapists to employ CRA. 
However, as already suggested, it seems possible to train therapists, 
especially those without concurrent premises on the terrain of addiction. 
Another issue concerning implementation is related to the tasks of physicians 
and CRA therapists. The CRA therapist should integrate the 
pharmacotherapy in the psychosocial context and monitor adherence to the 
medication regime. The change in tasks of both the mental health 
professional and physician makes it indispensable to govern the integral CRA 
treatment by well-trained health professionals. Bilateral communication 
between the physician and therapist seems an important issue in this respect. 
4. The role of CRA might influence the tasks and treatment strategies of 
inpatient facilities. CRA is preferably an outpatient treatment, which focuses 
on reinforcers in the natural context of the subject. This includes social 
interactions with concerned significant others, recreational and vocational 
development etc. The role of inpatient facility might compromise the 
reinforcement premises and therefore should be modified by aiming at 
pragmatic goals such as the treatment of overdoses and detoxification in 
patients at high risk for psychiatric and medical complications. However, 
subjects without a social network or stable housing might benefit from 
inpatient treatment that aims on (synthetic) network development. This might 
be also the case for treatments provided in prison. Later on in treatment, CRA 
can be provided in an outpatient treatment context. These propositions might 
have drastic effects on the landscape of inpatient and outpatient facilities.  
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Addiction is a chronic relapsing disorder with medical, legal, psychological and 
social causes and consequences (see Chapter one). Treatment should take all 
these aspects into account. Therefore, pharmacological interventions should be 
integrated with psychosocial treatments. Treatment goals vary from cure, through 
care, to palliation. An important goal of many patients is abstinence. 
To facilitate change in addictive behaviors a broad spectrum of psychosocial 
and pharmacological treatments has been developed. A comprehensive 
treatment, which integrates psychosocial and pharmacological approaches, is the 
Community Reinforcement Approach (CRA). Nathan Azrin and George Hunt 
devised CRA in the early seventies and based it on Skinner’s operant learning 
paradigm. CRA focuses on the replacement with an alternative lifestyle that is 
more rewarding than a substance using one. CRA attempts to increase natural 
positive reinforcement from different life-areas such as vocational, recreational 
and social, by sampling rewarding resources contingent on non-substance related 
behaviors. Because of this, CRA is regarded as time-consuming and labor 
intense. CRA interventions such as home visits and social and recreational clubs 
may illustrate this issue. This may be an important reason that CRA is hardly ever 
implemented in normal clinical practice.  
Although several reviews have outlined the benefit of CRA in terms of the cost-
effectiveness, there is lack of evidence of CRA integrated with pharmacological 
agents such as the opioid antagonist naltrexone (NTX). NTX has been approved 
for the treatment of opioid and alcohol use disorders in Europe and the USA. 
This dissertation focuses on an evaluation of the CRA concept and its 




patients. Furthermore, the efficacy of NTX, and its combination with CRA are 
explored. These issues are addressed by means of reviews and empirical studies 
about the content and effectiveness of CRA, the prescription of NTX, and the 
combination of both interventions for patients with substance use disorders. 
Chapter two deals with the content of CRA. This study examined the concept 
of CRA by means of the extraction of CRA components out of the available 
literature. A literature search in electronic databases up to March 2002 was 
conducted. The analysis ascertained an increase in the CRA components during 
three consecutive seminal studies. More recent studies varied substantially in 
number of CRA components. Several new components have been included over 
time, and have consequently obscured the mechanism of treatment actions. 
Eighteen components are identified. Dismantling studies are needed to explain 
the variability of each component in the effectiveness of CRA. 
Chapter three examines the effectiveness of CRA by way of a systematic 
review with meta-analyses. The objectives of this study were to assess the 
effectiveness of (1) CRA compared with usual care, and (2) CRA versus CRA 
plus contingency management. Studies were selected through a literature search 
in electronic databases up to March 2002. Evidence was obtained for the 
effectiveness of CRA in various substance-related disorders, including alcohol, 
cocaine and heroin. More studies are needed to substantiate the findings. 
Chapter four reviews the effectiveness of NTX and the added value of 
psychosocial treatment in the maintenance treatment of opioid and alcohol use 
disorders. The included studies were selected through a literature search, 
conducted in March 2004. Due to non-compliance, the role of NTX in the 
maintenance treatment of opioid dependence is unclear. The studies on alcohol 
dependence showed favorable results regarding the effects of NTX on the medium 
term, in terms of relapse rate and the percentage of drinking days. The opioid 
studies combined NTX with a broad variety of psychosocial interventions, which 
complicated the evaluation of the beneficial effects. Concomitant psychosocial 
interventions used in the alcohol studies were mainly cognitive behavioral, which 
may have synergistic action when combined with NTX. Nevertheless, the 
combination resulted in substantial levels of dropout and non-compliance. 
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In Chapter five data from a pilot study are provided regarding CRA combined 
with NTX in the treatment of opioid-dependence, by using a pre-post design. 
Rapid detoxified methadone dependent patients (n = 24) received CRA and NTX 
maintenance. After six months of treatment, 58% (14/24) of the patients had not 
relapsed and after one year at least 55% (12/22) still met the initial goal of 
continuous abstinence. 
In Chapter six more data are provided about the effectiveness of CRA 
combined with NTX in detoxified opioid dependent patients. Four outpatient 
addiction treatment centers in the Netherlands recruited 272 patients from 
methadone maintenance programs. After rapid detoxification all participants were 
transferred to CRA and NTX maintenance for a period of ten months. CRA was 
administered according a protocol encompassing 23 sessions (10 sessions 
delivered by a psychosocial therapist and 13 sessions delivered by a physician). 
At 6 months follow-up the cumulative abstinence rate was 24%. It can be 
concluded that for a relative large subgroup of abstinence-motivated patients, 
who are participating in a methadone maintenance program, stable abstinence is 
a feasible goal. As such, the combination of CRA and NTX may comprise a 
clinically significant alternative for opioid dependent patients. 
Chapter seven describes the effects of another pilot study, in which the 
combination CRA, NTX, and transdermal nicotine patches were explored. 
Twenty-five smoking recovered spontaneous pneumothorax participants received 
8 weeks of treatment. The transdermal nicotine patches were administered for 1 
week. The CRA treatment was protocol driven and took 5 sessions. Craving 
significantly declined between each measurement and there was a significant 
interaction between decline in craving and the craving measured at baseline. 
Although not statistically significant, the abstinence rate in the CRA group was 
higher than in the non-therapy group (46% versus 25%) at three months of follow-
up.  
Chapter eight involves a discussion on reviews and empirical studies included 
in this dissertation. The conclusion can be drawn that CRA constitutes an 
effective treatment to manage a wide range of addictive behaviors. Furthermore, 




patients are compliant. The combinations of the various CRA components, 
including pharmacological options such as NTX, were found to contribute to 
successful outcome in the treatment of substance use disorders. CRA can be 
employed to address either abstinence or non-abstinence (moderation) goals to 
deal with addictive behaviors combined with a broad range of pharmacological 
agents. Several new strategies are discussed to increase the efficacy of 
pharmacotherapy, but all call for psychosocial integration. Psychosocial 
interventions should encompass both behavioral regulation and cognitive-
motivational techniques. Both aspects may be sequenced to benefit from the 
immediate effects of behavioral reinforcement principles, followed by enduring 
cognitive motivational therapy. More research is needed on how these structures 
interact. 
Finally, CRA is a powerful multi-modal strategy. It outweighs the rewarding 
value of alcohol and drugs and increases the exposure and uptake of natural 















Communitiy Reinforcement Approach en Naltrexon in de Behandeling van 
Verslaving 
 
Verslaving is een chronisch recidiverende stoornis met medische, justitiële, 
psychologische en sociale oorzaken en consequenties (zie hoofdstuk 1). Om 
positieve behandelresultaten te bevorderen dient bij behandeling met al deze 
aspecten rekening te worden gehouden. Om deze redenen dienen 
farmacologische interventies geïntegreerd te worden met psychosociale 
behandelingen. De behandeldoelen variëren van abstinentie, naar stabilisatie van 
het gebruik, tot palliatieve zorg. Een belangrijk doel voor veel patiënten is 
abstinentie. 
Verschillende psychosociale alsmede farmacologische behandelingen zijn 
ontwikkeld met als doel verandering te bewerkstelligen in verslavingsgedrag. Een 
behandeling die de psychosociale en farmacologische benadering integreert is de 
Community Reinforcement Approach (CRA). Nathan Azrin en George Hunt 
ontwikkelden CRA begin jaren '70 en baseerden het op de operante leertheorie 
van Skinner. Middelengebruik wordt in deze context beschouwd als gedrag dat 
onder invloed staat van operante bekrachtiging, waarbij de relatie tussen gedrag 
en uitkomst relevant is. CRA benadrukt dat afhankelijkheid van middelen in stand 
wordt gehouden door drugsgerelateerde bekrachtigers en door een gebrek aan 
alternatieve niet verslavingsgebonden bekrachtigers. Daarom richt CRA zich op 
het ontwikkelen van een nieuwe leefstijl die meer belonend is dan 
middelengebruik, door te interveniëren op bekrachtigers in de directe omgeving 
van de verslaafde, zoals in het gezin, het werk, woonomgeving, vrienden, 
tijdsbesteding en dergelijke. Om deze reden wordt CRA gezien als een 
tijdsconsumerende, intensieve behandelvorm. CRA interventies, zoals 




gezelschappen, illustreren deze kwestie. Het is wellicht een belangrijke reden 
waarom CRA slechts beperkt wordt toegepast in de klinische praktijk. 
Hoewel een aantal reviews laat zien dat CRA een kosteneffectieve 
behandeling is, is er gebrek aan bewijs voor CRA geïntegreerd met 
farmacologische interventies, zoals de opiaatantagonist naltrexon (NTX). NTX is 
geregistreerd voor de behandeling van heroïne en alcoholverslaving in Europa en 
de VS. 
Deze dissertatie richt zich op de evaluatie van het CRA concept en de 
effectiviteit in de behandeling van middelen gebonden stoornissen. Verder wordt 
de effectiviteit van de combinatie CRA en NTX onderzocht door middel van 
systematische reviews en empirische studies. Deze gaan over de inhoud en de 
effectiviteit van afzonderlijk CRA en NTX, en de combinatie van beide interventies 
voor patiënten met een heroïne verslaving. 
Hoofdstuk 2 heeft betrekking op de inhoud van CRA. In deze studie is het 
concept CRA onderzocht door middel van een zoekstrategie, waarbij 
elektronische databestanden tot maart 2002 werden geraadpleegd. De resultaten 
gaven een toename aan in het aantal CRA componenten in de eerste drie 
opeenvolgende studies. Meer recente studies variëren in het aantal gebruikte 
CRA componenten. Verschillende nieuwe componenten zijn in de loop der tijd 
toegevoegd. De samenvoeging van deze componenten zorgde ervoor dat het niet 
duidelijk is welke componenten een actieve rol spelen. Achttien verschillende 
componenten zijn geïdentificeerd. Ontmantelende studies zijn nodig om de 
effectiviteit van elke individuele component te verklaren ten opzichte van de totale 
effectiviteit van CRA. 
Hoofdstuk 3 onderzoekt de effectiviteit van CRA middels een systematische 
review met behulp van meta-analyses. De doelstelling van deze studie was het 
vaststellen van de effectiviteit van: (1) CRA vergeleken met de gewone zorg, en 
(2) CRA versus CRA met 'contingency management' (d.m.v. vouchers). Studies 
werden geselecteerd op basis van een literatuurstudie in elektronische 
databestanden tot maart 2002. Over het algemeen is er bewijs voor de effectiviteit 
van CRA bij diverse middel gebonden stoornissen. Er zijn meer studies nodig om 
de bevindingen te bevestigen en te kunnen generaliseren. 
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Hoofdstuk 4 gaat in op de effectiviteit van NTX en de toegevoegde waarde van 
psychosociale behandeling in de onderhoudsbehandeling van heroïne- en 
alcoholverslaving. 
De studies zijn geselecteerd door een literatuurstudie, uitgevoerd in maart 
2004.Ten gevolge van beperkte therapietrouw blijft de rol van NTX in de 
onderhoudsbehandeling van opiaatverslaving onduidelijk. De alcoholstudies laten 
zien dat NTX effectiever is dan een placebo in termen van terugvalpercentage en 
het percentage drinkdagen op de middellange termijn. De opiaatstudies 
combineerden NTX met een breed scala aan psychosociale interventies, hetgeen 
de evaluatie van de meerwaarde compliceerde.  De psychosociale interventies 
die gebruikt werden in de alcoholstudies waren hoofdzakelijk cognitief 
gedragsmatig van aard. De combinatie heeft wellicht een gunstig effect op het 
voorkomen van terugval. Echter, de psychosociale interventies hebben 
onvoldoende invloed op het voorkomen van uitval en gebrek aan therapietrouw.  
In hoofdstuk 5 worden er gegevens gepresenteerd vanuit een pilotstudie, 
waarin heroïneverslaafden een gecombineerde behandeling van CRA met NTX 
kregen aangeboden. Er werd gebruik gemaakt van een pre- en postmeting. 
Vierentwintig methadonafhankelijke patiënten ontvingen, na snelle detoxificatie, 
CRA en een onderhoudsdosering NTX. Na zes maanden behandeling bleef 58% 
(14/24) abstinent, na een jaar haalde ten minste 55% (12/22) het vooraf gestelde 
doel van continue abstinentie. De combinatie CRA en NTX, in de vorm van een 
intensieve ambulante begeleiding, lijkt daarmee een veelbelovende benadering. 
In hoofdstuk 6 worden er meer gegevens gepresenteerd met betrekking tot de 
effectiviteit van de combinatie CRA en NTX behandeling bij gedetoxificeerde 
heroïneverslaafden. Vier ambulante behandelcentra in Nederland rekruteerden 
272 patiënten vanuit methadonprogramma's. Na een snelle detoxificatie kregen 
de deelnemers, voor de periode van tien maanden, de gecombineerde 
behandeling van CRA met NTX onderhoudsdosering aangeboden. De 
behandeling was geprotocolleerd en omvatte 10 sessies bij de CRA therapeut en 
13 sessies bij de CRA arts. Op maand zestien is 32% van de patiënten abstinent 
en is 24% van de patiënten gedurende de gehele follow-up van 16-maanden 




terugval. Voorts zijn er verschillen in termen van gezondheidswinst tussen de 
deelnemers die abstinent bleven ten opzichte van de deelnemers die terugvielen 
in heroïnegebruik. Deze gezondheidswinst geldt o.a. voor het gebruik van 
psychotrope stoffen, psychische klachten ernst van verslaving (ASI), craving en 
kwaliteit van leven. Voor een relatief grote subgroep methadonpatiënten, die 
gemotiveerd zijn voor abstinentie, is stabiele abstinentie een haalbaar doel. 
Hoewel het design het niet toelaat om de effecten volledig toe te schrijven aan de 
CRA en NTX behandeling, zijn de uitkomsten op zijn minst bemoedigend te 
noemen en lijkt de combinatie van CRA met NTX een klinisch significant 
alternatief voor patiënten met een heroïneverslaving. 
Hoofdstuk 7 geeft een beschrijving van een andere pilotstudie waarbij de 
combinatie CRA en NTX en nicotinepleisters werd onderzocht bij de behandeling 
van rookverslaving. Vijfentwintig deelnemers die hersteld waren van een 
spontane klaplong (Spontaneous Pneumothorax) kregen acht weken een 
combinatie behandeling. Nicotine pleisters werden voor de duur van één week 
aangeboden en langzaam afgebouwd. NTX werd verstrekt gedurende de gehele 
behandeling. Het CRA programma bestond uit 5 geprotocolleerd sessies. De 
craving verminderde voor de gehele groep statistisch significant over de tijd. Meer 
patiënten in de CRA conditie waren abstinent in vergelijking tot de non-therapie 
groep, na 3 maanden follow-up (46% versus 25%). Echter deze bevinding was 
niet statistisch significant. Desalniettemin lijkt CRA een interessante interventie 
voor deze doelgroep. 
 Hoofdstuk 8 bevat een discussie over de reviews en empirische studies die 
gedaan zijn in deze dissertatie. De bevindingen laten zien dat CRA effectief is in 
de behandeling van verschillende middelen gebonden stoornissen. Er kan 
worden verondersteld dat NTX alleen een effectief middel is als voldaan wordt 
aan therapietrouw. De combinaties van de verschillende CRA componenten, 
waartoe ook  farmacologische opties zoals NTX gerekend kunnen worden, 
dragen bij tot een succesvolle uitkomst in de behandeling van verslaving. Welke 
componenten precies effectief of overbodig zijn blijft onduidelijk. Studies gericht 
op een verdere ontleding van deze kwestie zijn nodig om meer helderheid te 
kunnen verschaffen over de specifiek werkzame CRA-componenten. 
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De CRA behandeling kan worden toegepast voor zowel abstinentie- als niet 
abstinentiedoelen (moderatie van het gebruik) en kan worden gecombineerd met 
een breed aanbod aan farmacologische middelen. Diverse nieuwe strategieën 
worden bediscussieerd om het effect van farmacotherapie te vergroten, maar alle 
strategieën dienen geïntegreerd te worden in een psychosociale behandelvorm. 
Psychosociale interventies zouden zowel gedragsregulatie als cognitief-
motivationele technieken moeten bevatten. Er lijkt bestaansrecht voor de stelling 
dat beide aspecten opeenvolgend zouden moeten plaatsvinden voor optimaal 
effect. Echter, meer onderzoek naar de interactie tussen deze structuren is nodig. 
Ten slotte, CRA is een multi-modale strategie om de blootstelling aan positieve 
bekrachtigers te vergroten, zodat het repertoire van natuurlijk beloningsgedrag 
wordt uitgebreid, om de belonende waarde van alcohol en drugs te reduceren. 
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In the spring of 1995 a new treatment became available for Dutch opioid addicts: 
Naltrexone (NTX) assisted rapid detoxification under full anesthesia (Legarda & 
Gossop, 1994). The treatment was offered by a commercial organization in Spain: 
Centro de Investigatión y Tratamiento de la Addición (CITA). This approach (Ultra 
Rapid Opioid Detoxification (UROD®)) attracted many drug users, since it claimed 
that UROD was painless and much faster (within 24 hours) than regular 
detoxification programs, which usually take weeks to complete. Following 
detoxification, patients were encouraged to continue with oral NTX as a 
maintenance treatment to prevent relapse. CITA claimed that about 70% of the 
eligible clients were abstinent for 6 months or longer. 
Some Dutch opioid dependent patients flew to Spain to enroll in this new 
treatment. The first patients were referred from a methadone maintenance 
program in Roosendaal to the CITA treatment center in Sevilla. Following 
discharge, several patients with a long history of opioid abuse remained abstinent 
for several months. The first impression was that the observed results were much 
better than those of regular clinical methadone tapering programs followed by 
usual relapse prevention programs. 
Encouraged by these results, I decided to go to Madrid to meet Dr. Juan Jose 
Legarda, founder of CITA, to obtain information about this experimental 
procedure. In this meeting in autumn 1995, Dr. Legarda provided detailed 
information about the UROD procedure. It was allowed to observe a rapid 
detoxification procedure with two patients from Greece. 
The new medical procedure was interesting, but what really drew attention 
were the elaborate family involvement and the friendly and professional attitude of 
the staff. Dr. Legarda acknowledged the mandatory need for appropriate aftercare 
to prevent relapse. In his perspective, available family resources were to be 
sampled to foster abstinence, by monitoring and guarding compliance of 
treatment attendance and the medication (NTX) regime. Furthermore, the family 
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was involved in the treatment program to explore reinforcers contingent on 
abstinence. Finally, patients were not treated as addicts, but as patients situated 
in a general hospital.  
The key components of this method seemed to be (1) the innovative medical 
approach, to quickly detoxify subjects from opioids and induce a NTX 
maintenance program, (2) the integral treatment using a network approach, and 
(3) selection of subjects motivated to be charged by approximately Euro 5,000.  
This introduction into the UROD methodology suggested that the claimed 
successes of the treatment were primarily based on the biological ingredients. 
However, the active psychosocial components, such as the embedding of the 
treatment in the traditional South-European family structure and addressing in 
many respects positive reinforcement, seemed also to contribute to the positive 
treatment outcomes.  
In observing the program, there was a resemblance with components of the 
Community Reinforcement Approach (CRA) as it was developed and practiced in 
the US by Hunt and Azrin (e.g. Azrin et al., 1982). 
CRA integrates pharmacological agents and/or medical procedures, family 
support and psychological interventions. A positive reinforcement approach 
seems to constitute a key concept in the successful treatment. However, literature 
reviews indicated that CRA had not been extensively studied (e.g. Finney & 
Monahan, 1996). Despite its resemblance, the Spanish authors did not mention 
CRA as source for the psychosocial component of their success story. In fact, no 
studies were available on CRA combined with rapid opioid detoxification (ROD), 
with or without anaesthesia, let alone on CRA integrated with NTX as a relapse 
prevention treatment.  
Therefore, in February 1996, we started a program to detoxify methadone 
maintenance patients with a rapid NTX assisted detoxification procedure without 
anaesthesia, embedded in a CRA-based psychosocial program. The initial results 
of this pilot were encouraging (Roozen et al., 1997). Subsequently, we 
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participated in a randomized multi-center study with the acronym EDOCRA2, in 
which two types of NTX assisted rapid opioid detoxification (with and without 
anesthesia) were followed by NTX maintenance treatment combined with a CRA-
based treatment (De Jong et al., 2004). These experiences with CRA and NTX 
assisted rapid detoxification form the underpinning of this dissertation.  
In Europe research on ways to bolster the therapeutic efficacy of CRA is 
negligible. This dissertation scientifically evaluates the concept and the 
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